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9Human papillomaviruses (HPV) underlie the carcinogenesis of a substantial fraction of human can-
cers, including cancer of the uterine cervix. Cervical cancer is the second leading cause of cancer-
related deaths among women worldwide, and it is the ﬁ rst malignancy acknowledged by the World 
Health Organisation to be virally induced in essentially all cases [ 1-3]. The close association between 
an infectious agent and cancer provides an important opportunity to target this disease by means 
of immunotherapeutic strategies. The fact that anogenital HPV infections are extremely common 
implies that HPV infection itself is not the decisive factor in cancer development. Rather, it is the 
failure to control HPV infection and the subsequent establishment of persistent infection that pre-
disposes progression towards malignancy [4, 5]. This failure of immunosurveillance is observed only 
in a minority of infected subjects, whereas most infected individuals fortunately clear the infection 
without the development of HPV induced lesions. Clues as to how lesions expressing viral antigens 
can progress in the face of immune defence are likely to be found in the immune response against 
HPV antigens. Detailed knowledge of this HPV-speciﬁ c immunity, both in individuals successfully 
controlling HPV infection and those who have evidently failed to do so, will assist the rational design 
of therapeutic interventions in the course of HPV induced disease. 
Introduction
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Human Papillomaviruses
Human papillomaviruses are small double-stranded DNA viruses, and over a hundred types have 
been identiﬁ ed and fully or partially sequenced to date [6]. All identiﬁ ed types are strictly epithelio-
tropic, and depend on the differentiation process of the external epithelium for viral propagation. 
Papillomaviruses infect the epithelial cells either of the skin or of the anogenital and oropharyngeal 
mucosa. Based on their oncogenic potential, human papillomaviruses can be divided into low-risk 
types, causing benign epithelial proliferations, and high-risk types, which can incidentally result in 
malignant transformation of epithelial cells [7]. HPV type  16 (HPV 16) is the most prevalent high-risk 
type in HPV-associated anogenital malignancies – HPV 16 DNA is present in more than 50 % of cervi-
cal tumors [8] – and forms the focus of the HPV-speciﬁ c immunity outlined in this thesis. 
 HPV 16 viral particles contain the double-stranded closed circular DNA genome, associated with 
histone-like proteins and encapsidated by 72 capsomers. The HPV 16 genome consists of approxi-
mately 7900 base pairs harbouring 8 open reading frames (Figure  1). The genome can be divided 
into three regions: a non-coding long control region (LCR), an early (E) and a late (L) region. The late 
genes encode structural proteins, whereas the early genes mainly encode proteins with regulatory 
functions engaged in genome persistence and DNA replication. The LCR harbors speciﬁ c enhancer 
elements, which are responsive to both viral and cellular regulatory factors [9]. The functions of the 
HPV 16 encoded proteins are described in Table  1.
Viral life cycle
The papillomavirus life cycle differs from all other virus families by its tight restriction to the differenti-
ating epithelium. Establishment of infection requires the availability of epidermal or mucosal epithe-
lial cells that are capable of proliferation (basal cells). After infection of the basal stem cell, the virus 
utilises the host DNA replication machinery to multiply a few of its viral genomes [9]. In the basal cell, 
HPV genomes are established as episomes at low copy number, which replicate in synchrony with the 
cellular DNA replication. The viral gene expression is largely suppressed in the basal layer, although 
the limited expression of speciﬁ c early viral proteins (e.g. E5,E6,E7) results in enhanced proliferation 
of the infected cells and their lateral expansion [6, 25]. The restricted expression of viral genes in the 
basal cells is suggested to be the result of tight control by cellular factors [26, 27]. 
 The episomal HPV genomes persist in the nucleus of the infected stem cells and are distributed 
during mitosis on to the daughter cells. Therefore, the infected stem cell acts as a reservoir. In con-
Table  1. HPV 16 protein function
Protein Function
 E 1 DNA helicase. Essential for initiation of viral replication [ 10]
 E2 Interacts withs E 1, facilitating the binding of E 1 to origin of replication [ 1 1]
  Viral transcription factor [ 12,  13]
 E4 Associates with keratin cytoskeleton of epithelial cells resulting in collapse of cytokeratin network facilitating 
viral particle release [ 14]
 E5 Interferes with endocytic trafﬁ cking, reducing IFNg-induced HLA class II surface expression [ 15,  16]
  Stimulates cell growth by enhancing effect of growth factors [ 17]
  Prevents apoptosis following DNA damage [ 18]
 E6 Prevents apoptosis by targeting the degradation of p53 and Bak [ 19, 20]
  Activation of telomerase [2 1]
 E7 Prevents cell-growth arrest / differentiation by the release of E2F transcription factor from pRB-E2F complex 
(E7 binds to pRB and pRB family members), resulting in deregulation of G 1 / S cell cycle checkpoint [22]
  Blocks function of cyclin-dependent kinases p2 1 and p27 [23, 24]
 L 1 Major capsid protein
 L2 Minor capsid protein
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trast to uninfected keratinocytes, which exit the cell cycle as soon as they detach from the basement 
membrane, HPV infected cells enter into the S phase after reaching the suprabasal layer. This entry 
into the S phase results in ampliﬁ cation of the viral genomes to thousands of copies per cell [9]. 
Papillomaviruses herewith possess a mechanism to overcome the block in DNA synthesis that occurs 
along with the differentiation of the epithelial cells, although this does not result in full replication 
of the genome of the differentiated host cells [28]. ‘Late’ viral gene expression is initiated in the 
upper layers of the epithelium, where the viral particles are assembled and released (Figure 2). The 
virus actually delays nuclear condensation in differentiating keratinocytes by halting apoptosis until 
viral replication is completed [29].
The development of cervical cancer
Persistence of high-risk cervical HPV infection is characterized by the formation of dysplastic precur-
sor lesions, which can be classiﬁ ed cytologically (Pap  1-5) or histologically (CIN I-III). The histologi-
cal features of more advanced dysplastic lesions include a signiﬁ cant extension of actively replicat-
ing cells into the upper parts of the epithelium, loss of coordinated epithelial differentiation, and 
together with this loss of the complete viral life cycle. It has been proposed that CIN lesions constitute 
a progressive neoplastic disease continuum leading up to invasive cervical carcinoma. However, the 
majority of low-grade lesions (CIN I/II) will regress spontaneously indicating that the development of 
CIN and cervical carcinoma is not a one-way process [30, 3 1]. Furthermore, the disease process can 
show considerable variation; low-grade lesions can persist for years in some patients, whilst in others 
immediate progression to high-grade dysplasia (CIN III) is observed [32, 33]. So far, treatment of HPV-
induced high-grade lesions and cancer is mostly limited to surgical removal, which has proven suc-
cessful in those cases in which the lesions are locally conﬁ ned. Because this treatment modality is 
symptomatic and lacks an anti-viral component, there is a risk of recurrent disease [34-36]. 
The role of HPV (onco)proteins in malignant transformation
Persistence of high-risk HPV infection, causing genomic instability is a prerequisite for disease 
progression and the development of precursor lesions. However, malignant transformation of the 
infected keratinocytes requires an additional step, involving the integration of HPV DNA into the 
host genome. During this process of viral integration, a substantial part of the genome is frequently 
deleted [37, 38]. In the resultant organization of HPV DNA, the viral transcripts spanning the E6 
and E7 region are often linked to ﬂ anking cellular sequences, and subsequently the transcription 
E6 E7
E1
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E4
E5
L1
L2
HPV16
LCR
Figure  1. HPV 16 genome. Schematic representation of the circular HPV genome. The open reading frames (ORFs) are depicted 
as shaded fragments and the three circles correspond to the three reading frames in which the sense strand can be translated. 
The region between L 1 and E6 (long control region, LCR) is an important transcriptional regulatory region. 
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of the oncogenes can be modulated (enhanced) by ﬂ anking host-cell promoters [39]. In addition, 
co-transcribed cellular sequences may result in increased stability of the mRNA encoding the viral 
oncoproteins [40]. Overall, the integration of high-risk HPV into the host genome results the consti-
tutive expression of the viral oncogenes. 
 The E2 protein is described to be the major regulator of viral protein expression, and capable of 
suppressing E6 and E7 oncogene expression [4 1]. Therefore, the deletion of the E2 gene in the process 
of viral integration has been held responsible for the unleashed expression of both oncoproteins. This 
has, however, been contradicted by a recent study in which the suppressive effect of E2 on E6 and 
E7 expression was observed only for integrated and not for episomal viral DNA [42]. Therefore, the 
increased oncoprotein expression after viral integration may more likely be explained by factors other 
than the absence of the controlling function of E2, such as the aforementioned enhanced transcrip-
tion of the oncogenes by ﬂ anking host-cell promoters, and the increased stability of chimeric tran-
scripts. Although the E 1 and/or E2 genes are often disrupted and part of the viral genome deleted 
in HPV 16 positive cervical carcinoma, episomal copies of the viral DNA can often still be detected in 
the tumor cells, resulting in a variable expression of the HPV 16 proteins. However, the lack of cellular 
differentiation at this stage of disease precludes completion of the viral life cycle. 
 The oncoproteins E6 and E7 proteins play a signiﬁ cant role in the process of malignant transforma-
tion. Independently they have the capacity to immortalize various human cell types in vitro; the efﬁ -
ciency of which is increased when the oncoproteins are expressed together [43]. A number of interac-
tions have been reported between high-risk E6/E7 and host-cell proteins (Figure 3). For E6, the most 
prominent functions originate from its interaction with, followed by the degradation of, p53 and the 
pro-apoptotic protein Bak. These events result in resistance to apoptosis and an increase in chromo-
somal instability. In addition, E6 has been shown to associate with myc proteins in vivo, resulting in 
the cooperative activation of the telomerase reverse transcriptase promoter (references in Table  1). 
 E7 interacts with the RB protein, which releases the transcription factor E2F from RB inhibition. 
Figure 2. HPV infection and propagation. HPV infection of the cervix often occurs at the so-called squamocolumnar junction 
or transformation zone. This is where the columnar epithelium of the endocervix is connected to squamous epithelium of the 
exocervix, and the undifferentiated basal stem cell is readily accessible for HPV infection. After entry of the HPV virion into 
the basal epithelial (stem)cell, the viral genome is ampliﬁ ed to several copies. The infected cell divides along the basement 
membrane and then matures vertically. In the suprabasal layers of the epithelium HPV early proteins are abundantly expressed 
and the viral replication takes place. Several of these proteins (e.g. E6 and E7) interfere with epithelial differentiation. Only in 
the most superﬁ cial layers of the epithelium, E4 and the late viral genes L 1 and L2 and the E4 re-expressed, and the HPV DNA is 
encapsidated and the virions are released at the epithelial surface.
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The released E2F functions as a transcriptional activator, resulting in deregulated G 1/S transition. 
Moreover, E7 is shown to block the function of the cyclin-dependent kinase inhibitors p2 1 and p27. 
High E2F activity might lead to apoptosis in E7-expressing cells, however, E6 in turn prevents this by 
guiding the degradation of apoptosis-inducing proteins p53 and Bak (references in Table  1). Taken 
together, the interference of E6 and E7 with cell cycle control, allows the accumulation of mutations 
in host cell DNA, thereby promoting malignant cell transformation. 
Immune responses against hpv
Immune evasion and regulation in the HPV-infected epithelium 
Anogenital HPV infections are extremely common, and the cumulative lifetime incidence is esti-
mated to be as high as 80-85 % [44]. The fact that most infections are cleared and that low-grade 
CIN lesions often regress spontaneously, indicates that in the majority of individuals the immune 
system succeeds in eliminating the virus before malignant disease can develop. Indirect evidence for 
the major role of the cellular immune response in this process is given by the fact that the prevalence 
of persistent HPV infections and HPV-positive lesions is greatly increased in immunosuppressed sub-
jects, such as transplant recipients and HIV-positive patients [45-48].
 The duration of a transient anogenital HPV infection ranges from 7– 14 months [32, 49], indicat-
ing that the virus is capable of persisting in the host for some time before elimination. This lag time 
between HPV infection and clearance is at least partially linked to the evasion of and/or interference 
with innate immune defences [50]. Lack of innate immune triggering will in turn avoid activation 
of the adaptive immune system to eradicate virus-infected cells. Several characteristics of the viral 
infection contribute to the temporary circumvention of immune triggering, including the minimal 
disturbance of the epithelial architecture initially caused by the virus and the absence of signiﬁ cant 
keratinocyte lysis and inﬂ ammation. Furthermore, the differentiation dependent protein expression 
limits abundant production of viral proteins to the top epithelial layer, less accessible and visible to 
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Figure 3. Mechanisms of E6 and E7 interference with cell cycle control. Together with E6-AP, the E6 protein facili-
tates the ubiquitination and proteasomal degradation of p53. The combination of Bak inactivation and reduced p53 activity 
results in loss of cell cycle control by the prevention of apoptosis. Both the activation of telomerase by E6 and the release of E2F 
transcription factor by the binding of E7 to pRB contribute to cell proliferation.
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cells of the immune system. Moreover, the uptake of HPV 16 virus-like particles (VLP) by Langerhans 
cells – the antigen presenting cells (APC) present in the epithelium – does not result in activation 
of these cells [5 1]. This in contrast to the uptake of VLP by monocyte-derived dendritic cells (DC), 
which does induce the upregulation of maturation markers on the DC and the secretion of IL- 12. 
Taken together, the overall lack of inﬂ ammatory signals involved in papillomavirus infection allows 
a temporary evasion of immune surveillance. 
 Besides the avoidance of immune system activation, papillomaviruses also harbour mechanisms 
to actively interfere with innate immune triggering. The oncoproteins E6 and E7 have been shown 
to prevent the immunoregulatory effects of the type I interferon pathway by physically interfering 
with speciﬁ c components of this pathway, e.g. inhibition of Interferon regulatory factors IRF 1 and 
IRF3 (reviewed in [52]). Furthermore, the selective downregulation of MCP- 1 expression by E6 and E7 
in epithelial cells may also contribute to the program of HPV immune evasion, as this chemokine is 
particularly relevant in the setting of viral infection due to its ability to attract monocytes, memory T 
cells and NK cells in vivo [53]. Interference with the initiation of an adaptive immune response has 
been suggested by Matthews et al., who demonstrated E6-mediated downregulation of E-cadherin, 
resulting in Langerhans cell (LC) depletion of HPV 16-infected epithelium [54]. This may limit the pre-
sentation of viral antigens by LC, thus preventing the initiation of a cell-mediated immune response 
and promoting survival of the virus.
 Although keratinocytes have the capacity to secrete pro-inﬂ ammatory cytokines under certain 
conditions, they can also produce immunoregulatory factors such as TGFb and IL- 10. Both these 
cytokines play an essential role in the differentiation of Langerhans cells (LC) and their retention in 
the epidermis [55, 56]. Furthermore, these factors can inhibit the induction of LC maturation by pro-
inﬂ ammatory factors. It is evident that LC-mediated activation of T cells in the regional lymph nodes 
requires the pro-inﬂ ammatory signals to dominate over the homeostasis of LC as controlled by TGFb 
and IL- 10. Lack of sufﬁ cient pro-inﬂ ammatory signals will result in immunological ignorance or toler-
ance [57]. Several reports describe increased levels of IL- 10 in HPV-induced high-grade CIN lesions 
[58-60], and an increase in this immunoregulatory cytokine may have profound effects both on 
the resident LC in the skin, inﬂ uencing their migration pattern and their antigen presenting capac-
ity after migration to draining lymph nodes [6 1]. Furthermore, local IL- 10 secretion in the HPV-
induced lesion may negatively affect the functionality of many types of effector cells migrating to 
the lesions [62]. Giannini et al. suggested that immunosurveillance within the epithelium of the 
transformation zone – compared to the exocervix – is intrinsically perturbed by the altered expres-
sion of chemokines/cytokines (e.g. TNF-a, MIP3a) and by the concomitant diminished density of 
immature LC. Furthermore, the allo-stimulatory capacity of LC derived from the transformation zone 
was reduced compared to those from the exocervix, and the function of high-grade CIN-derived LC 
appeared even further incapacitated [63]. 
 Notwithstanding these considerations, the situation during natural HPV infection appears to gen-
erally favor the induction of effective immunity rather than tolerance, as indicated by the fact that 
the vast majority of active HPV infections are eventually eliminated. However, in susceptible indi-
viduals, a period of decreased vigilance of the immune system can result in minor disturbance of 
the balance between pro- and anti-inﬂ ammatory signals and thereby allow the virus sufﬁ cient time 
to establish a status quo in which HPV infected and/or HPV-transformed cells are difﬁ cult to elimi-
nate. The fact that – in contrast to low-grade CIN lesions – more advanced cervical lesions rarely show 
spontaneous regression, underlines the need for the immune system to act during the early pre-
malignant phase in order to be effective against the virus. 
 HPV-positive keratinocytes that have undergone malignant transformation have a pronounced 
capacity to secrete immunomodulatory cytokines. Cervical carcinoma cells were found to secrete 
IL- 10 [64], VEGF [65], PGE2 [66], TGFb [67], and IL-6 [68]. In vitro experiments have shown that 
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activation of dendritic cells (DC) or LC in the presence of these cytokines was shown to result in APC 
with decreased costimulatory capacity, lacking IL- 12 secretion, which are poor stimulators of Th 1/CTL 
immunity and which can even induce T cell tolerance [69-73]. In several cases such APC were shown 
to rather induce Th2-type immunity [74, 75], which is suggested to be relatively ineffective against 
solid tumors and which seems to prevail in patients with progressed cancers [64, 76]. 
Viral latency
Many lines of evidence point towards the existence of a latent phase of papillomavirus infection, 
which can be deﬁ ned as the presence of viral DNA in the absence of differentiation-dependent virion 
production [77]. Indications for viral latency are mainly derived from both the Canine oral papil-
lomavirus (COPV) and Cottontail rabbit papillomavirus (CRPV) model by the detection of viral DNA 
in post-regression tissue [78] and the induction of viral protein expression in previously infected 
sites by UV irradiation [79]. In humans, HPV latency has been suggested in the larynx and trachea 
of patients with recurrent respiratory papillomatosis (RRP). HPV DNA could be detected in biopsies 
from clinically normal laryngeal and tracheal tissues derived from RRP patients [80]. Indirect evi-
dence for a latent phase in HPV infection is given by the rapid appearance of multiple HPV lesions in 
immunocompromised patients [77]. Most studies do not allow distinction between true latency and 
subclinical infection. In the immunocompetent host, HPV infection may be held in a subclinical state 
by effective cellular immunity, which can then readily evolve under immunosuppressive conditions.
Mechanism of viral clearance
The term clearance is used to indicate the absence of active viral infection; regarding the presumed 
viral latency phase, this does not indicate a complete eradication of viral DNA. Little is known of the 
clearance process of HPV infections and HPV-induced lesions in the female genital tract. The regres-
sion of genital warts – associated with low-risk HPV infection of the external genital mucosa – is 
shown to be characterized by an active cell-mediated immune response [8 1]. Regressing warts con-
tained signiﬁ cantly more T cells and macrophages than did non-regressing controls, and in this 
regression process, CD4+ T cells predominated in both the wart stroma and the surface epithelium. 
The great importance of CD4+ T cells in the control of HPV infections, is substantiated by reports 
showing that low CD4+ T cell count is strongly associated with multiple HPV infections, high viral 
load, and viral persistence in HIV-infected individuals and by the extensive HPV induced lesions 
observed in HIV negative patients with idiopathic CD4+ T-lymphocytopenia [47, 82-84].
 Although the study of genital wart regression provides information on the cellular immune 
response, the unpredictable regression/clearance pattern of HPV infections makes it difﬁ cult to obtain 
a complete chronological picture of the regression process. In contrast, the COPV model does provide 
the opportunity to study the process of wart regression, because the experimentally induced mucosal 
papillomas undergo a rapid and predictable regression after maturity [85]. This revealed that regress-
ing papillomas had a marked inﬂ ux of ab T cells, both CD4+ and CD8+. The peak of CD4+ inﬂ ux 
preceded that of CD8+, and CD4+ T cells were clearly predominant in the regressing lesions [86]. 
 Both animal and human studies point at a major role of the adaptive cellular immune response in 
the clearance of papillomavirus infections, and this suggests the formation of papillomavirus-speciﬁ c 
immune memory. In the case of COPV, there is a clear immunity to rechallenge with the virus, after reso-
lution of the primary infection [85]. Regarding human papillomaviruses, indirect evidence for the devel-
opment of HPV-speciﬁ c immune memory is given by the fact that the prevalence/incidence of anogenital 
infections decreases with increasing age in individuals with a similar exposure rate [87]. Furthermore, a 
second infection with the same HPV type has been shown to result in rapid viral clearance [88].
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Cellular immunity against HPV proteins
The conﬁ nement of HPV infection to the epithelium renders the Langerhans cell (LC) the profes-
sional APC primarily responsible for the induction of T cell immunity against HPV antigens. Impor-
tantly, as the HPV infection cycle is speciﬁ cally adapted to the keratinocyte differentiation program, 
it is unlikely that HPV infection of LC will result in the expression of the HPV antigens by the LC 
themselves. Therefore, the priming of T cell immunity against HPV will depend on the uptake and 
(cross)presentation of HPV antigens by the antigen presenting cells. The efﬁ ciency of this process 
will be affected by the levels to which the viral proteins accumulate in the infected keratinocytes that 
serve as antigen source and by the release of HPV proteins from apoptotic/(necrotic) keratinocytes. 
 Effective intervention of the cellular immune system in productive HPV infection is likely to ben-
eﬁ t from T cell immunity against papillomavirus immediate early antigens, because these antigens 
are expressed throughout suprabasal layers of the infected epithelium [9]. Although T cells directed 
against ‘late’ HPV antigens can deﬁ nitely play a role in the anti-HPV immune response, these anti-
gens are only expressed when the viral infection cycle is almost complete and the differentiating 
keratinocyte has moved up in the epithelium [89]. Therefore, cellular immune responses against 
these antigens will most likely not result in effective viral clearance. Studies addressing T cell immu-
nity against HPV have focused primarily on type  16 (HPV 16) because of the high prevalence of this 
oncogenic type high-grade CIN lesions and cervical carcinoma. More speciﬁ cally, responses against 
the E6 and E7 oncoproteins of HPV 16 have been extensively studied, due to their constitutive expres-
sion in HPV 16-positive (pre)malignant lesions. However, during productive viral infection and in low-
grade CIN, other early proteins (E 1, E2 and E5) are also widely expressed in the (supra)basal epithe-
lium and may also provide targets for the cellular immune system [90, 9 1].
 So far, no clear-cut association has been established between HPV-speciﬁ c T cell responses and 
protection against progression of HPV-induced disease. In a cross-sectional analysis by de Gruijl et al. 
it was shown that strong Th responses against HPV 16E7, as determined by cytokine-induced prolifera-
tion of a reporter cell line, were associated with persistence and progression of HPV 16-positive lesions. 
However, a longitudinal analysis by the same group showed that HPV 16E7-speciﬁ c Th responses were 
associated with both clearance and persistence, in which it was suggested that these responses devel-
oped as a consequence of increased antigen availability resulting from either clearance of progression 
of cervical lesions [92, 93]. Our previous cross-sectional analysis of HPV 16E7 responses by IFNg ELISPOT 
in healthy individuals and patients with HPV 16-positive cervical cancer or high-grade CIN showed fre-
quent E7-speciﬁ c responses in HPV 16+ patients, whereas these were rarely detected in healthy controls 
[94]. In a longitudinal study performed by Kadish et al. proliferative responses against HPV 16E7 and/or 
E6 in CIN patients were found to be associated with clearance of HPV infection and regression of CIN 
[95]. It must be noted, however, that only a fraction of the CIN patients participating in this study was 
HPV 16 positive, and only the C-terminal part of E7 was used as a readout. Several other studies report 
highly variable percentages of HPV 16E7- and/or E6-speciﬁ c Th-responses in patients [96, 97]. 
 Like in the case of Th responses, contradictory results have been obtained regarding CTL responses 
against the HPV 16-derived oncoproteins. Lack of E6-speciﬁ c CTL was found to be an important factor 
in HPV 16 persistence [98], whereas a study by Bontkes et al suggested that CTL against E6 and 
E7 are generally only found in persistent CIN [99]. In concordance with the latter study, Ressing 
et al. detected CTL responses against the – previously determined – HLA-A*020 1 restricted epitope 
HPV 16E7 1 1-20 in cervical carcinoma and CIN patients (HPV 16- and HLA-A*020 1-positive) and not in 
healthy individuals [ 100]. Youde et al. showed by HLA-A*020 1 tetramer staining that – after a short 
in vitro stimulation – the frequency of CD8+ T cells speciﬁ c for E7 1 1-20 was signiﬁ cantly higher in 
HPV 16+ CIN III patients than in healthy controls [ 10 1]. 
 Many of the inconsistencies observed between the different studies of cellular immunity against 
the HPV 16 oncoproteins may be explained by the patient selection (whether or not included patients 
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are HPV 16 positive) and, more importantly, by the differences in technical approach. Several older 
studies involve multiple in vitro stimulations, and do therefore not truly reﬂ ect the in vivo situation. 
Furthermore, the choice of antigen – recombinant protein or synthetic peptides spanning only a lim-
ited region of the total protein – has most likely inﬂ uenced the outcome of the analyses. 
 A limited number of studies has addressed the cellular immunity against other HPV antigens. 
Bontkes et al. studied the HPV 16E2-speciﬁ c Th-response in CIN patients and observed that Th cell 
responses against the C-terminal domain of E2 frequently occurred at the time of HPV clearance, 
although no signiﬁ cant association between E2-speciﬁ c Th responses and disease outcome was 
observed [ 102]. Proliferative responses against the E5 protein of HPV 16 were signiﬁ cantly reduced in 
the patients with high-grade CIN and cervical carcinoma, as compared to patients with low-grade 
lesions [ 103]. The responses were exclusive to those with HPV 16-positive lesions, but the difference in 
response frequency lost statistical signiﬁ cance when only the HPV 16-positive patients were included 
in the analysis. Therefore, the observed results require conﬁ rmation in a larger HPV 16-positive popu-
lation. T cell responses against the E4 antigen of HPV 16 have shown no correlation with infection 
and/or disease [ 104]. As for the late antigens L 1 and L2, expression of E4 is restricted to the upper 
differentiated layers of the epithelium [89], and as such T cell responses against this antigen are not 
likely to contribute signiﬁ cantly to viral clearance. The late antigen HPV 16L 1 is a major target of the 
cellular immune system, as L 1-speciﬁ c responses were abundantly detected in the peripheral blood 
of HPV 16+ CIN patients [ 105,  106]. The analyses were not performed with the entire L 1 antigen, but 
only with a predetermined immunogenic region. Again, these T cell responses were not associated 
with disease severity, as they were observed both in those with virus clearance and in those with per-
sistence, irrespective of CIN grade. The high degree of L 1 conservation between HPV types, brings up 
the question whether L 1 cross-reactive T cells – recognizing the HPV 16L 1 peptides in vitro – have con-
tributed to the high percentage of responders. Overall, these studies that addressed HPV 16-speciﬁ c 
cellular immunity indicate that responses against the viral proteins are occasionally induced at one 
point during HPV 16-induced disease, but their role in protection against disease remains unclear.
Humoral immune responses against HPV
Serum IgG antibodies against HPV 16 capsid are generally related to persistent HPV 16 infection, 
although a large fraction of patients with HPV 16-positive CIN fails to mount a systemic antibody 
response against the virus [ 107]. In transient HPV 16 infections, type-speciﬁ c serum IgG antibodies 
are induced in only a minority of individuals and antibody levels wane over time [ 108]. Similarly, 
mucosal IgG is barely induced in transient infections. Mucosal IgA responses on the other hand, 
were detected more frequently and appeared to reﬂ ect recent or ongoing HPV infection [ 109]. In 
established HPV infection type-speciﬁ c antibodies may have a role in limiting the spread of active 
HPV infection by preventing viral reinoculation after virion release. Their role as a diagnostic marker 
in the process of HPV-induced disease is limited due to the lack of detectable antibody levels in a 
large fraction of persistently infected individuals.
HPV vaccination
Prophylactic vaccines 
The identiﬁ cation of high-risk papillomaviruses as a necessary cause of the development of malig-
nancy implies that prevention of HPV infection should prevent the development of cancer. A success-
ful example of such prophylaxis is given by Hepatitis B virus (HBV) vaccination, which has dramati-
cally decreased the incidence of HBV infection and thus the subsequent risk of developing liver cancer 
[ 1 10,  1 1 1]. Prophylactic HPV vaccines have focused on the induction of type-speciﬁ c neutralizing anti-
bodies against the viral capsid (L 1 and/or L2) capable of blocking the interaction of the virions with 
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the keratinocytes and thereby preventing subsequent viral entry steps. Several animal models of papil-
lomavirus infection have provided convincing evidence that neutralising antibodies can prevent new 
infection [ 1 12,  1 13]. In humans, encouraging results have been obtained with an HPV 16 virus-like particle 
(VLP) vaccine. Virus-like particles consist of L 1 major capsid protein, which mimics the natural virus by 
self-assembly into virion conformation. In a double-blind, randomized, placebo-controlled vaccination 
trial an HPV 16 VLP vaccine or placebo was administered to  1533 HPV 16-negative women aged  16-23 
[ 1 14]. Over the follow up period, persistent HPV 16 infections – deﬁ ned as detection of HPV 16 DNA on 
two consecutive 6 monthly visits – and CIN were detected in the placebo group only. A small number 
of vaccine recipients was HPV 16 DNA positive at a single visit, indicating that the vaccine does not 
establish sterilizing immunity in all cases. However, the fact that persistent infection does not ensue, 
suggests that the vaccination may reduce the viral load and limit rounds of reinoculation. 
 The results from the initial VLP-based prophylactic vaccination trial are very promising. However, 
several important issues remain to be addressed, such as duration of protection – which is required 
to be several decades – and efﬁ cacy in immunocompromised individuals; this in view of the high 
incidence of HIV in the target population in the developing world. The fact that VLPs offer genotype-
speciﬁ c protection implies that a multivalent vaccine is required, targeting the most common high-
risk HPV types in order to achieve maximal protection against HPV-induced malignancy. Follow-up 
studies on immunized individuals may also shed light on the signiﬁ cance of oncogenic HPV in the 
development of other cancers (e.g. oral and oesophageal cancer). 
Therapeutic vaccines 
Once HPV infection has been established it is unlikely that antibodies will contribute substantially 
to eradication of infected cells. The clearance of HPV-infection or established HPV-induced disease 
likely requires T cells speciﬁ c for the viral antigens. The E6 and E7 oncoproteins are the only viral 
antigens that are constitutively expressed from infection up to malignancy; therefore, all therapeutic 
vaccines designed to date target these oncoproteins. Low-grade lesions harbour more potential tar-
gets, as the complete viral cycle occurs and these lesions are genetically stable. However, the addi-
tional contribution of targeting other viral proteins in the treatment of low-grade lesions is largely 
unexplored. Results from animal studies suggest that targeting of early antigen E 1 and E2 can con-
tribute to therapeutic vaccine efﬁ cacy. In the COPV model, which may serve as a model for low-grade, 
low-risk lesions, DNA vaccination with codon-optimized E 1 and E2 showed both prophylactic and 
therapeutic efﬁ cacy [ 1 15]. The E2 antigen was also shown to be a preferable target in the CRPV model 
[ 1 16]. In addition, targeting of oncoproteins E6 and E7 was effective in this model [ 1 17]. However, 
results obtained in papillomavirus animal models demand caution when extrapolating these to the 
human situation [89]. Differences in tissue tropism, transmission route and persistence have shown 
to result in distinct gene expression patterns (also between human HPV types), which in turn affect 
the accessibility of viral antigens to the immune system. The value of natural host – papillomavirus 
combinations, however, exceeds that of mouse models for the prediction of therapeutic vaccine efﬁ -
cacy. These models make use of HPV-positive transplantable tumors and ignore the fact that, in 
humans, tumor development is preceded by a period of persistent HPV infection, in which tolerance 
to the viral antigens can be induced as a result of continuous exposure of the immune system to 
these antigens in a non-inﬂ ammatory environment. Furthermore, transplantable tumors grow out-
side the epithelial context in which these tumors normally arise. The importance of the latter is dem-
onstrated in transgenic mouse models expressing HPV 16 E7 under control of a keratinocyte-speciﬁ c 
promoter. E7-transgenic skin grafted onto non-transgenic littermates was not rejected, even if the 
mice received an E7-speciﬁ c immunization that resulted in effective E7-speciﬁ c immunity capable 
of rejecting E7-expressing transplantable tumors [ 1 18]. This demonstrates the major inﬂ uence of the 
epithelial site of antigen expression and of the nature of the keratinocyte and its environment. 
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At present, several vaccines have been tested in phase I/II clinical trials. They include peptide-
based vaccines, fusion proteins, antigen-pulsed DC or recombinant vaccinia viruses (reviewed in 
[ 1 19,  120]). Clinical responses observed in these studies were limited to those patients with prema-
lignant lesions. Modest clinical responses have been observed in patients with high-grade vulvar 
intraepithelial neoplasia (VIN) upon vaccination with recombinant vaccinia virus encoding the modi-
ﬁ ed oncogenes of HPV 16 and  18 or a heterologous prime-boost regimen consisting of three recombi-
nant HPV 16L2E6E7 protein vaccinations followed by the recombinant vacciniavirus vaccine [ 12 1- 123]. 
It must be noted, however, that these trials were not placebo controlled and therefore the naturally 
occurring ﬂ uctuation of lesion size was not accounted for. Nevertheless, the initial results are encour-
aging, and VIN is a candidate condition for therapeutic vaccination in view of the multifocality of the 
disease and limited effective treatment options. In a fraction of patients, systemic T cell responses 
against E6 and/or E7 associated with IFNg were detected. However, the results of the immunologi-
cal analyses lacked a clear-cut correlation with clinical outcome. In a double-blind, randomised, 
placebo-controlled clinical trial, a plasmid-DNA based vaccine containing deﬁ ned HPV 16/ 18 E6 and 
E7 encoding sequences (ZYC 10 1a) showed no signiﬁ cant effect on the resolution (deﬁ ned as normal 
or CIN I) in a population of CIN 2/3 patients. Again, no correlation was observed between HPV-
speciﬁ c immune response and clinical response [ 124]. 
 Initial trials involving synthetic peptide-based vaccines, focused on HLA*A-020 1 restricted CTL epi-
topes of HPV 16E7 [ 125,  126]. In a phase I trial of  15 HPV 16-positive cervical carcinoma patients with 
residual or recurrent disease, vaccination with two HPV 16E7 CTL epitopes and a non-related univer-
sal Th epitope (PADRE) resulted in the induction of PADRE-speciﬁ c Th responses but not HPV 16E7-
speciﬁ c CTL [ 127]. In contrast, E7-speciﬁ c responses were observed in a fraction of high-grade CIN 
and VIN patients upon vaccination with a similar E7 vaccine. Again, the immunological data did not 
clearly correspond to the clinical observations [ 128]. Pre-clinical studies suggest that longer peptides 
containing both Th- and CTL epitopes are more efﬁ cient at eliciting strong CTL responses than mini-
mal epitopes, and therapeutic efﬁ cacy with 30 amino acid long peptides has been demonstrated in 
both murine and CRPV model [ 1 17,  129]. The epitope linkage increases the chance of simultaneous 
presentation of both the MHC class I- and class II-restricted epitopes on the surface of a single APC, 
thereby facilitating the delivery of cognate T cell help to CTL priming [ 130]. Furthermore, in contrast 
to minimal CTL epitopes, the longer peptides require uptake and processing and therefore exclude 
unfavorable exogenous binding to non-professional APC that lack the proper costimulatory context 
for CTL induction (M. Bijker, personal communication). Currently we are conducting a phase I/II trial 
involving vaccination with 32-35 aminoacid long overlapping synthetic peptides spanning HPV 16 E6 
and E7. The preliminary immunological data reveal the induction of strong IFNg-associated T cell 
responses against the viral oncoproteins, predominantly E6, upon vaccination (unpublished data). 
 Vaccination trials involving cervical cancer patients have so far not demonstrated clinical efﬁ cacy. 
Generally, these trials have been carried out in patients with late-stage disease, who are often immu-
nocompromised due to radio- and/or chemotherapy and ongoing disease. In addition, mutations 
and deletions in antigen processing and antigen presentation are commonly observed in advanced 
cervical malignancies [ 13 1,  132]. Vaccination of patients with early cervical cancer and those with 
premalignant lesions will have to prove the true therapeutic value of vaccines. In high-grade lesions 
and cancer, they are not likely to succeed as a stand-alone therapy, but may function as adjuvant 
therapy combined with other treatment modalities. The great challenge in therapeutic vaccination 
strategies will be to overrule tolerance or redirect pre-existing non-protective T cell responses to HPV 
antigens, which are likely to be encountered in these patients. The generally unfavorable cytokine 
milieu in the lesions and the genetic instability of high-grade lesions and cancer pose additional 
hurdles for effective HPV-speciﬁ c immunotherapy. 
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Scope of this thesis
Previous studies of HPV-speciﬁ c immunity have focused primarily on patients with HPV-positive 
lesions, who have evidently failed to control HPV infection. In this thesis, the emphasis has been 
shifted towards successful HPV-speciﬁ c immunity, which is expected to be found in healthy individu-
als. Issues that have been addressed include the analysis of T cell memory, the associated cytokines 
and the viral antigens targeted by these T cells. Besides charting successful HPV-speciﬁ c immunity, 
we pinpointed several characteristics of HPV-speciﬁ c immune failure in cervical carcinoma patients. 
The importance of the latter lies in the fact that the efﬁ cacy of immunotherapeutic intervention in this 
patient group will strongly depend on the nature of the pre-existing HPV-speciﬁ c immune response. 
 As a ﬁ rst step, we investigated HPV 16-speciﬁ c immunity in the healthy population, which – given 
the common nature of HPV 16 infections – harbors a large fraction of individuals who have previously 
experienced HPV 16 infection. The cellular immunity against the HPV 16 early proteins E2 and E6 fre-
quently observed in healthy subjects (Chapters 2 and 3) most likely represents effective HPV 16-spe-
ciﬁ c immunity induced by prior HPV 16 infection, and we compared this with the immune responses 
in peripheral blood of patients with HPV 16-positive (pre)malignant lesions (Chapter 4). Together with 
the detailed analysis of virus-speciﬁ c CD4+ T cells derived from patients’ tumors and tumor-draining 
lymph nodes, this provided evidence for the existence of an anti-inﬂ ammatory cytokine polarization 
of the HPV 16-speciﬁ c T cell response in cervical carcinoma patients (Chapter 5). 
 The last two chapters both describe potential future treatment modalities. One involves TA-CIN, 
a fusion protein vaccine comprising of HPV 16 L2 E6 and E7, which was tested in a dose-escalating 
study in healthy volunteers (Chapter 6). The other therapeutic approach is based on the transfer of 
HPV 16-speciﬁ c T cells in advanced stage cervical cancer. Chapter 7 describes the ﬁ rst steps in the 
development of such a therapy, by the enrichment of Th 1 type HPV 16E6-speciﬁ c memory T cells from 
the peripheral blood of healthy blood donors, which could serve as T cell therapy after allogeneic 
stem cell transplantation. The efﬁ cacy of the latter treatment option is – in contrast to active thera-
peutic vaccination – independent of the presence of unfavorably polarized T cells in cervical cancer 
patients, because these are deleted in the pre-treatment for transplantation. Finally, the general dis-
cussion of this thesis outlines a hypothesis of successful and failing HPV-speciﬁ c immunity, and provides 
directions for future immunotherapeutic approaches of HPV-induced disease. 
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Abstract · The incidence of genital human papillomavirus (HPV) infections is high in young sexu-
ally active individuals. Most infections are cleared within  1 year after infection. The targets for the 
cellular immune response in this process of viral clearance remain to be identiﬁ ed, but the expression 
pattern of the E2 protein in early infection and low-grade CIN renders this early protein a candidate 
antigen. We therefore studied the HPV 16 E2-speciﬁ c T cell responses in more detail. Very strong 
proliferative responses against one or more peptide-epitopes derived from this antigen can be found 
in PBMC cultures of approximately half of the healthy donors. Further analysis revealed that at least 
a majority of these responses represent reactivity by memory CD4+ Th 1-type cells capable of secret-
ing IFNg upon antigenic stimulation. Interestingly, all E2-peptides against which strong responses 
were detected are clustered in the key functional domains of the E2-protein, which are conserved 
to considerable extent between HPV types. This suggests that HPV 16 E2-speciﬁ c Th memory may be 
installed through encounter with HPV types other than HPV 16. Indeed, one HPV 16 E2-speciﬁ c Th-
clone was found to cross-react against homologuous peptides from other HPV types, but three other 
Th-clones failed to show similar cross-reactivity. Part of the HPV 16 E2-speciﬁ c Th memory may there-
fore relate to previous encounter of other HPV types, whereas the majority of the immune repertoire 
concerned is most likely established through infection with HPV 16 itself. Our data are the ﬁ rst to 
reveal that the T cell repertoire of healthy donors can contain particularly high frequencies of E2-
speciﬁ c memory Th-cells, and suggest that boosting of this immunity can be employed for preventive 
and therapeutic vaccination against HPV-induced lesions.
Frequent detection of HPV 16 
E2-speciﬁ c T-helper immunity 
in healthy subjects
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Introduction
Genital infection with Human Papillomavirus (HPV) is one of the most common sexually transmitted 
diseases [ 1-3]. So-called high-risk HPV types (e.g. type  16) are causally related to the development 
of cervical intraepithelial neoplasia (CIN) and cervical carcinoma [4]. Fortunately, in a majority of 
immunocompetent individuals the HPV infection is asymptomatic, while most premalignant cervical 
lesions, in analogy to warts, are found to regress spontaneously [5-7]. This regression is likely to be 
mediated by cellular immune responses, since regressing genital warts are predominantly inﬁ ltrated 
with CD4+ T cells and macrophages, consistent with a delayed type hypersensitivity reaction [8, 9]. 
The role of immune surveillance in controlling infection by various HPV types is further indicated by 
the increased incidence of HPV infections, HPV-associated warts, CIN lesions and cervical carcinoma 
in immunocompromised subjects [ 10,  1 1]. Moreover, cervical neoplastic lesions frequently display 
deﬁ ciencies in the expression of HLA class I [ 12- 14].
 The investigation of anti-HPV immunity in humans has so far primarily focused on responses 
against the E6 and E7 oncoproteins of HPV 16/ 18, as expression of these proteins is tightly associated 
with HPV-induced dysplasia. Notably, these responses do not necessarily correlate with spontane-
ous regression [ 15- 19]. This suggests that the observed responses are in many cases not capable of 
eliminating the HPV-infected cells. In fact, although clearance of HPV infections as well as spontane-
ous regression of especially low-grade CIN lesions is frequently observed, more progressed lesions 
are rarely cleared. Importantly, the E6 and E7 oncoproteins are primarily expressed at high levels in 
more advanced lesions. During most stages of the productive infection cycle of HPV as well as in 
low-grade lesions the expression levels of these proteins are kept in check by the E2 protein and, as 
a consequence, are modest. The E2 protein is the major regulator of viral DNA replication and gene 
expression [20] and this antigen is uniformly and abundantly expressed in cells containing episomal 
HPV genomes. The highest E2 expression is found in koilocytes in low-grade cervical intra-epithelial 
neoplasia (CIN), whereas with progression of the lesions to invasive carcinoma, E2 expression is lost 
[2 1, 22]. This corresponds with the observation that in high-grade CIN and cervical carcinoma the E2 
gene is frequently disrupted due to linearization of the viral genome, which is required for integra-
tion of viral DNA into the cellular genome. 
 In terms of immune intervention, the E6 and E7 oncoproteins are the major targets in high-grade 
CIN and cervical carcinoma, as these proteins are constitutively expressed and are required for main-
tenance of the transformed state [20]. However, in the context of productive infection and low-grade 
CIN the E2 protein constitutes an attractive target for the immune system, as it is highly expressed 
in these settings, thereby exhibiting an expression pattern complementary to that of E6 and E7. 
In the cottontail rabbit papillomavirus (CRPV) model, which is the major animal model for cancers 
associated with papillomavirus infection, proliferative responses against the E2 protein were associ-
ated with spontaneously regressing papillomas [23]. Moreover, E2-speciﬁ c immunization was shown 
to enhance regression of CRPV-induced papillomas [24]. Finally, a follow-up study in HPV 16-positive 
women diagnosed with CIN revealed that T-helper (Th-) responses against the C-terminal domain 
of the E2 protein were frequently observed at the time of viral clearance, suggesting that these 
responses may contribute to viral clearance [25]. 
 The proposed role of the E2-speciﬁ c T cell response in control of HPV infection and in regression 
of HPV-induced lesions, as well as the high incidence of genital (sub-clinical) HPV infection [3, 7], 
suggests that a pool of E2-speciﬁ c memory T cells may be present in a sizeable fraction of the 
healthy population. We performed a detailed analysis of the E2-speciﬁ c Th-response in healthy indi-
viduals. Our data reveal that the E2 protein exhibits several highly immunogenic regions that contain 
naturally processed Th-epitopes. Moreover, the analysis of the CD45RO+ memory fraction of PBMC 
revealed the presence of E2-speciﬁ c memory Th-responses in a major fraction of healthy individuals. 
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Materials and Methods
Lymphocytes · Peripheral blood mononuclear cells (PBMC) and serum for proliferation assays were 
obtained from HLA-typed anonymous healthy blood donors after informed consent. Furthermore, 
for ELISPOT assays, PBMC were isolated from buffycoats of anonymous healthy blood donors after 
informed consent. Because these donors are anonymous, no data on medical history are available. 
Importantly, donors with a known recent history of infection, including abnormal pap-smear were, 
as part of normal regulations, discouraged to donate blood.
Antigens · A set of peptides spanning the whole HPV 16 E2 protein consisting of 23 overlapping 
peptides, 22 of which have a length of 30 amino acids and one of which (E233 1-365) has a length 
of 35 amino acids, was used. These peptides share an overlap of  15 amino acids. For epitope ﬁ ne-
mapping of HPV 16 E2 speciﬁ c Th-clones, peptides with a length of  15 and 20 amino acids were used. 
For determining the cross-reactivity of HPV 16 E2-speciﬁ c Th-clones the following peptides derived 
from different HPV types were used, with a length varying between 25-30 amino acids. Amino 
acid mismatches are underlined; amino acids with similar physico-chemical properties, but not 
identical are indicated in bold: KPYKELYSSMSSTWHWTSDNKNSKN (HPV33), FKKHKGLYCNVSST-
WHWTSNDTNQQ (HPV26), KYKQLYEQVSSTWHWTCTDGKHKN (HPV3 1), RKYADHYSEISSTWHWT-
GCN (HPV45), QRDKFLTTVKIPNTVTVSKGYMSI (HPV35), QRDDFLNTVKIPNTVSVSTGYMTI (HPV3 1), 
QRQQFLDVVKIPPTISHKLGFMSL (HPV6B), QRSQFLALVKIPKTIKHSLGMLTI (HPV7), QRNNFLTTVKIP-
QSITSTLGIMSL (HPV26). The peptides spanning the Inﬂ uenza Matrix protein of A/PR/8/34, which 
were used as control peptides in ELISPOT assays, consisted of  16 30-mer peptides overlapping by  15 
amino acids. Peptides were synthesized by solid phase technique on an automated multiple peptide 
synthesizer (Abimed AMS 422, Langenfeld, Germany), and analyzed by reverse phase HPLC. The 
lyophilized peptides were dissolved in 50 µl of DMSO, diluted in PBS to a ﬁ nal concentration of 
2.5 mg/ml. The HPV 16 E2 C-terminal (E2280-365) protein and HPV 16 E7 protein were produced accord-
ing to previously described procedures [26]. Memory Response Mix (MRM), consisting of a mixture 
of tetanus toxoid (0.75 LF/ml ﬁ nal concentration; National Institute of Public Health and Environ-
ment, Bilthoven, The Netherlands), Mycobacterium tuberculosis sonicate (2.5 µg/ml; generously 
donated by Dr.P. Klatser, Royal Tropical institute, Amsterdam, The Netherlands) and Candida albi-
cans (0.005 %, HAL Allergenen Lab, Haarlem, The Netherlands), was used to conﬁ rm the capacity of 
PBMC to proliferate and produce cytokine in response to common recall antigens.
HLA-DR peptide binding assay · Binding of peptides to HLA-DR was measured as reported pre-
viously [27]. Brieﬂ y, as a source of DR molecules B-LCL homozygous for DR were used: LG2. 1 
(DRB*0 10 1, DR 1), IWB (DRB 1*020 1, DR2), HAR (DRB*030 1, DR3), and BSM (DRB*040 1, DR4). DR 
molecules were puriﬁ ed by afﬁ nity chromatography and the purity conﬁ rmed by SDS-PAGE. The 
analysis of peptide binding to puriﬁ ed DR molecules was performed using N-terminally ﬂ uorescence-
labeled standard peptides. As standard peptide in the binding assays HA308-3 19 (PKYVKQNTLKLAT, 
DR 1 and DR2), hsp65 3- 13 (KTIAYDEEARR, DR3) or HA308–3 19 YRF (PKFVKQNTLKLAT) was used.
Short-term T cell proliferation assay · Immunogenicity of individual HPV 16 E2 peptides was deter-
mined by short term proliferation assays of healthy donor PBMC with HPV 16 E2 peptides, accord-
ing to previously described procedures [27]. Brieﬂ y, freshly isolated PBMC were seeded at a density 
of  1.5 ¾  105 cells/well in a 96-well U-bottom plate (Costar, Cambridge, MA) in 200 µl of IMDM 
(Iscove’s Modiﬁ ed Dulbecco’s Medium, Bio Whittaker, Verviers, Belgium) supplemented with  10 % 
autologous serum. HPV 16 E2 peptides were added at a concentration of  10 µg/ml. Medium alone was 
taken along as negative control; phytohemagglutinine (PHA, 0.5 µg/ml) served as a positive con-
trol. For each peptide 8 parallel micro-cultures were initiated; each donor was tested twice. Peptide-
speciﬁ c proliferation was measured at day 6 by [3H]-thymidine incorporation. Peptides were scored 
positive, when in both assays, the proliferation of > 50 % of the test wells exceeded the mean prolif-
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eration + 3 ¾ SD of the control wells, and the stimulation index (SI) of the positive test wells over 
medium control wells was higher than 3. 
Generation and analysis of long-term HPV 16 E2 speciﬁ c Th-cultures · Long-term HPV 16 E2-spe-
ciﬁ c T cell cultures and Th-clones were established according to previously described procedures [27]. 
Brieﬂ y, PBMC from healthy HLA-typed donors were stimulated in vitro with the following HPV 16 
E2 peptides (E227 1-300 +E2286-3 15; E230 1-330 +E23 16-345; E233 1-365).  15 ¾  106 PBMC were seeded in 25 cm2 cul-
ture ﬂ asks (Nalge Nunc, USA) in 6 ml IMDM supplemented with  10 % autologous serum. Peptides 
were added at a concentration of 5 µg/ml. At day 7,  15 ¾  106 PBMC were added, together with fresh 
medium and peptides. At day  14 and 2 1 viable T cells were harvested from the cultures, counted 
and restimulated with an equal amount of autologous irradiated PBMC and peptide (5 µg/ml). T cell 
growth factor (Biotest, Dreieich, Germany) was added 2 days after restimulation at a ﬁ nal concentra-
tion of  10 %. The T cell cultures were tested for peptide recognition by proliferation assay at day 28. 
Peptide-speciﬁ c T cell cultures were cloned by limiting dilution and T cell clones were subsequently 
tested for the recognition of E2-peptide and -protein-pulsed APC.
 Speciﬁ city of the Th-clones was analyzed as described previously [27]. Notably, in proliferation 
assays in which Th-clones were tested for protein recognition, autologous monocytes were used as 
APC. For measurement of proliferation, cultures were pulsed with 0.5 µCi [3H]-thymidine (5 µCi/mM, 
Amersham, UK) per well for  18 hours. Plates were harvested with a Micro cell Harvester (Skatron, 
Norway). Filters were packed in plastic covers containing  10 ml of scintillation ﬂ uid and subsequently 
counted on a  1205 Betaplate counter (Wallac, Turku, Finland). HLA class II blocking experiments 
were performed using murine monoclonal antibodies: anti-DQ SPV. L3, anti-DR B8. 1 1.2, and anti-DP 
B7/2 1. Supernatants of the proliferation assays were harvested 24 hrs after incubation and analyzed 
for the presence of IFNg by ELISA [27]. 
Detection of memory Th-cells by ELISPOT · Memory cells (CD45RO+) were isolated freshly from 
buffycoats by MACS after incubation with CD45RO microbeads (cat. no. 460-0 1, Miltenyi Biotec, 
Germany). The purity of the obtained CD45RO+ fraction was > 95 % as determined by ﬂ owcytometry 
after surface staining for CD45RO and CD45RA (CD45RA-FITC, cat. no. 347723, CD45RO-PE, cat. 
no. 347967, Becton Dickinson Biosciences, USA). CD45RO+ cells were seeded at a density of  106 
cells/well in a 24-wells plate (Costar) in  1 ml of IMDM supplemented with  10 % FCS.  106 irradiated, 
autologous cells were added to each well as APC. The responder cells were incubated with either 
medium alone, pools of HPV 16 E2 peptides at 5 µg/ml/peptide, MRM  1:50 dilution or pools of Inﬂ u-
enza Matrix peptides (positive controls) and cultured for  1 1 days in order to improve the detection of 
antigen-speciﬁ c cells [28]. The cells were then harvested, washed and seeded in 4 replicate wells at 
a density of 5 ¾  104 cells/well of a Multiscreen 96-well plate (Millipore, Etten-Leur, The Netherlands) 
coated with a IFNg catching antibody. Per well,  105 irradiated, autologous PBMC were added as APC 
together with 5 µg/ml peptide. ELISPOT analysis was further performed according to the instructions 
of the manufacturer (Mabtech AB, Natcha, Sweden). Analysis of the number of spots was done with 
a fully automated computer-assisted-video-imaging analysis system (Carl Zeiss Vision).
Intracellular cytokine staining (ICS) of memory T cells · Autologous monocytes were isolated from 
PBMC by adherence to a ﬂ at-bottom 48-wells plate during 2 hours in X-vivo 15 medium (Bio Whittaker, 
Verviers, Belgium) at 37° C, and then used as APC. CD45RO+ cells were stimulated for  1 1 days with 
peptide, then harvested, washed and suspended in IMDM + 0. 1 % BSA at a concentration of  1.5 ¾  106 
cells/ml. 200 µl of cell suspension was added to the monocytes + 200 µl of  10 µg/ml HPV 16 E2 peptide 
(stimulated) or 200 µl of medium (non-stimulated control). After  1 hour of incubation at 37° C, 800 µl 
of IMDM +  10 % FCS +  12.5 µg/ml Brefeldin A (Sigma) was added and cells were incubated for another 
5 hours. The cells were then harvested, transferred into a V-bottom 96-wells plate, washed twice with 
ice-cold PBS and ﬁ xed with 50 µl paraformaldehyde 4 % for 4 minutes on ice. Following ﬁ xation, 
the cells were washed once with cold PBS and once with PBS / NaAz 0.2 % / BSA 0.5 % / Saponin 0. 1 %. 
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This was followed by an incubation in 50 µl PBS / NaAz 0.2 % / BSA 0.5 % / Saponin 0. 1 % / FCS  10 % 
for  10 minutes on ice. Cells were washed twice with PBS / NaAz 0.2 % / BSA 0.5 % / Saponin 0. 1 % and 
supernatant was removed before 25 µl of PBS / NaAz 0.2 % / BSA 0.5 % / Saponin 0. 1 % containing  1 µl 
FITC-labelled mouse-anti-human IFNg (0.5 mg/ml, BD Pharmingen, cat.no. 55455 1) 2 µl PE-labelled 
anti-CD4 (BD Bioscience, cat.no. 345769), and 2 µl PerCP-labelled anti-CD8 (BD Bioscience, cat.no. 
3473 14) was added. Following 30 minutes of incubation at 4° C, the cells were washed, suspended 
in  100 µl  1 % paraformaldehyde and analyzed by ﬂ owcytometry.
Homology search in protein database · The search for sequence homology of the overlapping 
HPV 16 E2 peptides in a protein database (SwissProt) was performed using standard Basic Local Align-
ment Tool (BLAST: www.ncbi.nlm.gov/blast/blastcgi). Statistical signiﬁ cance threshold (EXPECT) was  10 
[29]. Reported matches revealing > 70 % aminoacid homology with HPV 16 E2 peptides were included. 
Statistical analysis · Statistical analysis of the E2-speciﬁ c responses as measured by ELISPOT were 
tested by the unpaired (two-tailed) T-test with Welch correction using GraphPad InStat (GraphPad 
Software Inc.).
results
High reactivity of healthy donor PBMC against HPV 16 E2-derived peptides 
We examined the proliferative responses of healthy donor PBMC against HPV 16 E2 protein by using 
an array of overlapping 30-mer peptides covering the entire E2 sequence. Incubation of freshly iso-
lated PBMC of 8 HLA-typed donors with each of the 23 E2-derived 30-mer peptides showed that 
4 out of 8 donors reacted to 2 or more of the peptides. The observed E2 peptide-speciﬁ c prolifera-
tive responses were remarkably strong (Table  1). In all cases more than 75 % of the parallel micro-
cultures reacted against the stimulating peptide. For instance, in two independent experiments we 
found the peptide-speciﬁ c proliferation of donor # 8 against peptides E23 1-60, E246-75, E29 1- 120, E2 15 1- 180, 
E227 1-300 and E2286-3 15 to exceeded background proliferation in 75-94 % of all eight parallel microcul-
tures tested (Figure  1). This points at the presence of a very high frequency of E2-speciﬁ c T cells in the 
PBMC isolates. In particular, PBMC of donors # 3, 5 and 8 displayed strong responses with a broad 
speciﬁ city. Please note that the 30-mer peptides have a  15 amino acid overlap with their neighbor-
ing peptides. Consequently, responses against adjacent peptides (e.g. donor # 3, E23 1-60 and E246-75) 
most likely involve the same epitope, whereas responses against non-adjacent peptides are directed 
against distinct epitopes. Not only the frequency of responding cultures but also the magnitude 
of the proliferative responses were remarkably high. The peptide-speciﬁ c proliferation of several cul-
tures from donors #3, 5 and 8 exceeded background with mean stimulation indices ranging from 
9.2– 16.5 and, as such, are comparable to responses found against the tetanus toxoid antigen in 
several of the donors (#3, 4, 5 and 7; SI ranging from  13.3–25; see Table  1). These stimulation indi-
ces clearly exceed the threshold (SI ≥ 3) that is commonly used for the detection of memory T cell 
responses [30, 3 1]. Note that responses against tetanus toxoid are considerably higher in some of 
the other donors (SI ≥ 50 in donors # 2, 6 and 8), but that these strong values most likely represent 
very broad responses against multiple epitopes comprised by an entire antigen, rather than against 
a single 30-mer E2-peptide. Taken together, our data indicate that the T cell repertoire of healthy 
donors can contain particularly high frequencies of T cells speciﬁ c for the HPV 16 E2 antigen resulting 
in vigorous proliferative responses, and suggest that these responses may reﬂ ect T cell memory.
HPV 16 E2-speciﬁ c Th cultures recognize naturally processed epitopes. 
The proliferation data pointed at the existence of multiple immunogenic Th-epitopes within HPV 16 
E2. We performed a more detailed analysis of the nature and speciﬁ city of such responses, thereby 
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focusing on the C-terminal region, which our data (Table  1) revealed to contain several highly immu-
nogenic peptides. The overlapping peptides comprised in this C-terminal region (E227 1-300; E2286-3 15; 
E230 1-330; E23 16-345; E233 1-365) were tested for their capacity to bind to HLA-DR molecules. Each of the 
ﬁ ve peptides showed intermediate to strong binding to two or more of the common HLA-DR mol-
ecules tested (Table 2), which supports the notion that these peptides can indeed represent class II 
MHC-restricted Th-epitopes. Subsequently, long-term E2-speciﬁ c Th cultures were generated through 
stimulation of PBMC from HLA-typed healthy blood donors at weekly intervals with either peptides 
E227 1-300 and E2286-3 15, peptides E230 1-330 and E23 16-345, or with peptide E233 1-365. PBMC from 2 donors 
showed strong peptide-speciﬁ c proliferative responses against one or more of the stimulating pep-
tides (data not shown). Through cloning via limiting dilution of these cultures, we succeeded in the 
isolation of stable T cell clones, uniformly displaying a CD4+CD8– phenotype, against four distinct 
peptide-epitopes. Two of these Th-clones were established from HLA-DR 15(2)-, -DQ6( 1)-PBMC stimu-
lated with E230 1-330 and E23 16-345. Although both Th-clones recognized E230 1-330, in depth analysis of 
the speciﬁ city of these Th-clones revealed that they recognized distinct, yet overlapping, sequences, 
restricted by different class II HLA molecules. One of the clones recognized peptide E23 16-330 in the 
context of HLA-DR 15(2), whereas the other clone was speciﬁ c for peptide E23 1 1-325 in the context 
of HLA-DQ6( 1) (Figure 2a,b). Fine-mapping of the peptides recognized by the two other Th-clones 
revealed a similar relationship, in that one recognized peptide E2346-355 in the context of DR 15(2), 
whereas the other reacted against the E235 1-365 peptide in a DR 1-restricted manner, both present in 
E233 1-365 (Figure 2a,b and not shown). Notably, these data are in correspondence with the peptide 
binding data in Table 2, in that longer variants of these DR 15(2) and DR 1-restricted epitopes were 
indeed found to bind to the restricting HLA molecules (binding assay not available for HLA-DQ6).
 Further evidence that the four E2 peptides identiﬁ ed represent physiologically relevant Th epit-
opes is provided by the fact that the E2-speciﬁ c Th-clones did not only respond against peptide-
loaded APC, but also speciﬁ cally responded against APC that were pulsed with the E2 protein (Figure 
2a-d, upper panels). Because in the latter case presentation of the peptide epitopes depends on 
Figure  1. The E2 protein contains highly immunogenic sequences. Freshly isolated PBMC derived from healthy blood donors 
were stimulated with the indicated HPV 16 E2 peptides ( 10 µg/ml) for 6 days after which proliferation was measured by [3H]-
thymidine incorporation. a + b represent two independent experiments in which donor 8-derived PBMC showed strikingly strong 
proliferative responses against multiple E2 peptides. Circles represent proliferation of the individual microcultures. The line indi-
cates the cut-off value of mean + 3 ¾ SD of medium control. 
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uptake and processing of the E2 antigen, and not merely on exogenous loading of class II molecules 
at the APC cell surface, these data provide deﬁ nite proof that the four E2 peptides recognized by 
our Th-clones correspond to naturally processed epitopes. Finally, all four Th-clones produced IFNg 
upon antigenic stimulation, which is indicative of a Th-type  1 cytokine proﬁ le. Taken together our 
data show that the T cell repertoire of healthy individuals harbors IFNg-secreting E2-speciﬁ c CD4+ 
Th-cells (Figure 2a-d, lower panels).
Table  1. Immunogenicity of HPV 16 E2-derived peptides.
 Donor  1a  Donor 2  Donor 3  Donor 4 Donor 5 Donor 6 Donor 7 Donor 8
 DR4, 7 DR4, 6 DR 1, 3 DR2, 4 DR2, 7 DR3, 5 DR 1, 4 DR2, 6
E2 1-30 b · · · · · · · ·
E2 16-45 · · · · · · · ·
E23 1-60 · ·  8 1 % (8,8)c · · · · 88 % (8,6)
E246-75 · · 88 % (5,5) · 8 1 % (6,8) · · 94 % (6,5)
E26 1-90 · · · · · · · ·
E276- 105 · · · · · · · ·
E29 1- 120 · · · · 94 % (4,8) · · 75 % (4,0)
E2 106- 135 · · · · · · · ·
E2 12 1- 150 · · · · · · · ·
E2 136- 165 · · · · · · · ·
E2 15 1- 180 · · 8 1 % (6,4) · · · · 8 1 % (4, 1)
E2 166- 195 · · 94 % ( 16,5) · 8 1 % ( 10,6) · · ·
E2 18 1-2 10 · · · · · · · ·
E2 196-225 · · · · · · · ·
E22 1 1-240 · · · · · · · ·
E2226-255 · · · · · · · ·
E224 1-270 · · · · · · · ·
E2256-285 · · · · · · · ·
E227 1-300 · · · · · · · 88 % (4,8)
E2286-3 15 · · 88 % ( 16,2) · · · · 94 % (9,2)
E230 1-330 · · · · · · · ·
E23 16-345 · · · · · · 94 % (4,7) ·
E233 1-365 · ·  100 % ( 1 1,4) · · · 75 % (4, 1) ·
TT  100 % (29, 1)  100 % (56,5)  100 % (25)  100 % ( 16,4)  100 % (23,5)  100 % ( 139)  100 % ( 13,3)  100 % (59)
Indicated are the percentages of positive wells and (mean stimulation index) for positive scoring peptides. Tetanus toxoid 
(TT) at a concentration of  1 LF/ml was used as a positive control.
a  PBMC from 8 healthy blood donors were tested against HPV 16 E2 peptides in short-term proliferation assays.
b  HPV 16 E2 peptides are indicated by the ﬁ rst and last amino acid. 
c  Peptides were scored positive, when the proliferation of ≥ 50 % of the test wells exceeded the mean proliferation + 3 ¾ SD 
of the control wells, and the mean stimulation index (SI) of all test wells over medium control wells was more than 3 in two 
independent assays. 
Table 2. Binding afﬁ nity of HPV 16 E2-derived peptides to different HLA-DR types.
Sequence HPV 16 E2 DR 1 DR2 DR3 DR4
FNSSHKGRINCNSNTTPIVHLKGDANTLKC 27 1-300a 22b 65 37 >70
TPIVHLKGDANTLKCLRYRFKKHCTLYTAV 286-3 15 8 68 20 >70
LRYRFKKHCTLYTAVSSTWHWTGHNVKHKS 30 1-330 6 8 >70  10
SSTWHWTGHNVKHKSAIVTLTYDSEWQRDQ 3 16-345 6 55 30 >70
AIVTLTYDSEWQRDQFLSQVKIPKTITVSTGFMSI 33 1-365 8 20  10  15
a  Sequence, ﬁ rst and last amino acid number of the peptide in the HPV 16 E2 protein are indicated.
b  Binding afﬁ nity of each peptide is expressed as the IC50 value: this is the peptide concentration (µM) at which binding of the 
standard ﬂ uorescence labeled peptide is reduced to 50 % of its maximal value. >70 respresents undetectable binding.
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Detection of HPV 16 E2 speciﬁ c memory Th-cells in healthy individuals
The strikingly frequent detection of HPV 16 E2-speciﬁ c Th immunity in healthy individuals, as 
described in the ﬁ rst paragraph, prompted us to analyze whether the underlying T cell repertoire 
would represent immunological memory as a the result of previous encounter with antigen, or 
whether it would primarily consist of particularly abundant naïve T cell precursors speciﬁ c for this 
antigen. In view of the high incidence of, generally transient, genital HPV infections in young sexually 
active individuals [2, 3, 6, 32], as well as the prominent expression of E2 during HPV infection [22], 
it is conceivable that T cell memory against E2 could be found in healthy subjects. We examined the 
nature of the HPV 16 E2-speciﬁ c immunity detected by us through analysis of the E2-speciﬁ c reactiv-
ity of the CD45RO+ fraction of healthy donor PBMC, which contains antigen-experienced T cells but 
is devoid of their naïve counterparts. Because we found the T cell repertoire of healthy donors to 
contain IFNg-producing Th-cells (Figure 2), we measured the antigen-speciﬁ c T cell responses through 
IFNg ELISPOT. We ﬁ rst analyzed the reactivity of CD45RO+ T cells of two healthy donors while focus-
ing our attention on a selection of E2 peptides that on basis of our previous experiments (Table  1) 
appear to be localized in the most immunogenic regions of HPV 16 E2. Interestingly, these CD45RO+ 
PBMC were found to respond against multiple E2 peptides (Figure 3a), supporting the notion that 
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Figure 2. The C-terminal domain of HPV 16 E2 contains naturally processed Th-epitopes. PBMC of HLA-DR and -DQ 
homozygous healthy blood donors (respectively DR 15(2), DQ6( 1) and DR 1, DQ 1) were stimulated at weekly intervals with 
peptides E230 1-330+E23 16-345 or peptide E233 1-365. Four stable Th-clones (A-D) derived from these polyclonal cultures were tested 
in 3-day proliferation assay, or stimulated for 24 hrs to measure the production of IFNg by ELISA. Th-clones recognized 
not only peptide-loaded (5 µg/ml) APC but also E2 protein-loaded APC ( 10 mg/ml) indicating that the recognized peptides 
represent naturally processed Th-epitopes (upper panels). Fine-mapping of the minimal epitope (middle panels) and HLA-class II 
restriction using HLA-DR, -DQ and -DP blocking antibodies (lower panels) of these Th-clones is shown.
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healthy subjects can display HPV 16E2-speciﬁ c T cell memory. We conﬁ rmed that the responding IFNg-
producing cells belonged to the CD4+ Th-cell subset by employing IFNg intracellular cytokine stain-
ing instead of ELISPOT as a readout (Figure 3b). A broader survey of E2-speciﬁ c reactivity against 
the full array of peptides, using CD45RO+ PBMC from 8 additional healthy donors, revealed that 4 
of these PBMC isolates responded against one or more of the HPV 16 E2 peptides (Figure 4 and not 
shown). Taken together, our data reveal the presence of CD45RO+ memory-type, IFNg-secreting Th-
cells reactive against HPV 16 E2 peptides in approximately half of the healthy donors tested. Notably, 
the incidence by which these responses are detected is very similar to that of the strong (SI ≥ 3) pro-
liferative responses found in total PBMC (Table  1), implicating that also these responses are likely to 
represent reactivity by memory T cells rather than by in vitro primed naïve T cells.
Cross-reactivity of HPV 16 E2 speciﬁ c Th-clones with peptide sequences of other HPV types
Due to the common nature of HPV infections, a majority of the human population is likely to 
encounter multiple HPV types [3, 33]. Furthermore, the protein sequences of the viral gene products 
are conserved to considerable extent between HPV types. It is therefore possible that at least a frac-
tion of the T cell repertoire induced by a previous encounter with a given type of HPV could cross-
react, and therefore cross-protect, during subsequent infection with other HPV types. Alignment of 
the sequence of the HPV 16 E2 protein with that of various other HPV types revealed that it is most 
prominently conserved with that of other high-risk types (Figure 5c). Although this conservation is 
somewhat less conspicuous when the HPV 16 E2 sequence is compared to that of low risk or common 
types (Figure 5a,b), it is evident that in all cases maximal conservation is conﬁ ned to certain regions 
within the E2 sequence. In particular, three areas of HPV 16E2 share homology with E2 of other 
HPV types: the N-terminal portions E23 1- 120 and E2 15 1- 195 and the C-terminal portion E227 1-365. These 
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Figure 3. HPV 16 E2-speciﬁ c Th-cells are contained within the CD45RO+ memory fraction of healthy donor-derived PBMC. 
CD45RO+ PBMC of two different donors (upper and lower panels of a and b) were isolated by MACS magnetic bead isolation 
and stimulated with the indicated pools of two peptides (e.g. E2 3 1-75: E23 1-60 and E246-75). The number of antigen-speciﬁ c T cells 
was analysed by IFNg ELISPOT at day  1 1 (a). The mean number of spots + SD per 50,000 PBMC are shown; bars ± SD. A mix 
of three recall antigens (MRM) was used as a positive control. HPV 16 E2-speciﬁ c T cells are contained in the CD4+ T cell subset 
(b). In an independent experiment, CD45RO+ PBMC of the same subjects were stimulated with indicated peptide pools and the 
percentage of IFNg-producing cells were analyzed by intracellular cytokine staining. The percentage of CD45RO+ PBMC produc-
ing IFNg in response to peptide stimulation (right panels) versus medium control (left panels) is indicated. 
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regions co-localize with the major functional domains of E2, in that the N-terminal domain harbors 
the transcriptional activation functions of this protein whereas the C-terminal portion mediates its 
sequence-speciﬁ c DNA-binding properties. The intervening sequences ranging from residues 2 10 
to 270 constitute the so-called hinge-region connecting the two key functional domains, which is 
poorly conserved between HPV types and also shows considerable intratypic variation for HPV 16 
[34-36]. Interestingly, our analyses of E2-speciﬁ c responses in short-term proliferation assays have 
revealed that the most immunogenic peptides are clustered in the two conserved domains of the 
HPV 16 E2 sequence (see Table  1 and summary in Figure 5d). In view of these considerations, we 
tested whether our established Th-clones, raised against epitopes derived from the C-terminal part 
of the HPV 16 E2 sequence (Figure 2), would be capable of cross-reacting with E2 peptides of a 
number of other HPV types that shared maximal homology with HPV 16 with respect to this particu-
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Figure 4. HPV 16 E2-speciﬁ c memory Th-responses are frequently detected in healthy individuals. The CD45RO+ PBMC frac-
tion of 8 healthy blood donors were incubated with the full array of HPV 16 E2 peptides divided in six pools of 4 peptides (e.g. 
E2  1-75: E2 1-30, E2 16-45, E23 1-60 and E2 46-75). The number of antigen-speciﬁ c T cells was analyzed by IFNg ELISPOT at day  1 1. In 4 out 
of 8 blood donors HPV 16 E2-speciﬁ c responses were detected at day  1 1. The mean number of spots + SD per 50,000 PBMC are 
shown; bars ± SD. Responses that signiﬁ cantly exceeded the medium control, as determined by a student t-test, are indicated 
with an asterisk (*). Pools of Inﬂ uenza Matrix  1 peptides and a mix of recall antigens (MRM) were used as positive controls. 
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lar E2 sequence. Indeed, the DQ6-restricted E23 1 1-325-speciﬁ c Th-clone showed strong recognition of 
the corresponding peptides of HPV types 26, 3 1, 33 and 45 (Figure 6a). The amino acid homology 
within this epitope varies from 73 to 87 % (identical or amino acids with similar physico-chemical 
properties). Our other Th-clones did not reveal considerable cross-reactivity for highly homologous 
E2 peptides of other HPV types (Figure 6b and not shown). These data suggest that part of the 
HPV 16 E2-reactive Th memory detected in our assays may relate to encounter of HPV types other 
than HPV 16, but that the majority of this immune repertoire was most likely established through 
encounter with HPV 16 itself.
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Figure 5. Highly immunogenic regions, as determined in the T cell proliferation assays are contained in the most con-
served regions of HPV 16 E2. The sequences of the HPV 16 E2 30-mer peptides used in our immunological experiments were 
compared with the corresponding sequences of other HPV types using BLAST (see materials and methods). For each of these 
HPV 16 E2 peptides, the percentage of HPV types sharing > 70 % amino acid homology (identical or with similar physico-
chemical properties) with HPV 16 is depicted. Distinction is made between HPV types 2,3,4, 10,26,27,28,29,49 associated with 
common/ﬂ at warts (a), low-risk anogenital HPV types 6, 1 1,40,42,43,44,54,55,6 1,62,64,67,7 1,74 (b), and high-risk anogenital HPV 
types  16, 18,3 1,33,35,39,45,5 1,52,52,56,58,66,69,68,34,53,59 (c). The bottom panel of this ﬁ gure (d) constitutes a summary of the 
proliferation assay data as obtained with the overlapping set of HPV 16 E2 30-mer peptides (Table  1 and Figure  1). Indicated are 
the mean stimulation indices (SI) of all the assays (8 donors, tested twice). The mean SI is deﬁ ned as the mean of the test well 
values divided by the mean of the control wells. 
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Discussion
Through analysis of the proliferative responses in PBMC cultures from healthy subjects against the 
HPV 16 E2 antigen we have demonstrated that this protein contains highly immunogenic peptide 
sequences to which strong T cell reactivity is detected. Subsequent testing of the CD45RO+ memory 
fraction of healthy donor PBMC revealed the presence of HPV 16 E2-speciﬁ c IFNg-secreting CD4+ T 
cells in approximately half of these donors. Taken together, our data demonstrate that the T cell 
repertoire of a majority of the healthy subjects contains particularly high frequencies of Th-cells reac-
tive against the HPV 16 E2 antigen and that this repertoire has been established through previous 
encounter with HPV 16 and/or other HPV types.
 By employing the short-term proliferation assay we have previously monitored the reactivity of 
healthy donor PBMC against a series of HPV 16 E7-derived peptides [ 19]. In this former study we 
scored all responses positive that were above background (mean + 2 ¾ SD). We choose these non-
stringent criteria because we did not expect HPV 16 E7-speciﬁ c T cell memory in healthy subjects. 
Indeed, we did not record any HPV 16 E7-speciﬁ c responses in healthy donor PBMC with a stimu-
lation index of more than 3, the cutoff level commonly used for identiﬁ cation of memory type T 
cell responses [30, 3 1]. In contrast, proliferation assays with HPV 16 E2, as described in the present 
study, revealed overwhelmingly strong responses. Because half of the healthy donor PBMC showed 
responses with a magnitude comparable to that with recall antigens (SI ≥ 3), we decided to focus our 
study on these very strong responses. In agreement with the magnitude of these responses, we now 
demonstrate that the T cell repertoire of approximately half of healthy donors comprises CD45RO+ 
memory-type T cells against HPV 16 E2. Although the low numbers of individuals tested precludes 
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Figure 6. Cross-reactivity of HPV 16 E2-speciﬁ c Th-clones against corresponding peptide sequences derived from different 
HPV types. All four Th-clones were tested for cross-reactivity with peptides derived from other HPV types sharing maximal homol-
ogy with HPV 16 with respect to their cognate epitope. The DQ6-restricted E23 1 1-325-speciﬁ c Th-clone showed strong recognition 
of the homologous peptides derived from HPV types 26, 3 1, 33 and 45 (a), whereas the other three Th-clones, including the 
DR 1-restricted E235 1-365-speciﬁ c Th-clone (b), recognized only the HPV 16 E2-derived peptide. In the amino acid sequence of homolo-
gous peptides the amino acid mismatches (underlined) and non-identical amino acids with similar physico-chemical properties 
(bold) compared to the HPV 16 sequence are indicated. The irrelevant non-related peptide E22 1 1-240 was used as negative control.
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deﬁ nitive conclusions, the T cell reactivity detected by proliferation assay and ELISPOT revealed a 
similar peptide-reaction pattern.
 Importantly, we have not found any previous report concerning the presence of memory T cell 
responses against E2 or any of the other non-structural HPV 16 proteins in healthy individuals. In 
fact, HPV 16 infected individuals diagnosed with CIN were particularly found to display Th-responses 
against the C-terminal domain of HPV 16 E2 at the time of viral clearance, whereas no E2-speciﬁ c 
Th-responses were detected in the healthy control group [25]. However, the methodology applied 
for analysis of these responses is essentially different. The IL-2 bio-assay used in the study by 
Bontkes et al. measures the total response of all cultured cells and therefore lacks the sensitivity 
of single cell cytokine analysis applied in the present study. Furthermore, the pre-selection of the 
CD45RO+ memory PBMC pool directly ex-vivo (Figures 3 and 4) allows enrichment of HPV 16 E2-
speciﬁ c memory T cells, as well as re-activation of so-called central memory T cells by extended cul-
turing of these cells in vitro without the risk of in vitro priming of naive T cells. By employing this 
highly sensitive method, we now reveal the presence of E2-speciﬁ c Th-cells in healthy individuals. 
It is interesting to note that HPV 16 E2-speciﬁ c IgG and IgA responses have also been detected in 
healthy individuals [37, 38]. Since antibody isotype switching is Th-dependent, these observations 
constitute an independent conﬁ rmation of the presence of E2-speciﬁ c Th memory in healthy subjects 
as reported in the present study.
 In pre-clinical animal models, in particular the CRPV model, it was shown that the E2-speciﬁ c 
immune response plays a role in spontaneous papilloma regression [23] and, furthermore, that 
regression could be enhanced by E2-directed vaccination [24, 39]. Also in humans, there are strong 
indications that the E2-speciﬁ c immune response is associated with HPV clearance [25]. The strong 
immunogenicity of the E2 protein, together with the presence of E2-speciﬁ c Th-immunity in a large 
proportion of the human population, could be exploited in immunotherapy and prevention of 
HPV 16-positive CIN lesions. Boosting of pre-existing E2-speciﬁ c Th-memory, as established by previ-
ous encounters with HPV 16 or other HPV-types, can provide the powerful, pathogen-speciﬁ c T cell 
help that is required for optimal induction of CTL responses against various HPV 16 antigens includ-
ing E2, E6 and E7 [40, 4 1].
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Abstract · Genital HPV infection is common and the majority of infected individuals successfully 
deal with this virus. Clearance of HPV is presumably mediated by T cells but HPV 16 speciﬁ c T cell 
memory was usually detected in patients with progressive disease and not in healthy subjects, sug-
gesting that HPV-immunity comes too late. We now show the presence of HPV 16 E6-speciﬁ c memory 
T-helper responses in a major fraction ( 12/20) of healthy individuals by application of the IFNg-
ELISPOT assay. Although nearly all E6-peptides were recognized, the majority of the responders tar-
geted peptide sequences of the C-terminal half (E68 1- 158) of HPV 16 E6. In a direct comparison, the 
presence of HPV 16 E6-speciﬁ c T cells coincided with HPV 16 E2-speciﬁ c T cell reactivity in healthy 
individuals, whereas hardly any HPV 16 E7-speciﬁ c Th-immunity was found. This indicates that the 
induction of T cell reactivity against HPV 16 E7 is sub-optimal during infection when compared to 
that against HPV 16 E2- and E6. In conclusion, the presence of HPV 16 E6-speciﬁ c Th-memory in the 
healthy population demonstrates that HPV infection leads to T cell immunity against immediate 
early proteins expressed during infection. Because this HPV 16 E6-speciﬁ c T cell immunity was fre-
quently detected in healthy subjects, our data suggest that the observed IFNg-producing proliferat-
ing T cells circulating in the peripheral blood play a role in protection against persistent HPV infec-
tion and associated development of malignancies.
Frequent display of HPV16 
E6-speciﬁ c memory T-helper cells 
in the healthy population as witness 
of previous viral encounter
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Introduction
Genital infection of both men and women with oncogenic human papillomavirus (HPV) types is 
quite common [ 1-3], however, only a minor fraction of infected subjects develop progressing epithe-
lial lesions or cancer [4-6]. Most pre-malignant lesions regress spontaneously. This is likely mediated 
by cellular immune responses because regressing (genital) warts are inﬁ ltrated with CD4+ T cells, 
CD8+ T cells and macrophages [7, 8]. The role of immune surveillance in controlling infection by 
various HPV types is further indicated by the increased incidence of HPV infections, HPV-associated 
warts, cervical intra-epithelial neoplasia (CIN) lesions and cervical carcinoma in immunocompro-
mised subjects [9- 1 1]. This notion is sustained by the observations that papillomavirus-speciﬁ c T cell 
immunity can protect against malignant transformation of papillomas in rabbits [ 12]. 
 Examination of HPV-speciﬁ c T cell immunity in patients with HPV+ cervical lesions has revealed 
the occasional presence of cytotoxic T-lymphocyte (CTL) responses against the E6 and E7 oncopro-
teins [ 13- 18]. Because an overt correlation between the presence of such CTL immunity and regres-
sion or progression of the disease has so far not been found, the functional signiﬁ cance of these 
responses is at present a matter of debate. Most likely, not only CTL numbers, but also their activa-
tion state needs to be taken into account. Accumulating evidence pertinently shows that proper acti-
vation of CTL requires delivery by professional antigen presenting cells (APC) of strong co-stimula-
tory signals in addition to the antigenic signal. Especially in the case of anti-viral immunity in chronic 
infections, this co-stimulatory action of APC requires virus-speciﬁ c T-helper (Th) cell activity [ 19-23]. 
We previously found that E7-speciﬁ c Th immunity was frequently observed in HPV 16+ patients, but 
only rarely in healthy subjects [24]. In contrast, over 50 % of the healthy subjects tested showed very 
strong memory-type Th responses against one or more epitopes of HPV 16 E2. It is conceivable that 
this Th memory is a witness of previous encounter with HPV 16 or possibly other HPV-types encoding 
cross-reactive epitopes [25]. Apparently, the T cell immune system deals with the E2 and E7 antigens 
in a completely different manner. Because high expression of E6/E7 and E2 is mutually exclusive 
during infection and subsequent tumor development, these ﬁ ndings prompted us to now also moni-
tor Th-immunity against HPV 16 E6 in patients and healthy subjects. Similar to what was found for 
E2, memory Th-immunity against E6 was frequently and abundantly observed in healthy subjects, 
suggesting a role for these Th-cells in protection against re-infection by high-risk HPV and as such 
the HPV-mediated induction of anogenital lesions and cervical cancer.
Materials and Methods
Subjects and Controls · PBMC of anonymous healthy blood bank donors (D) were obtained after 
informed consent. Because these donors are anonymous only a general age and gender distribu-
tion can be given. The currently studied healthy individuals displayed a median age of 44 years old 
(range 25–68) and comprised of 40 % women and 60 % males. No additional data is available, nor 
was serum available to determine the HPV infection status by serological analysis. However, donors 
with a known recent history of infection, including abnormal pap-smear, were as part of normal regu-
lations, discouraged to donate blood. The study of the subjects (P) with cervical carcinoma in this 
paper was nested in the “CIRCLE study” that investigates cellular immunity against HPV 16 infected 
cervical lesions. Women presenting with histological proven cervical carcinoma at the department of 
gynecology of the Leiden University Medical Center (LUMC) were, after informed consent, enrolled 
in this study. The study design was approved by the Medical Ethical Committee of the LUMC. Blood 
was drawn at day of treatment prior to surgery. Subjects with stage IB-IIA were treated by a radical 
hysterectomy. The age of the patients ranged between 29 and 76 years old and these women were 
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typed for HPV 16 using HPV 16-speciﬁ c primers on DNA isolated from parafﬁ n-embedded sections of 
biopsies or surgical resection specimens [26]. 
Antigens · A set of peptides spanning the whole HPV 16 E2 protein, consisting of 22 30-mer peptides 
with  15 amino acids of overlap and the C-terminal peptide with a length of 35 amino acids, were 
used for the T cell proliferation assays. They are indicated by the ﬁ rst and last amino acid in the 
protein (e.g. E2 1-30, residues  1-30, and the last peptide E233 1-365). For the ELISPOT assays a large set of 
22-residue long HPV 16 E6 overlapping ( 12 residues) peptides were used to obtain a detailed insight 
in the immunogenic regions of the E6 protein. In addition, 8 HPV 16 E6-derived 32-mer overlapping 
( 14 residues) peptides and 4 HPV 16 E7 35-mer overlapping ( 14 residues) peptides were used for the 
T cell cultures and proliferation assays. These long HPV 16 E2, E6 and E7 peptides were used in the 
proliferation assay to lower the number of PBMC required, as we wanted to use pools of maximal 
two peptides. Pools of four 30-mer peptides, with  15 amino acids overlap, spanning the inﬂ uenza 
matrix  1 protein of A/PR/8/34 (M 1) were used as positive control in the ELISPOT assay. The peptides 
were synthesized and dissolved as described previously [27]. Tetanus toxoid (TT,  1 LF/ml; National 
Institute of Public Health and the Environment, Bilthoven, The Netherlands) was used as positive 
control in the short-term T cell proliferation assays. Recombinant HPV 16 E6 protein and HPV 16 E7 
protein (the latter protein served as control protein in proliferation assays) were produced in recom-
binant E. coli transformed with pET- 19b-HPV 16 E6 and pET- 19b-HPV 16 E7 [24].
Analysis of antigen-speciﬁ c Th-cells by IFNg-ELISPOT · The presence of HPV 16 E6-speciﬁ c Th-cells 
was analyzed by ELISPOT as previously described ADDIN ENRfu [24]. Brieﬂ y, peripheral blood mono-
nuclear cells (PBMC) were seeded at a density of 2 ¾  106 cells/well of a 24-well plate (Costar, Cam-
bridge, MA) in  1 ml of Iscove’s medium (Bio-Whittaker, Verviers, Belgium) enriched with  10 % fetal 
calf serum (FCS; Greiner, Mannheim, Germany), in the presence or absence of 5 µg/ml of indicated 
E6-derived 22-mer peptide. As a positive control, PBMC were cultured in the presence of indicated 
pools of inﬂ uenza A/PR/8/34 M 1 protein-derived peptides, consisting of four overlapping 30 amino 
acid long peptides in each pool, because previous analyses showed that all healthy individuals dis-
played reactivity against one or more of these M 1 peptide pools [24]. Following four days of incuba-
tion at 37° C PBMC were harvested, washed and seeded in six replicate wells at a density of  105 
cells/well on a Multiscreen 96-well plate (Millipore, Etten-Leur, The Netherlands) coated with an 
IFNg catching antibody (Mabtech AB, Nacha, Sweden). Then, the ELISPOT plates were incubated 
for  18 hours at 37° C to allow catching of the antigen-speciﬁ c produced IFNg. The ELISPOT assay was 
further performed according to the instructions of the manufacturer (Mabtech). The number of spots 
was analyzed with a fully automated computer assisted video imaging analysis system (Carl Zeiss 
Vision). Speciﬁ c spots were calculated by subtracting the mean number of spots plus 2 ¾ SD of the 
medium only control from the mean number of spots of experimental wells. Antigen-speciﬁ c T cell 
frequencies were considered to be increased compared to non-responders when T cell frequencies 
were ≥  1 /  104 PBMC [24].
Short-term T cell proliferation assay · Healthy donor-derived PBMC were incubated with  12 pools 
of HPV 16 E2-derived 30-mer peptides, four pools of E6 32-mer peptides and two pools of E7 35-mer 
peptides (each pool containing two overlapping peptides), according to procedures described previ-
ously [25, 27]. Brieﬂ y, freshly isolated PBMC were seeded at a density of  1.5 ¾  105 cells/well in a 
96-well U-bottomed plate (Costar, Cambridge, MA) in 200 µl of Iscove’s medium (Bio-Whittaker) 
supplemented with  10 % autologous serum. In previous experiments, we observed that proliferative 
responses to HPV 16 E2 peptides were relatively reduced with the use of (heat-inactivated) human 
AB serum (Sigma) as compared to autologous serum. HPV 16 E2-, E6- and E7-derived peptides were 
added at a concentration of  10 µg/ml. Medium alone was taken along as a negative control and TT 
served as a positive control. For each peptide pool, 8 parallel microcultures were incubated. Peptide-
speciﬁ c proliferation was measured at day 6 by [3H]-thymidine incorporation. Cultures were scored 
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positive, when the proliferation of ≥ 75 % of the test wells exceeded the mean proliferation plus 
3¾SD of the medium only control wells, and the stimulation index (SI) of the mean test wells over 
mean medium control wells was ≥ 3.
Long-term HPV 16 E6-speciﬁ c T cell cultures · PBMC derived from healthy blood donors were 
incubated with 8 overlapping 32-mer peptides spanning the entire HPV 16 E6 protein at a concentra-
tion of  1 mg/ml in Iscove’s medium (Bio-Whittaker) supplemented with  10 % re-calciﬁ ed autologous 
plasma. One day after stimulation, T cell growth factor (TCGF; Biotest, Dreieich, Germany) was added 
at a ﬁ nal concentration of 5 %. At day  10, the cell culture was harvested and incubated with autolo-
gous monocytes and E6 peptides ( 1 mg/ml) at a  10: 1 ratio for  16 hours, after which T cells producing 
IFNg in response to the E6 peptides were enriched by means of a cytokine secretion assay (Miltenyi, 
Biotech, Bergisch Gladbach, Germany). This assay is based on a bi-speciﬁ c antibody recognizing  1) 
the IFNg molecule and 2) the CD45 molecule. The captured IFNg is detected by a PE-labeled second-
ary antibody, and subsequent magnetic labeling allows enrichment of the antigen-speciﬁ c cells. The 
isolated cells were cultured for  10- 14 days with irradiated autologous PBMC at  1: 10 ratio and  10 % 
TCGF without any further addition of antigen. The polyclonal T cell culture was tested for recognition 
of E6 peptides (5 mg/ml) and protein ( 10 mg/ml) in a 3-day proliferation assay. Autologous adherent 
monocytes were used as APC, and proliferation was measured by [3H]-thymidine incorporation.
Results
E6-speciﬁ c IFNg-secreting Th-cells in HPV 16 positive cervical cancer patients 
In addition to E7, the E6 oncoprotein is essential for maintenance of the transformed state in cervi-
cal carcinoma. Both proteins are thus interesting targets for anti-tumor T cell immunity. We therefore 
extended our previous analysis of HPV 16 E7-speciﬁ c Th-immunity in HPV 16+ cervical cancer patients 
[24] to the E6 antigen. Hence, PBMC of  1 1 HPV 16+ cervical cancer patients were stimulated with a 
set of overlapping 22-mer peptides covering the complete HPV 16 E6 protein, after which the number 
of IFNg-producing E6-speciﬁ c Th-cells was determined by ELISPOT. In 3 of the  1 1 HPV 16+ patients 
(P4, P5, and P8), HPV 16 E6-speciﬁ c Th-frequencies ≥ 1/ 10,000 PBMC were demonstrated. Based on 
our experience, responses of such a magnitude are clearly positive whereas responses lower than this 
frequency may fall within background reactivity [24]. Patient P4 responded to peptide E63 1-52 and 
E6 13 1- 152 indicating the presence of memory Th-cells speciﬁ c for two distinct epitopes. The other two 
patients (P5 and P8) responded to only one E6 peptide, suggesting that in both cases a single E6-
epitope was recognized (Table  1). Overall, the frequency and magnitude of Th 1 type response against 
E6 detected in patients is comparable to that previously found for E7 [24]. 
Frequent memory Th-reactivity against HPV 16 E6 in healthy blood donors
We subsequently analyzed whether these E6-speciﬁ c responses are also detectable in healthy donors, 
because this population undoubtedly includes individuals who have effectively dealt with HPV 16 
infection [3, 6, 28]. Therefore, we assessed the presence of HPV 16 E6-speciﬁ c Th-cells in the blood 
of a group of 20 healthy individuals. Interestingly,  12 out of 20 healthy blood donors showed HPV 16 
E6-speciﬁ c Th type  1 responses upon stimulation with one or more of the HPV 16 E6 22-mer peptides 
(Table  1). Analysis of the reactivity pattern revealed that most responses detected were directed 
against peptide sequences of the C-terminal half (E68 1- 158) of HPV 16 E6 (Table  1). The magnitude 
of the E6-speciﬁ c responses was very similar to that found in patients. However, the fraction of 
healthy donors showing strong IFNg Th responses against E6 peptides appears higher than that of 
the patients (60 % versus 27 %). Furthermore, some of the healthy subjects reacted even against 
four or more E6-peptides (range  1–7) whereas the three patients responded to one or two peptides 
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only. It must be noted, however, that also the incidence and breadth of the response against the 
inﬂ uenza M 1 antigen is higher in healthy subjects (Table  1), indicating an overall reduced immunity 
in patients.
 To further characterize the observed HPV 16 E6-speciﬁ c IFNg-responses in healthy subjects, the 
E6-induced proliferation capacity of PBMC was analyzed. Freshly isolated PBMC of 5 healthy donors 
were stimulated with a pool of eight of the long 32-mer overlapping HPV 16 E6-peptides for  10 
days and the responding T cells were isolated based on the E6-speciﬁ c IFNg-production using 
cytokine secretion assay and magnetic cell sorting (MACS). Flow cytometric analysis of the T cells 
speciﬁ cally responding to E6 revealed that these T cells resided in the CD4+ fraction only (Figure  1). 
Following a  14-day period of non-speciﬁ c expansion, the resulting T cell cultures were tested for their 
proliferative capacity to both E6 peptides and E6 protein, as the latter will indicate their capacity 
to respond to naturally processed and presented antigen. From 3 of these 5 cultures we were able 
to isolate IFNg-producing HPV 16 E6-speciﬁ c Th-cells able to proliferate not only upon stimulation 
with peptide but also to E6 protein pulsed APC (Figure  1). Two subjects (D2 1 and D23) predominantly 
responded to E673- 109 and E6 127- 158 whereas the third donor (D22) displayed a broader reaction 
pattern (Figure  1). The area covered by E673- 109 and E6 127- 158 was also frequently recognized when 
the E6-response was analyzed by ELISPOT (Table  1). Taken together, our data demonstrate that 
the memory T cell repertoire of the majority of healthy individuals contains proliferative and IFNg-
producing CD4+ Th-cells capable of reacting against the HPV 16-derived E6 oncoprotein.
Table  1 . HPV 16 E6-speciﬁ c T-helper responses as measured by IFNg-ELISPOT.
 HPV 16 E6a Inﬂ uenza M 1
  1-22  1-32  1-42  1-52 4 1-62 5 1-72 6 1-82 7 1-92 8 1- 102 9 1- 1 12  10 1- 122  1 1 1- 132  12 1- 142  13 1- 152  137- 158 P 1  P2  P3  P4
P 1 · · · · · · · · · · · · ·  · · · · · ·
P2 · · · · · · · · · · · · · · · · ·  10 ·
P3 · · · · · · · · · · · · · · · · · · ·
P4 · · · 28b · · · · · · · · ·  13 · · · · ·
P5 · · · · · · · · · · · · · 22 · · · 62 30
P6 · · · · · · · · · · · · · · · · · · ·
P7 · · · · · · · · · · · · · · · · · · ·
P8 · · · · ·  1 1 · · · · · · · · · 3 1 ·  13 ·
P9 · · · · · · · · · · · · · · · · · · ·
P 10 · · · · · · · · · · · · · · · · ·  15 ·
P 1 1 · · · · · · · · · · · · · · · · · · ·
D 1 · · · · · · · · · · · · · · · ·  16 · ·
D2 · · · · · · · · · · · · · · · · 26  12 ·
D3 · · · · · · · · · · · · ·  18 · 30 ·  19 ·
D4 · · ·  10 · · · · · · · · · · · 22  15  14  10
D5 · · · · · · · · ·  10 · · · · · ·  10  12 37
D6 · 34 · · · · · ·  1 1  14 ·  12  10 · · · 33 4 1 ·
D7 · · · · · · · · ·  14 · · · ·  14 · 2 1 57 28
D8 · · · · · · · ·  12  14 · · · · · 27 38 34  16
D9 · · · · · · · · · · · · · · · 22  10  14 ·
D 10 · · · · · · · · · · · · · · ·  13 23  19  1 1
D 1 1 · · · · · · · ·   · ·  15  10 27  17 33 28 24 52
D 12 · · · · · · · · · · · ·  14  15 · ·  10  12 ·
D 13 · · · · · · · · · · · · · · · · · · 2 1
D 14 · · ·  10 · · · 20  12 · 28  18 37 40 ·  12 42 28 45
D 15  18  16 ·  15 · · · ·  12 2 1 ·  1 1 · · · 52 68 64 ·
D 16 · · · · · · · · · · · · · · · 39 66 49 48
D 17 · · · · · · · · · · · · · · · · · · 66
D 18 · · · · · · · · · · ·  1 1 · · · · ·  10 ·
D 19 · · · · · · · · · · 33 38 ·  16  13  16  19 27 2 1
D20 · · · · · · · · · · · · · · · · ·  10 38
 a PBMC were stimulated with the indicated HPV 16 E6 22-mer peptides and subsequent IFNg-production by T-helper cells was measured by ELISPOT. 
Inﬂ uenza M 1-derived peptide pools were used to compare HPV-speciﬁ c T cell frequencies with T cell reactivity to a common recall antigen.
 b Number of HPV 16 E6-speciﬁ c memory T-helper lymphocytes per  100,000 PBMC in HPV 16+ subjects with cervical cancer (P) or healthy blood donors (D) 
is given. Speciﬁ c T-helper cell frequencies ≥  1/ 10,000 are depicted.
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Healthy individuals display coinciding Th-responses against HPV 16 E2 and E6, but not against E7. 
We have recently demonstrated frequent HPV 16 E2-speciﬁ c Th-responses in healthy individuals [25], 
whereas Th-immunity against the E7 oncoprotein was rarely found in these subjects [24]. The pres-
ent study revealed that the HPV 16 E6 protein is also frequently targeted by Th-cells in healthy sub-
jects. To deﬁ ne the relationship between the E2-, E6- and E7-speciﬁ c Th response in healthy individu-
als, the presence of Th reactivity against these three antigens was analyzed in parallel. Fresh PBMC 
samples derived from  12 healthy blood donors were stimulated with  18 pools of two overlapping 
30-35mer peptides that together cover the entire sequences of HPV 16 E2, E6 and E7, and T cell 
proliferation was evaluated after 6 days of culture as described previously [25]. A stimulation index 
(SI) exceeding 3 was applied as a threshold, as this is commonly used for the detection of memory T 
cell responses [29, 30]. The incidence and speciﬁ city of the proliferative responses against HPV 16 
E2 and E6 were comparable to our previous ELISPOT experiments (Table  1) [25]. One donor (D33; 
Figure 2) displayed responses against all 3 antigens and 3 donors (D27 (Figure 2), D30 and D37) 
showed speciﬁ c proliferation against E2 and E6 (Table 2). In three other cases (D26, D29, D34) 
responses were only found against E2, whereas one PBMC sample (D3 1) only responded to E6 pep-
tides. Most importantly, a vast majority (8/ 12) of the healthy subjects displayed memory type Th 
responses against HPV 16 E2 and/or E6 in their blood, supporting the notion that encounter with 
high-risk HPV types, including HPV 16, is very common [ 1-3]. Although in certain cases this event may 
result in the prevalence of Th memory against either E2 or E6, rather than against both antigens, 
such immunity against the E7 antigen is only rarely installed (Table 2, Figure 2).
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Figure  1 HPV 16 E6-peptide speciﬁ c INFg-producing Th-cells are able to proliferate against E6 protein-pulsed APC. Freshly 
isolated PBMC of donors (D) D2 1-D25 were stimulated with a pool of 8 of the long 32-mer overlapping HPV 16 E6-peptides 
( 1 mg/ml/peptide) for  10 days, and T cells producing IFNg in response to restimulation with E6-peptides were isolated by IFNg-
secretion assay and MACS. a. Flow cytometric analysis showed E6-speciﬁ c IFNg production in the CD4+ T cell subset only. One 
representative example (D2 1) is shown. b-d. Following a  14-day period of non-speciﬁ c expansion T cell cultures were tested for 
their capacity to proliferate upon stimulation with 5 mg/ml of each single E6 peptide (or pools of two peptides) indicated by the 
number of their ﬁ rst and last amino acid or the negative control peptide from HPV 16 E2 (E2 1-30). In addition, T cell proliferation, 
upon stimulation with  10 mg/ml HPV 16 E6 protein or the negative control HPV 16 E7 protein is shown. Subjects D24 and D25 did 
not speciﬁ cally respond after the expansion period and are therefore not shown. 
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Discussion 
Data obtained in the few studies that scrutinized HPV-speciﬁ c immunity in HPV 16 positive patients 
suggested that HPV 16 E6-speciﬁ c T cell immunity might play a role in the protection against pro-
gressive HPV 16 infection [ 14, 3 1]. Successful control of viral infection by the cellular immune system 
induces T cell memory and therefore E6-speciﬁ c T cells are expected to be present in those individu-
als who have effectively dealt with infection. Based on the cumulative 24-month incidence of infec-
tion with HPV 16 of 7 % [6], a substantial fraction of the healthy population is expected to harbor 
such T cell memory. Indeed, we could detect HPV 16 E6-speciﬁ c memory Th-immunity in more than 
half ( 17/32) of the healthy subjects by both IFNg-ELISPOT and short-term proliferation assays. Iso-
lated E6 peptide-speciﬁ c Th-cells from such healthy subjects speciﬁ cally reacted upon stimulation 
with HPV 16 E6-protein showing their capacity to respond not only to peptide but also to naturally 
processed HPV 16 E6 protein. 
 Because E6 protein sequences are conserved to considerable extent between HPV types, it is con-
ceivable that infection with a given HPV type induces T cells, which are also able to react with 
peptides of HPV 16. Amino acid sequence analysis revealed that especially the genital high-risk HPV 
types displayed strong homology with HPV 16 E6 (data not shown). Therefore, part of the memory Th 
responses measured in this study might be a reﬂ ection of previous infections with high-risk HPV types 
other than HPV 16. Furthermore, the relatively high incidence and prevalence of (sub-clinical) infection 
with high-risk HPV [3, 6, 28] implies that some of these responses reﬂ ect current HPV infection. 
 In PBMC from patients diagnosed with HPV 16+ cervical carcinoma E6-speciﬁ c Th type  1-immunity 
was detected in about 30 % (3 out of  1 1) of the patients tested. As such, the number of E6-speciﬁ c 
responders does not differ from that of HPV 16+ patients with E7-speciﬁ c Th type  1 reactivity (6 out 
of  16; about 40 %) ([24], and unpublished observations). Based on the frequency of E6-responses in 
Table 2 . Short-term proliferation assay of PBMC from healthy blood donors. 
 E2            E6     E7  TT 
  1-45 3 1-75 6 1- 105 9 1- 135  12 1- 165  15 1- 195  18 1-225 2 1 1-255 24 1-285 27 1-3 15 30 1-345 33 1-365  1-50 37-86 73- 122  109- 158  1-56 43-98
 D26a · 75 %b · · · · · · · 88 % 88 % · · · · · · ·  100 %
   (8.7)        (5.7) ( 1 1.5)        (23.9)
 D27 · 88 %  100 % · · · · · · ·  100 % · 75 %  75 %  75 %  · · ·  100 %
   ( 16.5) (22.9)        (25.5)  (4.8) (8.5)  (20.9)    ( 140.0)
 D28 · · · · · · · · · · · · · · · · · ·  100 %
                    (35.0)
 D29 · ·  100 %  · · · · · · · 88 %  · · · · · · ·  100 %
     (4.7)        (6.3)         ( 15.9)
 D30  · · · · · · · · · · 88 %  · · · 88 %  · · ·  100 %
            ( 13. 1)    (7.5)    ( 125.6)
 D3 1 · · · · · · · · · · · · · · 75 %  · · ·  100 %
                (4.8)    ( 17. 1)
 D32 · · · · · · · · · · · · · · · · · ·  100 % 
                    (25.7)
 D33  · 88 %   100 %   75 %  · · · · · ·  100 %  75 %  · 88 %   100 %  · ·  100 %   100 % 
   (5.4)  (6.0)  (3.5)       (8.8)  (3.4)   (4.2)  (4.6)    (4.6)  ( 16. 1) 
 D34  · 75 %  · · · · · · · 75 %   100 %  · · · · · · ·  100 % 
    (4.8)        (4.4)  (8.2)        (76. 1)
 D35  · · · · · · · · · · · · · · · · · ·  100 %
                    (22. 1)
 D36  · · · · · · · · · · · · · · · · · ·  100 % 
                    (56.5)
 D37 · 75 %  · · · · · · · 75 %  · · · ·  100 %  · · ·  100 %
   (8.9)         (4.3)      (9.5)     (20.7)
 a PBMC from  12 healthy blood donors (D) were tested against HPV 16 E2, E6 and E7 peptide pools, consisting of 2 subsequently overlapping peptides per pool, 
in a short-term proliferation assay. Tetanus Toxoid (TT) at a concentration of  1 LF/ml was used as a positive control. 
 b Indicated are the percentages of positive wells and (mean stimulation index) of all wells for positive scoring peptides. Peptides were scored positive, when 
the proliferation of ≥ 75 % of the 8 test wells exceeded the mean proliferation plus 3 ¾ SD of the medium only control wells, and the mean stimulation index 
(SI) of all test wells over control wells was ≥ 3.
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healthy individuals, the HPV 16 E6 speciﬁ c Th-cells in patients are likely to represent the remnants of a 
failing immune response, whereas Th-reactivity to E7 may reﬂ ect de novo responses following cross-
priming of E7 derived from a progressive tumor. Interestingly, a direct comparison of Th responses 
against HPV 16 E6 and E7 in healthy individuals reveals a different trend of immune activity. Only 
one out of  12 healthy blood donors displayed E7-speciﬁ c Th-immunity, whereas 5 out of these  12 
healthy subjects reacted upon stimulation with HPV 16 E6 peptides. Moreover, we demonstrated that 
E6-speciﬁ c Th responses in general coincided with responses against HPV 16 E2. In addition, if one 
takes into account that probably not all of these anonymous healthy blood donors have encountered 
HPV 16, whereas the patients are all HPV 16+, the percentage of healthy subjects responding to HPV 16 
E6 after successful clearance of the HPV infection is likely to be underestimated. Failure of boosting 
the E6-speciﬁ c Th 1 type immunity may thus be related to progressive infection, which was also sug-
gested by the work of Kadish et al. [3 1]. To address this, a more comprehensive study of HPV 16-speciﬁ c 
immunity in relation to disease and HPV infection status is required.
 Collectively, our data suggest that the induction of Th-cell reactivity against the HPV 16 E7 protein 
is sub-optimal when compared to that against HPV 16 E2 and E6. Recently it was shown that CD4+ 
T cell reactivity against the plantar wart causing low-risk HPV type  1 was predominantly directed 
against the E4 protein (50 %) and to a lesser extent against E6 (20 %). Th-cell reactivity against HPV 1 
E7, like our results with HPV 16 E7, could not be demonstrated [32]. Presently, it is not clear why 
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Figure 2. Proliferative Th-responses against HPV 16 E2, E6 and E7 of two representative donors. Freshly isolated PBMC 
derived from healthy blood donors were stimulated with the indicated HPV 16 peptides ( 10 µg/ml) for 6 days, after which prolif-
eration was measured by [3H]-thymidine incorporation. Tetanus toxoid ( 1 LF/ml) served as a positive control. The open circles 
represent proliferation in each individual microculture, and the line indicates the cut-off value deﬁ ned by mean + 3 ¾ SD of the 
medium control. PBMC of healthy blood donor D27 (a) show signiﬁ cant responses against both E2 and E6, and donor D33 (b) 
displays reactivity against all three antigens.
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Th-reactivity is preferentially induced against the HPV 16 E6 protein and not against E7. Due to the 
nature of HPV infection, induction of T cell immunity is exclusively dependent on cross-presentation 
by epithelial resident dendritic cells (DC), the Langerhans cell [33]. Possibly, the localization of the 
antigen in the infected cell may determine the accessibility of these antigens for Langerhans cells. 
Low-risk and high-risk E7 proteins are expressed in the nucleus of the cell [34] and Th responses 
against this antigen are hardly detected in healthy subjects [24, 32]. The expression of HPV 1 E4 pro-
tein is predominantly cytoplasmic and a large fraction of healthy subjects mount an HPV 1 E4-speciﬁ c 
Th response [32]. Interestingly, the expression of low-risk HPV E6 protein is also restricted to the 
nucleus but E6 of high-risk HPV is expressed in the nucleus and the cytoplasm [34]. This difference 
in localization seems to be reﬂ ected by the low Th-response rate against HPV type  1 E6 protein and 
the frequent induction of HPV 16 E6-speciﬁ c Th-reactivity in healthy subjects. Moreover, the similar 
cytoplasmic and nuclear expression of HPV 16 E2 induces Th-memory in healthy individuals [25, 35].
 In conclusion, the high rate of spontaneous clearance of high-risk HPV infections suggests that in 
general, the Langerhans cell-driven antigen presentation machinery is capable of inducing an effec-
tive immune defense against HPV. Our study is the ﬁ rst to demonstrate the presence of HPV 16 E6-
speciﬁ c memory Th-immunity in the healthy population and shows that HPV infection indeed leads to 
T cell immunity against the (immediate) early proteins E2 and E6 expressed during infection. Because 
the population, in which E2- and E6-speciﬁ c T cell immunity frequently is found, consists of healthy 
subjects, the observed IFNg-producing T cells circulating in the peripheral blood may play a role in 
protection against newly and/or persistent HPV infections and as such the development of cancer. 
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Abstract · Cervical cancer is the possible outcome of genital infection with high-risk Human Pap-
illomavirus (HPV) and is preceded by a phase of persistent HPV infection during which the host 
immune system fails to eliminate the virus. Fortunately, the majority of genital HPV infections are 
cleared before the development of (pre)malignant lesions. Analysis of CD4+ T-helper (Th) immu-
nity against the E2, E6 and E7 antigens of HPV type  16 (HPV 16) in healthy women revealed 
strong proliferative E2 and E6-speciﬁ c responses associated with prominent IFNg and IL-5 secretion. 
This indicates that the naturally arising virus-induced immune response displays a mixed Th 1/Th2 
cytokine proﬁ le. Of all HPV 16+ cervical cancer patients approximately half failed to mount a detect-
able immune response against the HPV 16-derived peptides. The other half of the patients showed 
impaired HPV 16-speciﬁ c proliferative responses, which generally lacked both IFNg and IL-5. This 
indicates that the HPV 16-speciﬁ c CD4+ T cell response in cervical cancer patients is either absent 
or severely impaired, despite a relatively good immune status of the patients, as indicated by intact 
responses against recall antigens. It is highly conceivable that proper CD4+ T cell help is important 
for launching an effective immune attack against HPV, because infection of cervical epithelia by 
this virus is, at least initially, not accompanied by gross disturbance of this tissue and/or strong pro-
inﬂ ammatory stimuli. Therefore, our observations concerning the lack of functional HPV 16-speciﬁ c 
CD4+ T cell immunity in patients with cervical cancer offer a possible explanation for the develop-
ment of this disease. 
HPV 16-positive cervical cancer is 
associated with impaired CD4+ 
T cell immunity against early 
antigens E2 and E6
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Introduction
Cervical encounter with Human Papillomavirus (HPV) generally results in a transient infection, with 
the majority of individuals showing clearance of the virus within  1 year of detection [ 1-4]. Factors 
underlying the lag time between HPV infection and clearance are related to the minimal disturbance 
of the epithelial layer initially caused by the virus, lack of HPV-induced Langerhans cell activation, 
and the capacity of viral proteins to evade innate immune recognition by physically inhibiting spe-
ciﬁ c components of the innate immune system, such as interference with the type I interferon path-
way [5- 10]. Once the process of regression of HPV-induced dysplasia is initiated, it is characterized by 
an inﬂ ux of macrophages and T-lymphocytes, resembling a delayed type hypersensitivity response 
[ 1 1]. Indirect evidence that the adaptive cellular immune system plays a major role in the protection 
against HPV-induced lesions is given by the high incidence of persistent HPV-infections and subse-
quent HPV-related dysplasia in both immunosuppressed transplant patients and HIV infected indi-
viduals [ 12,  13]. An underlying cause of the failing anti-HPV immune response in immunocompetent 
individuals with persistent infection was suggested to be a locally altered cytokine environment with 
an increase in IL- 10 production and a decrease in proinﬂ ammatory cytokines [ 14- 16]. Others have 
shown that a so-called Th2 type cytokine bias in the peripheral blood of CIN patients was associated 
with more extensive cervical disease [ 17], but the implication of such altered cytokine balance on 
HPV-speciﬁ c immunity has not been determined. 
 Studies analysing T cell responses against viral antigens from the high-risk type HPV 16 in the 
healthy population and several stages of disease do not present an unequivocal relationship 
between protection against HPV 16-induced (pre)malignant lesions and virus-speciﬁ c T cell immu-
nity [ 18-2 1]. We have previously described the presence of IFNg-producing memory CD45RO+CD4+ 
T-helper (Th) cells speciﬁ c for HPV 16 E2 and E6 proteins in the peripheral blood of the majority of 
healthy individuals [22, 23], suggesting a role for these Th cells in protection against HPV 16-induced 
progressive disease. In order to fully appreciate the importance of HPV 16 E2- and E6-speciﬁ c Th 
responses in managing infection and subsequent progressive (pre)malignant lesions, we have per-
formed a detailed analysis with respect to the magnitude and cytokine polarization of this immunity 
and have compared this between healthy subjects and HPV 16+ patients. 
Materials and Methods
Healthy blood donors and patients · A selected group of twenty sexually active young females, 
within the age of  19-3 1 years (median 23 years) participated in this study, after informed consent. 
It was expected that a large fraction of these individuals had experienced previous transient HPV 
infection, because most anogenital HPV infections are acquired soon after sexual debut and are also 
cleared at an early age. Older individuals were excluded because women who are HPV DNA posi-
tive at ages 35 and above may represent failure of viral clearance [24]. A Pap smear was performed 
for cytological examination, and an additional cervical swab specimen was obtained for HPV DNA 
analysis. Women presenting with histological proven cervical carcinoma or CIN at the department 
of gynecology of the Leiden University Medical Center (LUMC) were enrolled in this study, after 
informed consent. Blood was drawn at day of treatment prior to surgery. Carcinoma subjects enrolled 
were staged FIGO IB/IIA and were treated by radical hysterectomy. The age of the cervical cancer 
patients (n= 17) ranged from 34–72 years old (median 45 years), whereas the age of the CINIII 
patients (n= 13) ranged from 29–42 years (median 3 1 years) We preferred to use CINIII for analyses 
of cases in which the naturally occurring immune response has not been able to control the infec-
tion, because there is a substantial heterogeneity in the microscopic diagnosis and biologic mean-
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ing of CIN II lesions in particular. In general, the majority of CINIII lesions are incipient precancers 
that are destined to persist [2]. PBMC and serum was obtained for the analysis of HPV 16-speciﬁ c T 
cell reactivity and VLP L 1-speciﬁ c antibodies. The subjects were typed for HPV 16 using HPV 16-speciﬁ c 
primers on DNA isolated from cervical swab specimens, parafﬁ n-embedded sections of biopsies or 
surgical resection specimens [25]. The study design was approved by the Medical Ethical Committee 
of the LUMC. Two out of twenty healthy females were HPV positive, one type 62 and the other type 
3 1, but no HPV 16 was detected. Of the CIN III and cervical carcinoma patients, only the HPV 16 posi-
tive subjects were included in the immunological analyses. 
Antigens · A set of peptides spanning the whole HPV 16 E2, E6, and E7 protein were used in pools 
of 2 peptides for the T cell proliferation assays. The E2 peptides consisted of 22 30-mer peptides 
with  15 amino acids overlap and the C-terminal peptide with a length of 35 amino acids. The length 
of the E6 and E7 peptides were 32 and 35 amino acids respectively, with an overlap of  14 amino 
acids. The peptides were synthesized and dissolved as described previously [26]. The peptide pools 
are indicated by the ﬁ rst and last amino acid of the region in the protein covered by the two pep-
tides (e.g. E2 1-45 residues  1-30 +  16-45). Memory Response Mix (MRM), consisting of a mixture of teta-
nus toxoid (0.75 LF/ml; National Institute of Public Health and Environment, Bilthoven, The Nether-
lands), Mycobacterium tuberculosis sonicate (2.5 µg/ml; generously donated by Dr. P. Klatser, Royal 
Tropical Institute, Amsterdam, The Netherlands) and Candida albicans (0.005 %, HAL Allergenen 
Lab, Haarlem, The Netherlands), was used to conﬁ rm the capacity of PBMC to proliferate and pro-
duce cytokine in response to common recall antigens.
HPV 16 VLP ELISA · For the detection of HPV 16-speciﬁ c antibodies in serum we used an ELISA 
method previously described by Kirnbauer et al [27]. Each serum was tested for reactivity against 
HPV 16 virus-like particles (VLP, baculovirus-expressed capsids comprising the L 1 protein) and against 
bovine papillomavirus (BPV) capsids, the latter disrupted by treatment with 0. 1M carbonate buffer 
to serve as a negative control. Both VLP and BPV were kindly provided by Prof.dr. J. Dillner (LUNDS 
University, Sweden). The patients (all proven HPV 16-positive by PCR) were tested for HPV 16-speciﬁ c 
IgG only, whereas the healthy controls were tested for both IgG and IgA, as it has been described 
that transient infections more frequently lead to speciﬁ c serum IgA antibodies, than IgG. Overall, 
HPV 16-speciﬁ c antibodies can only be detected in a small fraction of individuals experiencing a 
transient HPV 16 infection, and only for a limited time period after infection [28]. Therefore, only the 
presence, but not the absence of HPV 16-speciﬁ c antibodies allows conclusions as to whether or not 
an individual has experienced a transient infection in the past. 
Short-term T cell proliferation assay · Freshly isolated derived PBMC were incubated with  12 pools 
of HPV 16 E2-derived 30-mer peptides, 4 pools of E6 32-mer peptides and 2 pools of E7 35-mer pep-
tides (each pool containing two overlapping peptides). PBMC were seeded at a density of  1.5 ¾  105 
cells/well in a 96-well U-bottomed plate (Costar, Cambridge, MA) in  150 µl of Iscove’s medium (Bio-
Whittaker) supplemented with  10 % autologous serum. HPV 16 E2-, E6- and E7-derived peptides were 
added at a concentration of  10 µg/ml/peptide. Medium alone was taken along as a negative control 
and MRM (dilution  1:50) served as a positive control. For each peptide pool, 8 parallel micro cultures 
were incubated. 50 µl of supernatant from the microcultures was taken at day 5 after incubation and 
stored at –20° C until cytokine analysis. Peptide-speciﬁ c proliferation was measured at day 7 by [3H]-
thymidine incorporation. Cultures were scored positive when the proliferation of ≥ 75 % of the test 
wells exceeded the mean proliferation plus 3 ¾ SD of the control wells containing medium only, and 
the stimulation index (SI), deﬁ ned as the mean of all test wells divided by the mean of the control 
wells, was ≥ 3. Previously performed short-term proliferation assays with immunologically naïve cord 
blood cells ( 10 samples) revealed no speciﬁ c proliferation against the E6 or E7 oncoprotein-derived 
peptides, indicating that the 7 day stimulation with peptides does not result in the in vitro induction 
of HPV 16-speciﬁ c proliferative responses.
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CFSE labeling · Freshly isolated PBMC were washed in cold PBS and incubated with 0.5 µM carboxy-
ﬂ uorescein diacetate succinimidyl ester (CFSE, Molecular Probes, Eugene, OR) in PBS at 37° C for 30 
min; 5 % autologous serum was added, and the PBMC were washed twice in PBS. The CFSE-labelled 
PBMC were then resuspended in IMDM supplemented with  10 % autologous serum and incubated 
with the HPV 16-derived peptides as described for the short-term proliferation assays. 
Analysis of cytokines associated with HPV 16-speciﬁ c proliferative responses · The detection of 
cytokines in the supernatants of the short-term proliferation assays was performed using the cytometric 
bead array (Becton Dickinson). Analysis of the cytokine kinetics revealed that at day 5, antigen-speciﬁ c 
production of all cytokines could be detected. IL-2 and IL-4 can both be consumed by proliferating 
cells; therefore, levels of these cytokines in this assay may be underestimated. Supernatants from the 
individual microcultures harvested at day 5 were pooled per peptide pool and 50µl of this supernatant 
was used for cytokine analysis. The cytometric bead array was performed according to manufacturers 
instruction. Cut-off values were based on the standard curves of the different cytokines (50 pg/ml for 
IFNg and  10 pg/ml for the remaining cytokines). Antigen-speciﬁ c cytokine production was deﬁ ned as a 
cytokine concentration above cutoff level and > 2¾ the concentration of the medium control [29]. 
Analysis of PHA-induced proliferation and cytokine production · Liquid nitrogen stored PBMC 
were used for these assays, enabling the analysis of all the samples at the same time for optimal 
comparison. The cervical carcinoma and the healthy control group consisted of the same individuals 
as those analysed in the short-term proliferation assays, minus those of whom an insufﬁ cient amount 
of PBMC was available (healthy subjects n= 17, cervical carcinoma patients n= 13). The CIN group 
included additional samples, which had previously been collected and stored in liquid nitrogen (CIN 
patients n= 13). PBMC were thawed and resuspended at a concentration of  106/ml in serum-free 
x-vivo 15 medium (BioWhittaker).  100 µl of cell suspension was seeded per well of a 96-well round-
bottom plate, in total 24 wells per subject. 50 µl of  1,5 µg/ml PHA (Murex Diagnostics, Dartford, 
UK) in x-vivo 15 was added to  12 wells, whereas 50 µl of plain x-vivo 15 medium served as a negative 
control in the remaining  12 wells. After 48 hours 50 µl of supernatant per well was harvested, and the 
supernatants from the PHA-stimulated wells were pooled, as were the controls. Supernatants were 
stored at –20° C until cytokine analysis by ELISA. PHA-induced proliferation was measured by [3H]-
thymidine incorporation 48 hours after stimulation. IFNg was measured by ELISA as described previ-
ously [26]. IL-4 and IL- 10 (CLB, Amsterdam) and IL-5 (Pharmingen) ELISAs were performed according 
to manufacturers instruction. 
Statistical analysis · Statistical analysis of the HPV 16-speciﬁ c proliferative responses associated with 
cytokine production was performed using a Fisher’s exact test. For the statistical analysis of the 
mitogen-induced proliferation and the cytokine levels in response to recall antigens an unpaired 
two-tailed t-test was applied, and an unpaired two-tailed t-test with Welch correction for the analysis 
of the mitogen-induced cytokine ratios.
Results
HPV 16 E2 and E6-speciﬁ c CD4+ T cell responses in healthy individuals are associated with 
Th 1 and Th2 type cytokines
Previously we have demonstrated the presence of HPV 16 E2 and E6-speciﬁ c memory CD4+ Th cells in 
the CD45RO+ fraction of peripheral blood of the majority of healthy individuals [22, 23]. These memory 
Th cells produced IFNg upon stimulation, indicating that they are of a Th 1 type. So far, it has not been 
determined whether the HPV 16-speciﬁ c responses in the healthy population consist solely of Th 1 type 
cytokines, or that other cytokines are also involved. We therefore analysed the cytokine proﬁ les of the 
HPV 16-speciﬁ c T cells in a cohort of 20 young sexually active healthy women. All women had a normal 
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cytology and were proven HPV 16 negative by PCR and VLP ELISA at the time of analysis, therefore 
presence of responses against the HPV 16 antigens are expected to represent memory T cells induced 
upon a transient HPV 16 infection in the past. Short-term proliferation assays were performed against 
peptides derived from the HPV 16 proteins E2, E6, and E7 as well as a mix of common recall antigens 
(Memory Response Mix, MRM). In accordance with our previous data [22, 23], half of the individuals 
show proliferative responses against E2 ( 10/20), and an even larger fraction shows responses against 
the E6-derived peptides ( 13/20). E7-speciﬁ c responses were detected in only a minority of subjects 
(2/20) (Figure  1a). CFSE labelling of PBMC demonstrated that exclusively CD4+ Th cells contributed 
to the HPV 16-speciﬁ c proliferation, as upon stimulation with E2 and E6 peptides, cell division could 
only be detected in the CD4+ fraction of PBMC (Figure 2). This is in line with our previous notion that 
HPV 16-speciﬁ c IFNg secretion was solely derived from CD4+ T cells ([22, 23] and data not shown).
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Figure  1. a. Freshly isolated PBMC from 20 healthy female individuals (HD) were tested in short-term proliferation assays using a 
complete set of HPV 16 E2, E6 and E7-derived peptide pools (indicated by the ﬁ rst amino acid of the region in the protein covered by 
the peptides). Responses were scored positive when the proliferation (cpm) of ≥ 6 out of 8 test wells exceeded the mean prolifera-
tion + 3 ¾ SD of the control (medium only) wells, and the mean stimulation index (SI) of all test wells over control wells was ≥ 3. 
Memory Response Mix (MRM), consisting of a mixture of recall antigens, was used as a positive control. Indicated are the stimula-
tion indices (SI) of responses scored positive. b. Supernatants of the positive proliferative responses indicated in a were analysed 
for the presence of IFNg, TNFa, IL-2, IL-4, IL-5, and IL- 10 by Cytometric Bead Array. The indicated layout is used for the six measured 
cytokines; a ﬁ lled square representing antigen-speciﬁ c cytokine production. Cut-off values were based on the standard curves of 
the different cytokines (50 pg/ml for IFNg and  10 pg/ml for the remaining cytokines). Antigen-speciﬁ c cytokine production was 
deﬁ ned as a cytokine concentration above cutoff level and > 2 ¾ the concentration of the medium control. c. 8 CINIII and  17 cervical 
cancer (CxCa) patients (all HPV 16-positive) were tested in short-term proliferation assays as described in (a). d. Supernatants of the 
positive proliferative responses of the patient group were subjected to cytokine analysis as described in (b). n.t. = not tested
58
Analysis of the supernatants of these T cell cultures for the presence of IFNg, TNFa, IL-2, IL-4, IL-5 
and IL- 10 revealed the secretion of both Th 1- and Th2-type cytokines in response to HPV 16-derived 
peptides (Figure  1b). The most predominantly secreted cytokines were IFNg and IL-5 (Figure  1b and 
Figure 3), often accompanied by IL-2, and to a lesser extent by TNFa and IL- 10. Antigen-speciﬁ c secre-
tion of IL-4 was rarely observed. In response to recall antigens (MRM) the majority of Th 1- and Th2-
type cytokines for which we analysed were detected. Taken together, the consistent HPV 16-speciﬁ c 
secretion of IFNg and IL-5 in healthy individuals suggests that both Th 1 and Th2 type immunity play 
a role in the effective control of HPV 16 infection. 
Impaired HPV 16-speciﬁ c T-helper immunity in patients with HPV 16+ (pre)malignant lesions 
Having characterized the HPV 16-speciﬁ c Th responses in healthy individuals, a fraction of whom have 
apparently succeeded in clearing HPV 16 infection, we questioned how these compare to patients 
who have evidently failed to establish an effective immune response against this virus. A group of 
HPV 16-positive patients, consisting of 8 subjects diagnosed with CINIII and  17 subjects with cervical 
carcinoma (CxCa), were analysed for E2, E6 and E7 reactivity by short-term proliferation assay. In 
only  1 out of 8 CINIII patients HPV 16-speciﬁ c proliferation was observed (Figure  1c), which was associ-
ated with the production of both IFNg and IL-5 (Figure  1d). The remaining 7 patients with high-grade 
CIN did not show any proliferative reactivity against the E2, E6 or E7 antigens, whereas all 8 patients 
did respond to the recall antigens. In contrast to the near absence of HPV 16-speciﬁ c responses in high-
grade CIN patients, cervical carcinoma patients showed a response frequency that resembled that of 
the healthy subjects (Figure  1c), with half of the patients showing proliferative responses against E2 
(8/ 16. CxCa 9 not tested against E2), and less frequent responses against the E7 antigen (3/ 17). The 
fraction of cervical carcinoma patients showing a proliferative response against HPV 16 E6 was lower 
(7/ 17) than of healthy individuals ( 13/20), but this difference was not statistically signiﬁ cant.
Despite this resemblance of the healthy female group in terms of frequency of proliferative responses 
against HPV 16 antigens, the corresponding cytokine production showed a completely different pic-
CFSE
CD4+ CD8+
control
E2 31-75
E6 37-86
MRM
Figure 2. Detection of HPV 16-speciﬁ c T cell proliferation in CD4+ fraction of PBMC. Freshly isolated PBMC derived from 4 
healthy subjects were labeled with CFSE, and incubated with the most immunogenic pools of peptides derived from E2 and E6 
(E23 1-75 and E637-86 respectively) and the mix of recall antigens (MRM). One representative example is shown. At day 6, the cells were 
counterstained with CD4 and CD8 antibodies, and the division in both T cell subsets was determined by ﬂ owcytometric analysis. 
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ture (Figure  1d). In the group of cervical carcinoma patients, only a minor fraction of the proliferative 
responses was associated with cytokine production. In fact, in most cases none of the cytokines 
were detected, despite the occasional broad proliferative response against all three HPV 16 antigens 
(Figure  1d and 4). In a large set of supernatants derived from microcultures lacking antigen-speciﬁ c 
proliferation, we were not able to detect speciﬁ c cytokine production, indicating that selection of 
supernatant samples based on proliferation does not result in an underestimation of the cytokine 
responses. Overall, compared to the healthy subjects, the responses against both E2 and E6 in cervical 
carcinoma patients are characterized by lack of IFNg and IL-5, as reﬂ ected by a signiﬁ cantly reduced 
fraction of total responses associated with either cytokine (IFNg: p < 0.05, IL-5: p ≤ 0.00 1, Fisher’s Exact 
Test). The secretion of other cytokines besides IFNg and IL-5 is also reduced in cervical carcinoma 
patients, but the antigen-speciﬁ c secretion of IL- 10 appears to be less affected. As a consequence, 
HPV 16 responses associated solely with the immunoregulatory cytokine IL- 10 can be observed. In 
healthy individuals HPV 16-speciﬁ c IL- 10 production was accompanied by IFNg and/or IL-5 in  1 1 out 
of  12 responses, whereas in only 2 out of 6 responses in cervical carcinoma patients (p < 0.05; Fisher’s 
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Figure 3. HPV 16-speciﬁ c T cell responses in healthy individuals are predominantly associated with IFNg and IL-5. Strong 
proliferative Th-responses against the HPV 16 E2 and E6-derived peptides were observed in healthy female-derived PBMC. One 
representative example (H7) displaying such proliferative responses is depicted in the upper panel. Each open circle represents 
the proliferation of an individual microculture; arrows indicating positive responses of which the supernatants were subjected to 
cytokine analysis. The corresponding cytokine levels are depicted in the lower panels, indicating the predominant secretion of 
IFNg and IL-5. Antigen-speciﬁ c cytokine secretion, as deﬁ ned in the legend of ﬁ gure  1, is indicated with an asterisk (*).
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Exact Test). The low number of responses in CINIII patients, and low number of E7 responses in all 
groups precluded these parameters from statistical analysis. Importantly, no signiﬁ cant differences in 
the magnitude and cytokine proﬁ les of the recall antigen (MRM) responses were observed between 
cervical carcinoma patients and healthy individuals. The mean IFNg and IL-5 levels in responses to 
MRM were lower in cervical cancer patients than in healthy women, however, this difference was not 
signiﬁ cant (Figure  1; IFNg: healthy subjects mean = 3 1 10 pg/ml range 307– 10500 pg/ml, CxCa patients 
mean = 2229 pg/ml range  150–8250 pg/ml. IL-5: healthy subjects mean = 466 pg/ml range  1 1–109 1 
pg/ml, CxCa patients 280 pg/ml  10–1276 pg/ml, two-tailed t-test). This indicates that the recall anti-
gen-speciﬁ c cytokine production was not signiﬁ cantly impaired in the patient population, which is in 
accordance with the fact that these patients had low-stage (mainly FIGO IB) disease. 
 Even though the frequency at which HPV 16 E2/E6-speciﬁ c T cell immunity was detected in 
patients and healthy females was roughly similar, it should be noted that all patients carried HPV 16+ 
cervical lesions and, therefore, that approximately half of the HPV 16+ cervical carcinoma patients 
had failed to mount any detectable HPV 16-speciﬁ c Th-response. Thus, failure of immune defence 
against cervical HPV 16 infection can embody either HPV 16 E2/E6-speciﬁ c T cell immunity with an 
impaired capacity to produce cytokines, or a complete lack of such T cell immunity. 
4074 492
* *
547
*
*
co
nt
ro
l 1
31 61 91 12
1
15
1
18
1
21
1
24
1
27
1
30
1
33
1 1 37 73 10
9 1 43
M
RM
E2 E6 E7
pr
ol
ife
ra
tio
n 
(c
pm
)
0
4,000
6,000
8,000
80,000
120,000
2,000
TNFaIFNg IL-2
IL-10IL-5IL-4
co
nt
ro
l
31 61 91 15
1
30
1 37 73
M
RM
pg
/m
l
E2 E6
pg
/m
l
E7
4327
1 1
12
1
co
nt
ro
l
31 61 91 15
1
30
1 37 73
M
RM
E2 E6 E7
4327
1
12
1 1
co
nt
ro
l
31 61 91 15
1
30
1 37 73
M
RM
E2 E6 E7
4327
1
12
1 1
0
100
200
300
400
500
0
50
100
150
200
0
50
100
150
200
0
50
100
150
200
0
50
100
150
200
0
50
100
150
200
Figure 4. Absence of detectable cytokine levels, despite HPV 16-speciﬁ c proliferation in cervical cancer patients. Approxi-
mately half of the HPV 16-positive cervical cancer patients (CxCa) revealed HPV 16-speciﬁ c proliferation. One representative exam-
ple is shown (CxCa 12, upper panel). HPV 16-speciﬁ c proliferative responses were generally not associated with detectable cytokine 
production (lower panels), where as the recall response (MRM) was associated with high levels of IFNg, TNFa and IL-5. For 
explanatory notes, see ﬁ gure 3. 
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Patients with HPV 16+ cervical disease display altered cytokine proﬁ le of peripheral T cells 
The local cytokine environment in HPV-induced lesions differs from that observed in healthy tissue 
[ 14,  16], and it has been suggested that this can inﬂ uence the overall polarization of peripheral T 
cells towards a Th2 type cytokine proﬁ le in patients bearing these lesions [ 17, 30, 3 1]. In our study, 
HPV 16-speciﬁ c CD4+ Th responses in patients with cervical cancer lack the clear Th 1/Th2 cytokine 
proﬁ le that is exhibited by such responses in healthy subjects, while the cytokine proﬁ le of MRM-
speciﬁ c T cell responses does not show signiﬁ cant differences between healthy and diseased indi-
viduals. We questioned whether the overall cytokine proﬁ les of peripheral T cells, as determined by 
mitogenic stimulation of PBMC, would reveal a difference between patients with HPV 16-induced 
disease and healthy subjects. Supernatants from PHA-stimulated PBMC were analysed for the levels 
of IFNg, IL-4, IL-5, and IL- 10. Per individual, the ratios of the different cytokines were calculated, 
which reﬂ ect the Th 1/Th2 polarization of the T cell repertoire. Cervical carcinoma patients revealed 
relatively higher levels of IL- 10 and IL-4 as compared to IFNg, suggesting the loss of Th 1 in favour 
of Th2 cytokines in the peripheral blood of the diseased population (Figure 5a,b; p < 0.0 1, unpaired 
two-tailed t-test with welch correction). However, the IFNg/IL-5 ratios did not differ between the 
groups (data not shown), indicating that the cytokine proﬁ les in cervical carcinoma patients do not 
represent a general Th2 bias. In line with this, the ratios of the Th2 type cytokines IL-5/IL-4 are also 
signiﬁ cantly lower in cancer patients (Figure 5c; p < 0.05). The high-grade CIN patients revealed cyto-
kine proﬁ les similar to that observed in the cervical carcinoma patients although the difference with 
the healthy subjects was less pronounced, and was only signiﬁ cant for the IFNg/IL-4 ratios (Figure 5a, 
p < 0.05). Overall, the PHA-induced proliferation was slightly lower in both high-grade CIN and car-
cinoma patients compared to healthy individuals (Figure 5d). Taken together, the mitogen-induced 
cytokine proﬁ les suggest the presence of an altered cytokine balance in HPV 16-induced disease, 
which may have determined the lack in cytokine polarization of HPV 16-speciﬁ c Th responses found 
in patients as well as affected the proliferative capacity of these T cells.
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Figure 5. Patients with HPV 16+ cervical disease display altered cytokine proﬁ le of peripheral T cells. Thawed PBMC derived 
from healthy female individuals (n= 17), CINIII patients (n= 13), and cervical carcinoma patients (n= 13) were stimulated with PHA 
(0,5 µg/ml) for 48 hours after which the proliferation was measured by [3H]-thymidine incorporation, and the supernatants were 
analysed for the presence of IFNg, IL-4, IL-5 and IL- 10 by ELISA. The ranges of measured cytokines were 3 1-97 ng/ml, 5- 109 pg/ml, 
0-479 pg/ml, and 50- 1390 pg/ml respectively. No signiﬁ cant differences in the absolute cytokine concentrations were observed 
between the groups. The cytokine ratios per subject were plotted, because these reﬂ ect the overall polarization of the T cell rep-
ertoire, independent of the absolute amounts of cytokine secreted. Signiﬁ cant differences between patients and healthy subjects 
are indicated with an asterisk (*) (p<0.05, two-tailed t-test with welch correction). 
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Discussion
Our analysis of CD4+ T cell-immunity against the HPV 16 E2 and E6 antigens in healthy women and 
patients with HPV 16+ cervical disease revealed that cervical cancer is associated with HPV 16-speciﬁ c 
immune failure. Of the HPV 16+ carcinoma patients tested, approximately half lacked any detectable 
proliferative E2, E6 and/or E7-speciﬁ c T cell responses. The other half of the carcinoma patients 
did show systemic proliferative responses, but this immunity was in general not associated with 
a strong inﬂ ammatory cytokine proﬁ le. Because speciﬁ c CD4+ T cell help is of crucial importance 
for the development of humoral and cellular effector mechanisms against viral infections, these 
impaired responses against the viral antigens can be considered unfavourable in view of protection 
against progressive HPV-induced neoplasia. In contrast to cervical cancer patients, healthy women 
frequently displayed strong CD4+ T cell responses against HPV 16 E2 and E6 and these responses 
were generally associated with the secretion of inﬂ ammatory cytokines, most predominantly IFNg 
and IL-5. Our observation that the HPV 16-speciﬁ c memory response in healthy subjects displays a 
mixed Th 1/Th2 cytokine proﬁ le is in accordance with the notion that both humoral and cellular 
immunity are required to clear viral infection and provide subsequent protection against reinfection 
(Figure 6, left panel). Others have previously observed a lack of E6 and E7-speciﬁ c IL-2 secretion in 
PBMC of cervical carcinoma patients, and have on the basis of this observation suggested that this 
loss of IL-2, a cytokine indicative of a Th 1 type response, might be accompanied by an increased 
Th2 type response [20]. Our data indicate that the HPV-speciﬁ c cytokine secretion in the diseased 
population indeed lacks IL-2, but is not skewed towards Th2 type. Instead, the HPV-speciﬁ c T cell 
response in patients features an overall defect in inﬂ ammatory cytokine production. 
 Compared to the frequency at which HPV 16-speciﬁ c proliferative responses are detected in cervi-
cal carcinoma patients, the frequency of such immunity in patients with high-grade CIN lesions is 
surprisingly low and this does not correspond with the idea of a gradual loss of HPV 16-speciﬁ c T cell 
reactivity along disease progression. A similarly low frequency of HPV 16-speciﬁ c T cell responses in 
CIN patients was also described by Nakagawa et al. [32]. On the basis of these accumulated data, 
we hypothesize that failure of the HPV-speciﬁ c CD4+ T cell response allows persistent HPV infec-
tion and subsequent establishment of high-grade CIN (Figure 6, right panel). Indirect evidence sup-
porting this hypothesis is given by reports showing that low CD4+ T cell count in HIV-infected 
individuals are associated with multiple HPV infections, higher viral load, viral persistence and cervi-
cal dysplasia [ 12]. Without surgical intervention, the majority of established high-grade CIN lesions 
will evolve towards cervical carcinoma. Our data suggest that in approximately half of the cervical 
carcinoma patients the presence of the tumor will eventually trigger the induction of a CD4+ T 
cell response. It is, however, conceivable that cervical cancers do not provide the appropriate pro-
inﬂ ammatory environment for the induction of a potent and well-polarized T cell response, and that 
CD4+ T cell priming at this stage of disease will most likely result in an ineffective HPV-speciﬁ c 
anti-tumor immune response. The lack of responses in the remaining patients could reﬂ ect either a 
complete failure at the induction level or could be the result of silencing of pre-existing impaired 
responses by tumor-induced or chronic infection-induced T-regulatory activity. We are currently per-
forming longitudinal studies in cohorts of women to investigate the dynamics of the HPV 16 E2/E6-
speciﬁ c CD4+ T cell response in relation to clearance or persistence of HPV infection. 
 We frequently detected E2-speciﬁ c CD4+ T cell immunity in cervical carcinoma patients, despite 
the fact that integration of viral DNA into the cellular genome often results in the loss of functional 
E2 gene expression. This may be explained by the ﬁ nding that in addition to integrated copies, 
episomal HPV 16 DNA capable of encoding E2, can be found in cervical carcinoma [33, 34].
 Comparison of the cytokine proﬁ les of mitogen-induced T cell responses in PBMC from cervical 
cancer patients versus healthy subjects showed the loss of the Th 1 type cytokine IFNg in favour of 
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the Th2 type cytokines IL-4 and IL- 10 in patients. Others have previously described a similar ﬁ nding 
in patients with extensive CIN lesions compared to healthy controls [ 17]. Although cross-sectional 
analysis does not allow deﬁ nite conclusions with respect to the order of events, it is likely that 
this altered systemic cytokine balance is a consequence of HPV-induced disease, because the local 
cytokine environment in HPV-induced lesions is directly and indirectly (via APC) capable of modify-
ing cytokine proﬁ les of T cells [ 15,  16, 30, 3 1]. Notably, we did not observe signiﬁ cant differences 
between patients and controls in the cytokine proﬁ le of recall (MRM)-speciﬁ c T cell responses. The 
discrepancy between the character of MRM-speciﬁ c responses on one side and mitogen-triggered 
and HPV-speciﬁ c responses on the other, can most readily be explained by the fact that MRM-
speciﬁ c T cell memory was established, and therefore properly polarized, before the development of 
cervical neoplasia. These strongly polarized MRM-speciﬁ c memory T cells are, in contrast to naïve T 
cells, relatively insensitive to modiﬁ ed APC function [35, 36], such as is expected to be found in cervi-
cal cancer patients [37]. Mitogen-induced cytokine secretion, on the other hand, reﬂ ects the cytokine 
production of all peripheral T cells, including that of naïve T cells and those that have been primed 
against other pathogens during this period of HPV-induced disease. 
 In conclusion, our data demonstrate an association between HPV 16+ cervical disease and partial 
or complete failure of CD4+ T cell function in E2- and E6-speciﬁ c immunity. The sophistically 
designed infection cycle of HPV 16, which does not involve destruction of virus-infected keratinocytes, 
and avoids pro-inﬂ ammatory signals that could stimulate recruitment and activation of APC, neces-
sitates the role of CD4+ T cell help in the process of anti-HPV immunity. In view of this consideration, 
our ﬁ ndings offer a possible explanation for the development of cervical disease. 
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Abstract · The development of HPV 16-positive cervical cancer is associated with failure to mount 
an effective immune response against the viral antigens. To gain insight in the local immune 
response against HPV 16, we performed a detailed analysis of the tumor draining lymph node of 
a patient with HPV 16-positive cervical cancer. Lymph node-derived HPV 16E6-speciﬁ c CD4+ T cell 
clones generally lacked a clear Th 1 or Th2 cytokine proﬁ le and predominantly secreted both IL- 10 and 
IFNg. Interestingly, when the E6 antigen was presented suboptimally, most clones secreted IL- 10 but 
not IFNg. The secretion of IFNg occurred only under optimal conditions involving high concentra-
tions of peptide presented by mature dendritic cells (DC). By contrast, inﬂ uenza M 1-speciﬁ c CD4+ 
T cells derived from the same tumor-draining lymph node showed predominant secretion of IFNg, 
irrespective of the type of antigen presenting cell (APC) and peptide concentration. This difference in 
HPV 16E6 – and inﬂ uenza M 1-speciﬁ c T cell cytokine proﬁ le suggests an impaired HPV-speciﬁ c T cell 
response in this patient. The optimal antigen presenting conditions required to induce HPV 16-spe-
ciﬁ c IFNg secretion are not likely to be encountered in the vicinity of the tumor. Therefore, IL- 10 
secretion is expected to dominate the HPV 16-speciﬁ c CD4+ T cell response in vivo. The fact that 
HPV-speciﬁ c IL- 10-secreting CD4+ T cells were also present in tumor inﬁ ltrating lymphocyte popula-
tions of the majority of cervical cancer patients, suggests these T cells may be a common feature 
of HPV-induced disease. HPV-speciﬁ c IL- 10 secretion may contribute to the lack of an effective anti-
tumor response at the level of T cell priming in the draining lymph node, and may hamper effector 
function at the site of the tumor. 
IL- 10 secretion characterizes HPV-
speciﬁ c CD4+ T cell repertoire in 
cervical tumor and tumor-draining 
lymph nodes
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Introduction
Papillomaviruses harbor several mechanisms to avoid innate immune triggering [ 1], which explains 
the lagtime that is generally observed between HPV infection and clearance [2]. However, in the 
case of persistent HPV infection and HPV-induced malignancies, it is highly unlikely that the fail-
ure to mount an effective HPV-speciﬁ c immune response is merely a result of ignorance caused by 
the avoidance of immune triggering. In line with this, we detected proliferative responses against 
the HPV 16E6 oncoprotein in peripheral blood mononuclear cells (PBMC) of approximately half of 
HPV 16-positive cervical cancer patients [3]. However, the supernatants of these cell cultures gener-
ally lacked detectable levels of Th 1 and Th2 cytokines, while IL- 10 was occasionally present. In PBMC 
of the other half of patients detectable HPV 16-speciﬁ c responses were lacking altogether. Thus, an 
improperly polarized or even actively suppressed HPV-speciﬁ c immune response offers a more plau-
sible explanation for the apparent immune failure in HPV-induced disease. 
 HPV-speciﬁ c T cells are likely primed in lymph nodes draining the cervix, by migrating Langerhans 
cells (LC) that have taken up antigen in the HPV-positive lesion. The non-inﬂ ammatory environment 
of HPV-positive lesions, with a local increase in IL- 10 levels [4], may adversely affect the capacity of 
LC to induce a potent anti-tumor immune response. IL- 10 is implicated both in the modulation of 
APC function, and in the subsequent induction of regulatory T cells [5, 6]. Consequently, the action 
of this cytokine may explain the impaired HPV 16-speciﬁ c T cell response detected in the peripheral 
blood of cervical cancer patients. To gain more insight in the characteristics of the HPV-speciﬁ c T 
cell responses in cervical cancer patients at the site of T cell priming, we embarked on the detailed 
analysis of HPV 16 oncoprotein-speciﬁ c T cells present in tumor-draining lymph nodes. We found 
these draining lymph nodes to harbor E6-speciﬁ c CD4+ T cells that secrete IL- 10 upon triggering with 
antigen. Similarly, HPV-speciﬁ c IL- 10-secreting T cells were detected in populations of tumor inﬁ ltrat-
ing lymphocytes (TIL). These observations offer a possible explanation for the functional deﬁ ciency 
of the HPV-speciﬁ c T cell response in patients with HPV-positive cervical disease.
Materials and Methods
Lymph nodes, tumors and blood samples · The analyses of cervical tumors and tumor-draining 
lymph nodes were nested in the “CIRCLE” study that investigates cellular immunity against HPV in 
patients with HPV-positive (pre)malignant lesions. The study design was approved by the Medical 
Ethical Committee of the LUMC. Blood was drawn immediately prior to surgery. Tumor and lymph 
node material described in this study was obtained after informed consent from patients with cervi-
cal carcinoma (FIGO stage  1B/IIA, IIB) during radical hysterectomy. From the same patients PBMC 
and sera were obtained from blood that was drawn prior to surgery. Typing for HPV 16 was performed 
using HPV 16-speciﬁ c primers on DNA isolated from surgical resection specimens [7]. The lymph 
nodes were derived from the pelvic region and contained tumor cells, indicative of metastatic cancer. 
To isolate the lymph node mononuclear cells (LNMC) from the tissue, the lymph node material was 
cut into pieces of approximately 5mm3 and incubated at 37° C for one hour after addition of col-
lagenase IV 200 IU/ml (Sigma) and DNAse 50 µg/ml (Sigma). A single cell suspension was obtained 
using a cell strainer (BD Falcon), and dead cells and erythrocytes were removed by ﬁ coll density gra-
dient. Tumor inﬁ ltrating lymphocytes (TIL) were obtained by culturing minced tumor tissue in IMDM 
(Cambrex) supplemented with  10 % AB serum (Sigma),  1 % T cell growth factor (TCGF, Zeptometrix, 
USA) and 5 ng/ml IL- 15 (PeproTech, USA) for 2-3 weeks. 
Antigens · For the short-term proliferation assays of lymph node- and peripheral blood-derived 
mononuclear cells, a set of peptides spanning HPV 16 E2, E6, and E7 proteins was used. The HPV 16E2 
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peptides consisted of 22 30-mer peptides with  15 amino acids overlap and the C-terminal peptide 
with a length of 35 amino acids. The 8 HPV 16E6 peptides were 32 amino acids long and the 4 E7 
peptides had a length of 35 amino acids, all with an overlap of  14 amino acid residues. In the short-
term proliferation assays pools of 2 peptides per pool were used, indicated by the ﬁ rst and last amino 
acid of the region in the protein covered by the peptides. For the generation of inﬂ uenza M 1-speciﬁ c 
T cell clones,  16 30-mer peptides with an overlap of  15 amino acids were used, spanning the inﬂ u-
enza matrix  1 protein of A/PR/8/34. For the analysis of the tumor inﬁ ltrating lymphocyte cultures, 
an additional set of HPV 18 E6 and E7 overlapping peptides was used. Peptides were synthesized by 
solid phase technique on an automated multiple peptide synthesizer (Abimed AMS 422, Langenfeld, 
Germany), and analyzed by reverse phase HPLC. The lyophilized peptides were dissolved in 50µl of 
DMSO, diluted in PBS to a ﬁ nal concentration of 2.5 mg/ml. Memory Response Mix (MRM), consist-
ing of a mixture of tetanus toxoid (0.75 LF/ml ﬁ nal concentration; National Institute of Public Health 
and Environment, Bilthoven, The Netherlands), Mycobacterium tuberculosis sonicate (2.5 µg/ml; 
generously donated by Dr.P. Klatser, Royal Tropical institute, Amsterdam, The Netherlands) and 
Candida albicans (0.005 %, HAL Allergenen Lab, Haarlem, The Netherlands), was used to conﬁ rm 
the capacity of PBMC and LNMC to proliferate and produce cytokine in response to common recall 
antigens. Recombinant HPV 16 E6 protein and HPV 16 E7 protein were produced in recombinant E. 
coli transformed with pET- 19b-HPV 16 E6 and pET- 19b-HPV 16 E7 as described previously [8].
Short-term proliferation assays · Freshly isolated PBMC respectively LNMC were seeded at a density 
of  1.5 ¾  105 cells/well in a 96-well U-bottomed plate (Costar, Cambridge, MA) in  150 µl of IMDM 
(Cambrex) supplemented with  10 % autologous serum. HPV 16 E2-, E6- and E7-derived peptide pools 
were added at a concentration of  10 µg/ml/peptide (2 peptides per pool). Medium alone was taken 
along as a negative control and MRM (dilution  1:50) served as a positive control. For each peptide 
pool, 8 parallel micro cultures were incubated. 50 µl of supernatant from the microcultures was taken 
at day 5 after incubation and stored at –20° C until cytokine analysis. Antigen-speciﬁ c proliferation 
was measured at day 7 by [3H]-thymidine incorporation. Cultures were scored positive when the 
proliferation of ≥ 75 % of the test wells exceeded the mean proliferation plus 3 ¾ SD of the control 
wells containing medium only, and the stimulation index (SI), deﬁ ned as the mean of all test wells 
divided by the mean of the control wells, was 3. 
Generation of HPV 16E6- and inﬂ uenza M 1-speciﬁ c T cell clones from LNMC · 5 ¾  106 LNMC were 
seeded in 25 cm2 culture ﬂ asks (Nalge Nunc, USA) in 3 ml IMDM supplemented with  10 % heat-inacti-
vated AB serum (Sigma),  1 % TCGF (Zeptometrix, USA) and 5 ng/ml IL- 15 (PeproTech, USA). HPV 16E6 or 
inﬂ uenza M 1 peptides were added at a concentration of 2.5 µg/ml. The speciﬁ city of the T cell cultures 
was tested at day  10, after which the cell culture was cloned by limiting dilution. T cell cloning was 
performed according to a protocol adapted from Evans et al. [9], replacing IL-2 for 5 % TCGF and 2 
µg/ml IL- 15, and adding 0.2 µg/ml phytohemagglutinin (Murex Diagnostics, UK) for TCR triggering. 
Proliferation assays for polyclonal lymph node T cell cultures, T cell clones and TIL cultures · 
Tumor inﬁ ltrating lymphocytes (TIL) and polyclonal lymph node T cell cultures were tested for the 
recognition of peptide- (5 µg/ml) and protein ( 10 µg/ml)-pulsed autologous monocytes in a 3-day 
proliferation assay. Autologous monocytes were obtained from PBMC by adherence as described 
previously [ 10]. Brieﬂ y, 2 days before performing the proliferation assay, 50 µl of PBMC suspension 
(4 ¾  106/ml in X-vivo 15 medium, Cambrex) was seeded in a 96-wells plate. After 2 hours of incubation 
at 37° C the non-adherent cells were washed away and the adherent cells were cultured in X-vivo 15 
medium containing GM-CSF (500 IU/ml). The T cell cultures (25,000 or 50,000/well) were tested 
in triplicate. At 48 hours, supernatants of the microcultures were harvested and stored at –20° C 
until cytokine analysis. Antigen-speciﬁ c proliferation was measured by [3H]-thymidine incorporation. 
The initial screening of the T cell clones for speciﬁ city was performed by a 3-day proliferation assay; 
autologous irradiated peptide-pulsed (pool of E6 respectively M 1 peptides, 5 µg/ml/peptide) PBMC 
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were used as APC ( 10,000/well). In this initial screening the clones were not harvested and counted, 
but the wells were split and an equal amounts of clone were seeded in the wells for analysis in 
duplicate. 48 hours after incubation, supernatant was harvested en stored at –20° C until cytokine 
analysis. In detail analysis of the cytokine proﬁ les of T cell clones was performed with irradiated HLA-
matched LPS-matured dendritic cells as APC pulsed overnight with increasing peptide concentrations 
(0, 0. 1,  1,  10,  100 µg/ml). Supernatant was harvested 6,  18, and 48 hours after incubation, and stored 
at –20° C until cytokine analysis. 
Cytokine analysis of supernatants · IFNg was measured by ELISA as described previously [ 1 1]. IL-4 
and IL- 10 (CLB, Amsterdam) and IL-5 (Pharmingen) ELISAs were performed according to manufactur-
ers instruction. Cytometric Bead Array (Becton Dickinson) was used for the cytokine analysis of the 
supernatants of the short-term proliferation assays and analysis of the polyclonal lymph node cultures. 
Supernatants from the individual microcultures were pooled per peptide pool and 50 µl of this superna-
tant was used for cytokine analysis. The cytometric bead array was performed according to manufactur-
ers instruction. Cut-off values were based on the standard curves of the different cytokines (50 pg/ml 
for IFNg and  10 pg/ml for the remaining cytokines). Antigen-speciﬁ c cytokine production was deﬁ ned 
as a cytokine concentration above cutoff level and > 2 ¾ the concentration of the medium control [ 12]. 
Analysis of IFNg and IL- 10 by cytokine secretion assay · For the single-cell analysis of the T cell 
clones for the secretion of IL- 10 and IFNg the cytokine secretion assay (Miltenyi biotech, Bergisch 
Gladbach, Germany) was used, with FITC-labeled anti-IFNg and PE-labeled anti-IL- 10. For the assays 
two different APC – autologous EBV-transformed B-cells (B-LCL) and HLA-matched LPS-matured den-
dritic cells (DC) – were used at a  1 : 5 ratio (APC : T cell). APC (5 ¾  104) were incubated overnight with 
increasing concentrations of peptide, after which the APC were washed and T cell clone (2.5 ¾  105) 
was added. For the E6-speciﬁ c T cell clones, the cognate epitopes were determined, and a single 
peptide was used for these assays. The use of a pool of peptides versus a single peptide did not 
show different results in cytokine proﬁ les, and for the M 1-speciﬁ c T cells clones a pool of overlap-
ping M 1 peptides was used. The optimal timepoint for the cytokine analysis was 3-4 hrs after stimula-
tion, as determined by a cytokine kinetics experiment. After the incubation of the T cell clone with 
the peptide-pulsed APC, the cytokine secretion assay was performed according to manufacturers 
instruction. Cells were counterstained with anti-CD4 APC (Becton Dickinson  1:50), and propidium 
iodide (40 µg/ml) was added prior to ﬂ owcytometric analysis. After detection of HPV reactivity in 
TIL cultures without prior stimulation with HPV antigen, these cultures were stimulated once (with 
autologous irradiated PBMC pulsed with  10 µg/ml cognate pool peptide, 5 % TCGF and 5 ng/ml 
IL- 15), and analyzed for cytokine proﬁ les  14 days later. Monocytes cultured for 2 days with GM-CSF 
(500 IU/ml) were used as APC. The IL- 10/IFNg secretion in response to stimulation with peptide-
pulsed ( 10 µg/ml) GM-CSF monocytes was measured by cytokine secretion assay according to manu-
facturers’ instruction. Cells were counterstained with anti-CD4 APC (BD  1:50), and propidium iodide 
(40 µg/ml) was added prior to ﬂ owcytometric analysis.
Results
Analysis of HPV 16E6-speciﬁ c CD4+ T cells derived from a tumor-draining lymph node
Patients with HPV 16-positive cervical tumors often lack detectable proliferative T cell responses in 
the peripheral blood against HPV 16 early antigens [3]. The underlying reason for this apparent 
absence of HPV 16-speciﬁ c proliferation is not known, and can theoretically vary from a low frequency 
of HPV 16-speciﬁ c T cells in the peripheral blood, to active in vitro suppression of the HPV 16-speciﬁ c 
T cell response. In the present study we had the opportunity to perform a detailed analysis of the 
HPV 16-speciﬁ c T cell response, not only in the peripheral T cell compartment, but also in the tumor-
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draining lymph node, which is the site where HPV 16-speciﬁ c T cells encounter their cognate antigen. 
We obtained lymph node material from a patient diagnosed with FIGO IIB HPV 16+ cervical cancer, 
who showed modest proliferative responses in the peripheral blood against HPV 16 E26 1- 105, E230 1-345, 
and E637-86 (Figure  1a, stimulation index >  1.5). None of these responses in PBMC exceeded the cut-
off level for the detection of memory T cell responses, which was deﬁ ned in our previous studies as 
≥ 75 % of the test wells above mean plus 3 ¾ SD of the medium control, and a stimulation index 
≥ 3 [ 13]. Therefore, this patient fell into the category of HPV 16-positive subjects that lack signiﬁ cant 
HPV 16-speciﬁ c memory T cell responses in the peripheral blood [3]. Mononuclear cells derived from 
the tumor-draining lymph node (LNMC) analyzed in a short-term proliferation assay showed a simi-
lar pattern as seen in the PBMC, in that responses were observed against HPV 16 E26 1- 105, E230 1-345, 
and E637-86. Immunity detected in LNMC appeared broader than that in PBMC, as it also covered 
peptides outside the aforementioned regions in E2 and E6 (Figure  1b). According to the deﬁ ned 
criteria for memory T cell responses (see above), the LNMC showed a signiﬁ cant response against 
E637-86 (Figure  1b). In correspondence with earlier analyses of HPV 16-speciﬁ c responses in cervical 
cancer patients [3], the proliferative responses in both PBMC and LNMC were not associated with 
detectable levels of cytokine secretion in the culture supernatants (data not shown). 
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Figure  1. HPV 16-speciﬁ c proliferative responses in PBMC and LNMC of an HPV 16+ cervical carcinoma patient. Freshly isolated 
mononuclear cells derived from (a) peripheral blood (PBMC) and (b) lymph node (LNMC) were stimulated with pools of HPV 16 
E2, E6, and E7 peptides ( 10 µg/ml) for 6 days after which proliferation was measured by [3H]-thymidine incorporation. The peptide 
pools, consisting of 2 peptides per pool, are indicated by the ﬁ rst and last amino acid of the region of the protein covered by the 
peptides. MRM, consisting of a mix of common recall antigens was used as a positive control. The open symbols represent prolifera-
tion of the individual microcultures. Squares represent responses with SI >  1.5, and diamonds represent responses with a SI ≥ 3, and 
at least 6 out of 8 microcultures with a proliferation higher than mean + 3 ¾ SD of medium control (deﬁ ned as memory response).
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For detailed analysis of the HPV 16-speciﬁ c response in LNMC of this patient, we focused on the 
E6 oncoprotein, because the strongest proliferation was observed against E6-derived peptides in 
the short-term proliferation assay. After  10 days of culture with overlapping E6 peptides, strong 
HPV 16E6-speciﬁ c responses were observed in the LNMC (Figure 2a). The LNMC proliferated in the 
presence of both E6 peptide- and protein-pulsed autologous monocytes, indicating the recognition 
of naturally processed E6 antigen. This HPV 16E6-speciﬁ c proliferation was associated with the secre-
tion of a diversity of cytokines, speciﬁ cally IFNg, TNFa, IL- 10 and IL-5 (Figure 2b), thus lacking a 
clear polarization towards either Th 1 or Th2 cytokines. To gain insight in the cytokine proﬁ les of 
individual E6-speciﬁ c T cells generating this array of cytokines, T cell clones were derived from the 
LNMC culture by limiting dilution. The resultant T cell clones, which all displayed a CD4+ phenotype, 
were tested in a proliferation assay, and supernatants were analyzed for the presence of IL- 10 and 
IFNg. We primarily focused on these two cytokines, because they represent the two outer ends in the 
spectrum of pro- and anti-inﬂ ammatory cytokines. 
 An initial screening of the T cell clones was performed using irradiated autologous PBMC pulsed 
with saturating amounts of E6 peptide antigen, and unpulsed PBMC as a negative control. Two out 
of  13 E6-speciﬁ c T cell clones predominantly secreted IFNg with (almost) no IL- 10, indicative of a Th 1 
type cytokine proﬁ le (Figure 3, cl. 1 and cl.8). The remaining T cell clones all secreted considerable 
amounts of IL- 10, accompanied by variable levels of IFNg. Interestingly, one of the T cell clones lacked 
antigen-speciﬁ c proliferation and IFNg, but did secrete IL- 10 in response to E6 stimulation (Figure 3, 
cl.3). The characteristics of the T cell clones that secreted both IL- 10 and IFNg in response to E6 stimu-
lation, suggest that these T cells may represent a T cell subset similar to Tr 1 cells, which have been 
found in connection to chronic infections and cancer, and display immunoregulatory functions. 
Ratio of IL- 10 and IFNg secreted by HPV 16E6-speciﬁ c CD4+ T cells critically depends on APC 
type and HLA-peptide density on APC surface
Further analysis of the E6-speciﬁ c T cell clones revealed that – upon optimal antigen-speciﬁ c stimu-
lation with peptide-pulsed LPS-matured dendritic cells – the majority of clones secreted low levels 
of IL-4 and IL-5 in addition to substantial amounts of IL- 10 and IFNg (Figure 4). CD4+ T cells 
with similar cytokine proﬁ les and with regulatory properties have recently been reported in mela-
noma patients [ 14]. Cytokine analysis of supernatants derived from the peptide titration experiments 
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Figure 2. Strong E6-speciﬁ c proliferative responses in cultured LNMC. LNMC were cultured with TCGF, IL- 15 and an overlapping 
set of 32-mer peptides spanning the entire HPV 16E6 protein (2.5 µg/ml). At day  10, the cultured LNMC were tested in a 3-day proliferation 
assay and showed strong recognition of both E6 peptide- and protein-pulsed autologous monocytes, as measured by [3H]-thymidine 
incorporation (a). The supernatants of the proliferation assay, harvested at 48 hours, were analyzed for the presence of cytokines by 
cytometric bead array. The positive proliferative responses were associated with the secretion of IFNg, TNFa, IL- 10, and IL-5 (b). 
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revealed that the peak levels of IL- 10 secretion were reached at at least a  100-fold lower peptide 
concentration than that for IFNg (Figure 4), and a  10-fold lower than for IL-4 and IL-5. This suggests 
that low antigen density on the APC (weak TCR triggering) results predominantly in IL- 10 secretion, 
whereas a higher antigen density favors the secretion of IFNg, IL-4 and IL-5. We decided to investi-
gate this feature at the level of cytokine secretion by single cell analysis.
 Two different types of APC were used, ( 1) HLA-matched LPS-matured dendritic cells (DC), which 
have optimal antigen presenting capacity, and (2) EBV-transformed autologous B-cells (B-LCL), 
which – compared to DC – are considered to be suboptimal APC [ 15]. These APC, pulsed with increas-
ing concentrations of 32-mer peptides, were used as stimulator cells for the E6-speciﬁ c T cell clones, 
after which the secretion of IL- 10 and IFNg was determined using the cytokine secretion assay. Eight 
out of  13 CD4+ T cell clones were available for analysis; the remaining 5 clones could not be main-
tained in culture. Within the 8 E6-speciﬁ c CD4+ T cell clones analyzed, 3 distinct cytokine proﬁ les 
were revealed. The ﬁ rst proﬁ le is represented by clones 3 and  13. When stimulated with peptide-
pulsed B-LCL, these clones only produced IL- 10 and almost no IFNg, even at high peptide concentra-
tions. Similarly, stimulation with peptide-pulsed DC (peptide concentration up to  1 µg/ml), triggered 
IL- 10 secretion only. Interestingly, these T cells started to produce IFNg in addition to IL- 10 when 
stimulated with DC pulsed with higher concentrations ( 1- 10 µg/ml) of peptide (Figure 5a). A second 
distinct cytokine proﬁ le was represented by clones 4, 7,  10,  1 1 and  12, in that these T cell clones 
displayed a shift from the secretion of only IL- 10 towards secretion of IL- 10 and IFNg when incubated 
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Figure 3. HPV 16E6-speciﬁ c T cell clones derived from tumor-draining lymph node generally secrete IL- 10 and IFNg. In an 
initial screening, the T cell clones derived from the HPV 16E6-speciﬁ c lymph node culture were tested for the recognition of E6 
peptide-pulsed irradiated autologous PBMC (+). Non-pulsed PBMC were taken along as a negative control (–). Supernatants 
harvested at 48 hours were analyzed for the presence of IL- 10 and IFNg by ELISA, and the proliferation was measured by [3H]-
thymidine incorporation. The results from the T cell clones showing E6 recognition are depicted. 
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with B-LCL that were pulsed with increasing concentration of peptides (Figure 5b). When incubated 
with mature DC these T cell clones produced both IFNg and IL- 10 at low (0.0 1-0. 1 µg/ml) peptide 
concentrations, with the majority of cells secreting IFNg only. A third cytokine proﬁ le was found for 
clone 6; stimulation of this T cell clone with either B-LCL or DC only triggered secretion of IFNg, 
almost no IL- 10 (Figure 5c). Notably, high amounts of peptide ( 1- 10 µg/ml) were required to induce 
the IFNg production in this T cell clone. Even though these 3 cytokine proﬁ les exhibit a different bal-
ance between IL- 10 and IFNg, they have one thing in common: IFNg secretion is only observed at 
the most optimal stimulatory conditions, either involving B-LCL loaded with high ( 10 µg/ml) peptide 
concentration and/or mature DC (see summary in Table  1).
 The highest peptide concentrations used for APC pulsing in the titration experiments will most 
likely result in a higher T cell epitope density on the APC surface than expected in vivo in the tumor-
draining lymph node. Furthermore, the costimulatory context offered by mature DC is not likely to 
be found in tumor-draining LN. This suggests that IL- 10 will be predominant in the overall in vivo 
response to tumor-derived E6 antigen in the context of the tumor-draining lymph node. 
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Figure 4. HPV 16E6-speciﬁ c T cell clones secrete low levels of IL-4 and IL-5 in addition to IL- 10 and IFNg. HLA-class II matched 
dendritic cells were pulsed with increasing E6 peptide concentrations and used – after LPS-induced maturation (24 hrs) – as APC 
in a 3-day proliferation assay. The HPV 16E6-speciﬁ c T cell clones were added and supernatants were harvested 6,  18, and 48 hours 
after stimulation. The supernatants were analyzed for the presence of IFNg, IL- 10, IL-5, and IL-4 by ELISA. The cytokine proﬁ le of 
clone 4 is depicted, which was representative of the proﬁ les observed for most other E6-speciﬁ c T cell clones (tested for clones  1, 
2, 3, 4,  12,  13). Cytokine kinetics revealed that the highest concentration of IFNg, IL- 10 and IL-5 could be measured at 48 hours, 
whereas the highest concentration of IL-4 at  18 hours. The cytokine concentrations are depicted as measured at the optimal 
timepoint for each individual cytokine. 
Table  1. HPV 16E6-speciﬁ c CD4+ T cell clones. 
     B-LCL   DC  
 Clone E6 HLA IL- 10  IFNg IL- 10  IFNg Proﬁ le
 3  1-32a DP 0. 1b   10 0.0 1   1 I
  13 55-86 DR 0. 1   10 0. 1   1
      
 4 73- 104 DP 0. 1   1 0.0 1  0.0 1 II
 7 9 1- 122 DR n.t.  n.t.  1   1
  10 55-86 n.t.  1   10  1   1
  1 1 n.t. n.t.  1   10 0. 1  0. 1
  12  19-50 DR  1   10 0. 1  0. 1
      
 6 55-86 n.t  10   1  10   1 III
 a Indicated is the 32-mer E6 peptide that is recognized by the corresponding T cell clone and its HLA class II restriction.
 b The concentrations of E6 peptide pulsed on the APC are expressed in µg/ml (32-amino acid long peptides). Indicated is the 
lowest peptide concentration at which the T cells clone secreted the corresponding cytokine. The cut off level for cytokine 
secretion was set at > 2 ¾ background and ≥ 2 %. n.t. = not tested.
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Lymph node-derived inﬂ uenza M 1-speciﬁ c CD4+ T cell clones display predominant secretion 
of IFNg
In view of our ﬁ ndings, we investigated whether the observed cytokine secretion proﬁ les are a typi-
cal feature of the HPV-speciﬁ c T cell response in this patient, or a more common characteristic of T 
cells residing in the lymph nodes, or even just a result of our in vitro culture approach. Therefore, we 
studied the T cell response against the inﬂ uenza M 1 antigen, which is commonly characterized by 
systemic Th 1 memory in both patients and healthy individuals [ 16- 18]. By the same in vitro culture 
method we obtained an inﬂ uenza M 1-speciﬁ c polyclonal T cell culture and subsequent limiting dilu-
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Figure 5. Single cell analysis of the HPV 16E6-speciﬁ c T cell clones at the level of cytokine secretion. Eight HPV 16E6-speciﬁ c 
T cell clones were analyzed for the secretion of IFNg and IL- 10 in response to autologous B-LCL and HLA-matched LPS-matured 
(24 h) dendritic cells pulsed with increasing peptide concentrations, using the cytokine secretion assay. This analysis revealed 3 
distinct cytokine secretion patterns, depicted in a (clone 3), b (clone 4) and c (clone 6). The percentages of cytokine-secreting T 
cells are indicated in the corners of the dotplots. The cells are gated for live CD4+ T cells.
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tion of this culture resulted in a total of 5 M 1-speciﬁ c CD4+ T cell clones. In the initial screening 
by ELISA, we found that in response to stimulation with irradiated PBMC and M 1 peptides, all 
clones secreted IFNg (Figure 6). Furthermore, in the supernatants of 3 out of 5 M 1-speciﬁ c T cell 
clones (clones  14,  15,  17) IL- 10 was detected. This IL- 10 secretion in combination with IFNg appeared 
similar to the cytokine proﬁ les of the E6-speciﬁ c T cell clones. However, analysis at the single cell 
level – using peptide-pulsed mature HLA-matched dendritic cells (DC) and autologous EBV trans-
formed B-cells (B-LCL) as APC – revealed a different picture. Two distinct cytokine proﬁ les were 
observed. The ﬁ rst, represented by clone  17, displayed the predominant secretion of IFNg in response 
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Figure 6. Inﬂ uenza M 1-speciﬁ c T cell clones derived from tumor-draining lymph node also secrete IL- 10. In an initial screen-
ing, the T cell clones derived from the inﬂ uenza M 1-speciﬁ c lymph node culture were tested for the recognition of M 1 peptide-
pulsed irradiated HLA class II matched PBMC (+). Unpulsed PBMC were taken along as a negative control (-). The supernatants 
harvested at 48 hours were analyzed for the presence of IL- 10 and IFNg by ELISA. Only the results from the T cell clones showing 
M 1 recognition are depicted.
Table 2. Inﬂ uenza M 1-speciﬁ c CD4+ T cell clones.
    B-LCL   DC  
 Clone IL- 10 IFNg IL- 10 IFNg Proﬁ le
  17 0.0 1 a 0.00 1 0.0 1 0.00 1  1
    
  14 · 0.0 1 · 0.0 1 2
  15 · 0. 1 n.t. n.t
  16 ·  1 n.t. n.t.
  18 ·  1 n.t. n.t.
 a The concentrations of M 1 peptide pulsed on the APC are expressed in µg/ml (30-amino acid long peptides). Indicated is the 
lowest peptide concentration at which the T cells clone secreted the corresponding cytokine. The cut off level for cytokine 
secretion was set at > 2 ¾ background and ≥ 2 %. n.t. = not tested and a dot indicates non-detectable cytokine secretion.
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to both DC and B-LCL. IL- 10 secretion was induced upon stimulation with APC pulsed with >0.0 1 
µg/ml of peptide in a signiﬁ cant percentage of T cells, and was most pronounced when B-LCL were 
used as APC. In contrast to the IL- 10-secreting E6-speciﬁ c T cell clones, this M 1-speciﬁ c clone initiated 
the secretion of IFNg at low peptide concentration (0.00 1 µg/ml), while IL- 10 secretion was induced 
only at higher peptide concentrations. The second cytokine proﬁ le, represented by the remaining 
clones, was characterized by the secretion of IFNg only, irrespective of the type of APC and peptide-
density on the APC surface (Figure 7b); a maximum of  1 % of the T cells (clones  14 and  15 upon 
stimulation with B-LCL) displayed the secretion of both IFNg and IL- 10. The discrepancy between 
this low percentage of IL- 10-secreting cells and the detection of IL- 10 in the culture supernatants 
of the stimulated cells (Figure 6), may be explained by the fact that IL- 10 concentration in the cul-
ture supernatant is related to its accumulation (determined by production and consumption) in 48 
hours, whereas the ﬂ owcytometric analysis measures the production of each individual cell within 
3 hours, which is apparently low for IL- 10 in these clones. Taken together, the cytokine proﬁ les of 
the M 1-speciﬁ c T cell clones revealed a predominance of IFNg and only limited IL- 10 secretion at 
the single cell level. An overview is presented in Table 2. Three M 1-speciﬁ c T cell clones were tested 
using only B-LCL as APC. In previous experiments we consistently observed that upon stimulation 
with B-LCL, T cell clones are more prone to secrete IL- 10 as compared to DC. Therefore, the fact that 
for these three clones only IFNg was detected in response to peptide-pulsed B-LCL, makes it highly 
unlikely that they will secrete signiﬁ cant amounts of IL- 10 in response to peptide-pulsed DC. 
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Figure 7. Single cell analysis of the Inﬂ uenza M 1-speciﬁ c T cell clones at the level of cytokine secretion. Five inﬂ uenza 
M 1-speciﬁ c T cell clones were analyzed for the secretion of IFNg and IL- 10 in response to autologous B-LCL and HLA-matched 
mature dendritic cells pulsed with increasing peptide concentrations, using the cytokine secretion assay. This analysis revealed 2 
distinct cytokine secretion patterns, depicted in A (clone  17) and B (clone  14). The percentages of cytokine-secreting T cells are 
indicated in the corners of the dotplots. The cells are gated for live CD4+ T cells.
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Despite the small numbers of M 1 and E6-speciﬁ c T cell clones analyzed, the presented data suggest 
a qualitative difference in the T cell response against these viral antigens in the lymph node of this 
patient. Whereas the E6-speciﬁ c response is dominated by IL- 10 secretion at suboptimal TCR trigger-
ing, the inﬂ uenza M 1-speciﬁ c response was characterized by the secretion of IFNg.
IL- 10-secreting HPV-speciﬁ c T cells present in tumor inﬁ ltrating lymphocyte (TIL) populations
The analysis of tumor-draining lymph nodes is limited to those patients with proven metastatic cervi-
cal cancer; in all other patients the lymph nodes are required for diagnostic purposes. This implies 
that lymph node analysis selects patients with advanced cancer, and as such, the described pre-
dominance of IL- 10-secreting T cells may not apply to patients with non-metastatic disease. For this 
reason, we embarked on the analysis of lymphocyte populations derived from tumors of nine cervical 
cancer patients without tumor-positive lymph nodes. 
 Tumor tissue was cultured with T cell growth factor (TCGF) and IL- 15, without the addition of 
antigen, until lymphocytes emerged from the tissue (TIL). These TIL were tested in short-term prolif-
eration assays for HPV 16 or HPV 18 reactivity, as were freshly isolated PBMC derived from the same 
patients (Table 3). Frequently, HPV-reactivity was observed in TIL cultures, while no detectable HPV-
speciﬁ c responses were present in PBMC of the same patient. This implies that the absence of detect-
able systemic HPV immunity does not exclude the local presence of HPV-speciﬁ c T cells. 
 TIL cultures with HPV-reactivity (6 out of 9) were subjected to cytokine analysis. The secretion of 
IL- 10 and IFNg by CD4+ T cells was determined at the single cell level, and in response to antigenic 
stimulation, these TIL cultures were all shown to harbor HPV-speciﬁ c CD4+ T cells secreting IL- 10, 
IFNg and/or a combination of both cytokines. The balance between IL- 10+ and IFNg+ HPV-speciﬁ c 
T cells showed a considerable variation. At chosen stimulatory conditions – involving high peptide 
concentrations ( 10 µg/ml) pulsed on GM-CSF cultured autologous monocytes – 3 out of 6 cultures 
showed a predominance of IL- 10+ T cells in response to HPV antigens (Table 3 and Figure 8a), 
whereas in 2 cultures IFNg+ T cells were more abundant (Figure 8b). In one culture similar percent-
ages of IL- 10+ and IFNg+ HPV-speciﬁ c T cells were detected. 
IFNg
IL
-1
0
0.1 0.0
0.0
0.8 3.2
23.2
a 0.3 0.1
0.0
2.1 0.2
0.1
b
control stimulated
Figure 8. Single cell analysis of TIL cultures at the level of cytokine secretion. TIL cultures that showed HPV-reactivity were 
analyzed for IL- 10 and IFNg using the cytokine secretion assay. The TIL were incubated with GM-CSF cultured monocytes, which 
were pulsed with  10 µg/ml peptide or medium only (control). In response to antigenic stimulation the TIL cultures showed either a 
predominance of CD4+ T cells secreting IL- 10 (A, patient 9) or IFNg (B, patient 2). A representative example of each is shown. The 
percentages of cytokine-secreting T cells are indicated in the corners of the dotplots. The cells are gated for live CD4+ T cells. 
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Overall, these data show that the local presence of IL- 10-secreting HPV-speciﬁ c CD4+ T cells is a 
common feature in cervical cancer patients. The implications of these ﬁ ndings are subject to future 
study, which shall address the immunoregulatory capacity of these T cells and their role in disease 
outcome. 
Discussion
HPV 16-positive cervical cancer patients frequently lack strong systemic HPV 16-speciﬁ c CD4+ T cell 
immunity associated with pro-inﬂ ammatory cytokines [3]. In this study we show that not only the 
HPV-speciﬁ c T cells in the peripheral compartment, but also those residing in the tumor and tumor-
draining lymph nodes are associated with a non-inﬂ ammatory cytokine proﬁ le. Detailed analysis of 
lymph node-derived HPV 16E6-speciﬁ c CD4+ T cell clones revealed that they predominantly secreted 
IL- 10 and IFNg upon antigen stimulation; the balance between both cytokines strongly depending 
on type of APC used for antigen presentation and the HLA class II – peptide density on the surface 
of the APC. At low antigen concentrations and suboptimal antigen presentation IL- 10 secretion was 
clearly favored, whereas IFNg was secreted only upon optimal T cell stimulation involving high pep-
tide concentrations and fully mature DC. A similar HPV-speciﬁ c T cell repertoire was found in the 
tumor-draining lymph node of a second patient that we recently analyzed (data not shown). Since 
cervical cancers do not provide the proper pro-inﬂ ammatory environment to induce potent T cell 
immunity, it is conceivable that T cell priming at this disease stage will affect the polarization of 
HPV 16-speciﬁ c CD4+ T cells. In contrast, inﬂ uenza M 1-speciﬁ c T cell clones derived from the same 
draining lymph node showed predominant secretion of IFNg, independent of APC type or HLA class 
II – peptide density. The clearly Th 1 polarized cytokine proﬁ le of the inﬂ uenza M 1-speciﬁ c T cells can 
be explained by the fact that these cells have been primed in a strong pro-inﬂ ammatory environment 
of the pulmonary lymphoid system during inﬂ uenza infection and then entered the circulation. 
Table 3. Tumor-derived lymphocyte cultures.
Patient HPV typea PMBCb TILc IL- 10d IFNg
   1  HPV 16 · HPV 16E6 + +
 2  HPV 16 · HPV 16E7 + ++
 3  HPV 16/ 18 · ·  
 4  HPV 16 · HPV 16E7 + ++
 5  HPV 18 · ·  
 6  n.t. HPV 18E7 HPV 18E7 ++ +
 7  n.t. · ·  
 8  HPV 16 · HPV 16E6 ++ +
 9  HPV 18 HPV 18E6E7 HPV 18E6E7 ++ +
 a HPV type detected in tumor tissue 
 b Freshly isolated PBMC from 9 cervical cancer patients were incubated with pools of HPV 16/ 18 E6 and E7 peptides ( 10 µg/ml) 
for 6 days after which proliferation was measured by [3H]-thymidine incorporation. A proliferative response was scored 
positive when the proliferation of 6 out of 8 parallel microcultures exceeded the mean + 3 ¾ SD of medium control and 
the stimulation index was >3. 
 c Cytokine-cultured tumor inﬁ ltrating lymphocytes (TIL) were incubated with monocytes loaded with pools of HPV 16/ 18 E6 
and E7 peptides and recombinant E6 and E7 protein. A positive response was deﬁ ned as a stimulation index > 3. All 
peptide-speciﬁ c cultures showed recognition of the corresponding protein.
 d TIL cultures displaying HPV-reactivity were analyzed at the single cell level for the antigen-speciﬁ c secretion of IFNg and IL- 10 
in response to monocytes pulsed with  10 µg/ml of peptide. A ‘+’ indicates that percentage of cytokine-positive CD4+ T cells in 
response to HPV antigen was at least 3 times that of unstimulated control.  ‘++’ indicates the most predominant cytokine (the 
percentage of CD4+ T cells secreting one cytokine is at least two times that of CD4+ T cells secreting the other cytokine). A 
dot indicates that no HPV-speciﬁ c response was detected. n.t. = not typed for HPV.
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The difference in cytokine proﬁ les of HPV 16E6 and inﬂ uenza M 1-speciﬁ c T cell clones suggests that the 
observed IL- 10-secreting HPV 16E6-speciﬁ c T cells are related to HPV-induced disease in this patient, 
rather than a general feature of the T cells residing in the tumor-draining lymph nodes. Furthermore, 
our observation that HPV 16-speciﬁ c T cell clones derived from the peripheral blood of healthy individ-
uals are generally clearly Th 1 (or Th2) polarized, sustains the notion that the IL- 10-secreting HPV 16-spe-
ciﬁ c T cells reﬂ ect failing HPV-speciﬁ c immunity. However, this should be conﬁ rmed by the analysis of 
lymph node cells from individuals who have successfully controlled HPV 16 infection. 
 The balance between the IFNg and IL- 10 secretion of the T cell clones was dependent not only on 
the peptide-HLA class II density on the surface of the APC, but also on the type of APC. Stimulation 
with peptide-pulsed B-LCL always resulted in a higher percentage of cells secreting IL- 10, than stimula-
tion with DC. A recent study by Brady et al. showed that the cytokine proﬁ les of melanoma-speciﬁ c 
CD4+ T cells were skewed even more towards IL- 10 secretion upon stimulation with HLA class II-
positive melanoma cells than when stimulated with B-LCL [ 19]. This suggests that interaction between 
the HPV 16E6-speciﬁ c T cells and HLA class II-positive cervical cancer cells will most likely result in 
pronounced IL- 10 secretion; cervical tumors have been shown to express HLA class II in approximately 
80 % of the cases [20]. Supporting the potential in vivo relevance of such interaction is the frequent 
presence in cervical cancer patients of HPV E6 and E7-speciﬁ c tumor-inﬁ ltrating CD4+ T lymphocytes 
with similar IL- 10/IFNg secretion proﬁ les as the lymph node-derived T cells. These T cells may thus 
contribute to local IL- 10 secretion by interaction with HLA class II expressing tumor cells. 
 The isolated secretion of IL- 10 in the absence of pro-inﬂ ammatory cytokines is likely to hamper 
effective induction of immune responses in vivo by modulating APC function, and to interfere with 
effector function of previously primed T cells [5, 2 1]. Currently, we are addressing the in vitro regula-
tory capacity of the HPV 16E6-speciﬁ c IL- 10-secreting T cells. The potential immunoregulatory proper-
ties of these T cells are of major relevance for vaccination strategies. Boosting of pre-existing immu-
nity by active vaccination may result in expansion of the IL- 10-secreting T cell pool, further incapaci-
tating the anti-tumor immune response. On the other hand, adjuvants with a strong Th 1 skewing 
capacity may be able to redirect the immune response in favor of effective anti-tumor immunity. In a 
pilot study, we have attempted to skew the cytokine proﬁ les of the IL- 10-secreting HPV 16E6-speciﬁ c 
T cell clones towards a Th 1 proﬁ le. However, antigen-speciﬁ c stimulation of the T cell clones with 
mature peptide-pulsed DCs or with plate-bound anti-CD3/CD28 both combined with exogenous 
IL- 12 did not result in a loss of IL- 10 secretion in favor of IFNg (data not shown). This suggests that 
the pre-existing HPV 16-speciﬁ c immunity present in patients is not likely to be skewed towards Th 1 
by vaccination. Therefore, in order to be effective, vaccination must result in de novo priming of 
HPV 16-speciﬁ c Th 1 type T cells, capable of overruling the unfavorable pre-existing immunity. 
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Abstract · TA-CIN is a vaccine that comprises the HPV 16 L2, E6 and E7 as a single fusion protein. 
In a mouse model, TA-CIN effectively prevented outgrowth of HPV 16-positive tumour cells. To assess 
the safety and immunogenicity of TA-CIN, a dose escalating (26 µg,  128 µg, 533 µg), double blind and 
placebo-controlled phase I study was conducted in 40 healthy volunteers. TA-CIN was administered 
without adjuvant by intramuscular injection on weeks 0, 4 and 8. No serious adverse events of the vac-
cination were reported during the study. Both IgG antibodies and proliferative responses against TA-CIN 
were elicited at all three doses. More importantly, T cell immunity against the HPV 16 E6 and E7 oncop-
roteins was detected by IFNg ELISPOT in 8/ 1 1 evaluable subjects vaccinated with the 533 µg dose. 
Enhancement of HPV16 E6 and E7-
speciﬁ c T cell immunity in healthy 
volunteers through vaccination with 
TA-CIN, an HPV 16 L2E7E6 fusion 
protein vaccine 
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Introduction
The causal link between oncogenic human papillomaviruses (HPV) and the development of cervical 
intraepithelial neoplasia (CIN) is now well established [ 1]. Current screening techniques and treat-
ment modalities have reduced the levels of cervical cancer in the developed world signiﬁ cantly. 
However, cervical cancer remains the second most common cancer in women (after breast cancer) 
worldwide [2].
 There are a number of observations that HPV infection is normally kept under control by the 
immune system and that vaccination could have a therapeutic effect in patients with HPV positive 
lesions. The incidence of HPV infection is often increased in immunosuppressed and immunodeﬁ cient 
patients [3, 4]. Furthermore, in the majority of immunocompetent individuals the HPV infection is 
asymptomatic, while most premalignant cervical lesions are found to regress spontaneously [5-7]. 
This regression is likely to be mediated by cellular immune responses, since regressing genital warts 
are predominantly inﬁ ltrated with CD4+ T cells and macrophages, consistent with a delayed type 
hypersensitivity reaction [8, 9]. The HPV E6 and E7 oncoproteins are exclusively expressed in virally 
infected cells, cervical intraepithelial neoplasia and cancer cells, as such these non-structural antigens 
form attractive targets for T-cell-based immunotherapy [ 10]. The use of animal models, in which vac-
cines inducing T cell immunity against these non-structural antigens controlled established tumours, 
points at the potential efﬁ cacy of therapeutic vaccination against HPV infection [ 1 1- 17]. 
 We have previously shown that a newly designed vaccine candidate, comprising the HPV 16 L2, E6 
and E7 as a single fusion protein (TA-CIN), elicited HPV 16-speciﬁ c CTL, T-helper cells and antibodies 
in a pre-clinical mouse model. Moreover, vaccination with TA-CIN effectively prevented outgrowth 
of HPV 16-positive tumour cells in a prophylactic setting as well as in a minimal residual disease 
setting [ 18]. In the present study, the safety and immunogenicity of TA-CIN in healthy volunteers 
was analysed. Vaccination with TA-CIN was safe and well tolerated. Furthermore, TA-CIN induced 
HPV 16-speciﬁ c antibodies as well as E6 and/or E7-speciﬁ c T cell responses in the majority of subjects.
Materials and Methods
TA-CIN vaccine · HPV 16 DNA was isolated from the W 12 cell line [ 19], derived from biopsy material, 
histologically determined to be CIN 1, recovered from a 22-year old female with a history of abnormal 
cervical Papanicolaou smears. The HPV 16 L2, E6 and E7 genes were speciﬁ cally ampliﬁ ed from the 
viral DNA by PCR to generate individual products. Target genes were cloned in pET plasmids under 
the control of the strong bacteriophage T7 transcription and translation signals; expression was 
induced by providing a source of T7 RNA polymerase in the host cell. The HPV 16 L2E7E6 fusion pro-
tein antigen was formed in a bacterial expression system consisting of the bacterial host Escherichia 
coli HMS 174 (DE3) carrying the plasmid pCIN 170. The construct contained a fusion gene encoding 
the HPV 16 L2E7E6 fusion protein antigen under the global control of a Lac promoter. The construct 
also contained a Kanamycin resistance gene selective marker. TA-CIN protein was produced in E. coli 
batch culture. Inclusion bodies were disrupted using a high pressure homogeniser, and the protein 
product was then solubilised in guanidine hydrochloride (GuHCl) and further puriﬁ ed using a 5-step 
chromatographic process. The puriﬁ ed L2E7E6 protein was then ﬁ ltered through a 0.2 µm membrane 
and stored at –80° C prior to QC testing, QA review and lot release procedures. The ﬁ nal product 
was formulated in 5 mM phosphate, 5 mM glycine buffer pH 8.0 containing 0.9 mM cysteine. The 
placebo consisted of vehicle alone.
Subjects · Forty healthy volunteers were recruited into the study at Pharma Bio-Research Group B.V. 
in the Netherlands. Thirty males and ten females (post menopausal, non-reproductive) were divided 
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into four groups: group  1-3 (3 ¾  10 males), group 4 ( 10 females). Volunteers were randomised to one of 
two arms in an 8:2 ratio: TA-CIN (n=8); placebo (n=2) using a randomisation schedule, drawn up in 
advance. The age of the male volunteers ranged between  19-55 years with a mean of 36.0 years. The 
age of the post-menopausal female volunteers ranged between 43-55. Subjects were considered to be 
healthy on the basis of medical history and a physical examination consisting of ECG, haematology 
(haemoglobin, mean cell volume, platelet count, white blood cell count and full differential), clinical 
chemistry (sodium, potassium, creatinin, total bilirubin, alkaline phosphatase, alanine aminotransfer-
ase (ALT), asparatase aminotransferase (AST), urea, albumin and glucose), urine analysis and vital 
signs (blood pressure, pulse and oral temperature) at day 0, 28, 56 and on day 84. Female patients 
were also required to have a negative PAP smear at the pre-vaccination screening visit. A negative 
urine pregnancy test at day 0, 28 and 56 was required, and a negative PAP smear at day 84. A clini-
cally signiﬁ cant value from any of these tests reported by the laboratory was entered as an adverse 
event. Adverse events were reported as an underlying diagnosis with the laboratory value included. 
Clinically signiﬁ cant values that were thought to be due to administration of the study drug were fol-
lowed up until week  12 (i.e. the last follow-up visit), which was 4 weeks after the last vaccination.
Immunization protocol · In this phase I, double blind, randomised, placebo-controlled, dose-esca-
lating study subjects were randomised to receive one of three dose levels, 25 µg,  125 µg and 500 
µg/dose. The actual doses administered (cohort P: placebo, cohort  1: 26 µg, cohort 2:  128 µg and 
cohort 3 and 4: 533 µg) were based on ﬁ nal protein concentration measurements of ﬁ lled vaccine. 
These varied slightly from the predicted dose levels due to the dilution required from bulk material 
during the ﬁ lling process. Vaccine was administered without adjuvant as three consecutive intramus-
cular injections into the same upper arm on weeks 0, 4 and 8. The primary objective of the study 
was to assess the safety and tolerability of TA-CIN. Samples were taken for immunogenicity assay 
on week 0 (pre-vaccination), week 4 (4 weeks after the ﬁ rst vaccination), week 8 (4 weeks after the 
second vaccination) and week  12 (4 weeks after the third vaccination).
Safety monitoring · Prompted and spontaneous adverse events, injection site reactions, clinical 
assessments and clinical laboratory parameters were used as safety parameters. Injection site reac-
tions were deﬁ ned as induration, erythema or tenderness.
Lymphocytes · Peripheral blood mononuclear cells (PBMC) were separated from fresh citrated blood 
directly upon receipt (<24 hours after bleeding) using Lymphocyte Separation Medium (ICN Bio-
medicals) density gradients. PBMC were cryopreserved in vapour phase nitrogen until use. 
T cell proliferative responses · T cell proliferation assays were set up in triplicate in 96-well round 
bottom plates. Cells, 2 ¾  105 cells/well in Dutch-modiﬁ ed RPMI- 1640 (Gibco BRL) containing 5 % (v/v) 
human AB serum (BioWhittaker) supplemented with penicillin ( 100 U/ml), streptomycin ( 100 µg/ml) 
and L-glutamine (4 mM) (all Gibco BRL), were cultured with serial dilutions of TA-CIN and TA-GW (a 
fusion protein consisting of L2 and E7 of HPV6 [20]) (both Xenova), and optimal concentrations of 
the positive control antigens: tetanus toxoid (Medeva), inactivated HSV- 1 (Xenova) or PHA (Murex) 
and incubated at 37° C in 5 % CO2 humidiﬁ ed atmosphere. Interassay variability was minimized by 
testing the samples of all subjects from one group together in the same assay. For each culture 
the stimulation index was calculated by dividing the mean of antigen-induced proliferation by the 
mean of the medium control. Wells were pulsed with 0.5 µCi of [3H]-thymidine for the ﬁ nal  18h of 
a six day culture, harvested and the incorporated radioactivity was determined with a  1450 Microb 
Plus counter (Wallac). Cultures were considered positive when the stimulation index (SI) of antigen-
induced proliferation was ≥ 3 and of which the proliferation induced [3H]-thymidine incorporation 
exceeded 5,000 counts per minute. Because TA-GW [20] was produced under comparable conditions 
as TA-CIN, this protein served as a control for HPV 16 L2E7E6 speciﬁ c induced T cell proliferation. 
Therefore, a vaccination speciﬁ c response was deﬁ ned as a positive proliferative response to TA-CIN 
of which the SI was at least 4 fold higher than that induced by TA-GW.
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HPV 16 E6 and E7-speciﬁ c T helper responses · Analysis of T cell responses using IFNg ELISPOT was 
performed as described previously [2 1]. Brieﬂ y, PBMC were thawed and seeded at a density of 2 ¾  106 
cells/well of a 24 well plate (Costar, Cambridge, MA) in  1ml of Iscove’s medium (Gibco) enriched 
with  10 % FCS, in the presence or absence of indicated E6 and E7 peptide pools. As a positive control 
PBMC were cultured in the presence of a memory recall mix (MRM), consisting of a mixture of tetanus 
toxoid (0.75 LF/ml ; National Institute of Public Health and Environment, Bilthoven, The Netherlands), 
Mycobacterium tuberculosis sonicate (2.5 µg/ml; generously donated by Dr. P. Klatser, Royal Tropical 
Institute, Amsterdam, The Netherlands) and Candida albicans (0.005 %, HAL Allergenen Lab, 
Haarlem, The Netherlands. The peptides used spanned the HPV 16 E6 and E7 protein and consisted 
of ﬁ fteen E6 and nine E7 overlapping 22-mer peptides. Peptides, as indicated by their ﬁ rst and last 
amino acid in the protein, were used in pools of 4-5 peptides at a concentration of 5 µg/ml/peptide. 
The following pools were made E6-I:  1-22,  1 1-32, 2 1-42, and 3 1-52, E6-II: 4 1-62, 5 1-72, 6 1-82 and 7 1-92, 
E6-III: 8 1- 102, 9 1- 1 12,  10 1- 122 and  1 1 1- 132, E6-IV:  1 1 1- 132,  12 1- 142,  13 1- 152 and  137- 158, E7-I:  1-22,  1 1-32, 2 1-42, 
3 1-52, E7-II: 4 1-62, 5 1-72, 6 1-82, 7 1-92 and 77-98. Following 4 days of incubation at 37° C, PBMC were 
harvested, washed and seeded in four replicate wells at a density of  105 cells/well of a Multiscreen 
96-well plate (Millipore, Etten-Leur, The Netherlands) coated with a IFNg catching antibody (Mabtech 
AB, Nacha, Sweden). The ELISPOT was further performed according to the instructions of the 
manufacturer (Mabtech). The number of spots were analysed with a fully automated computer 
assisted video imaging analysis system (Carl Zeiss Vision). Speciﬁ c spots were calculated by subtracting 
the mean number of spots + 2 ¾ SD of the medium only control from the mean number of spots of 
experimental wells. Antigen-speciﬁ c T cell frequencies were considered to be increased compared to 
non-responders when speciﬁ c T cell frequencies were ≥  1/ 10,000 PBMC [2 1].
Serology · L2E7E6 speciﬁ c antibodies were measured by ELISA. Ninety-six well plates were coated 
with TA-CIN L2E7E6 fusion protein in  100 mM carbonate buffer, pH9.6, overnight at 4° C. Wells were 
blocked with 2 % bovine serum albumin in PBS for  1 h at 37° C. Serial dilutions starting at  1:50, of 
test serum samples and known positive and negative samples diluted in PBS/2 %BSA were added to 
triplicate wells and incubated for  1 h at 37° C. After washing with PBS/0.05 %Tween-20, biotinylated 
monoclonal anti-human IgG (Sigma) was added and incubated for  1 h at 37° C. Plates were washed 
and incubated with horseradish peroxidase-streptavidin (Zymed) for  1 h at 37° C. Plates were washed 
and developed with o-phenylene diamine / H2O2 for 30 min at room temperature and the absorbance 
was measured at 490 nm. Antibody titres are recorded as the log 10 of the reciprocal of the dilution 
at an absorbance of  1.0 [ 18]. 
Results
Safety and tolerability of TA-CIN 
To test the safety of TA-CIN in humans, 40 subjects consisting of 30 males and  10 non-reproductive 
females were recruited. Of these subjects 6 males and 2 females were vaccinated with placebo. 
The other 24 males were divided into three cohorts vaccinated with either 26 µg,  128 µg or 533 µg 
doses of TA-CIN. Because it was anticipated that recruitment of non-reproductive post-menopausal 
females would be slow, the dose-escalation study was performed in males. The 8 females were 
injected with 533 µg doses of TA-CIN only. Subjects were vaccinated intramuscularly, three times at 
4-weeks intervals in the same upper arm.
 All 40 subjects completed the study without reporting any serious or severe adverse events. The 
majority of events were reported within 7 days of each vaccination (Table  1). As a local injection site 
reaction, tenderness was the most frequently reported event. The number of subjects reporting ten-
derness increased when higher doses of TA-CIN were administered (Table  1). The number of subjects 
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reporting moderate tenderness was higher after vaccination at the two highest doses (4/8 at  128 µg; 
7/ 16 at 533 µg) compared to placebo (0/8) or the lowest dose (0/8) of TA-CIN administered. Local 
reactions such as redness and swelling were rarely reported with most occurrences only lasting for 
one or two days. The number of females reporting injection site reactions was relatively high com-
pared to the number of males. However, the mean age of the female volunteers was substantially 
higher than that of the male volunteers. The most frequently reported systemic adverse events of 
moderate severity, possibly related to the study medication, were headache and fatigue. The study 
showed no relation between the number and severity of systemic adverse events and the dose of 
TA-CIN administered or the number of injections given. Results obtained from vital signs, clinical 
chemistry, ECG parameters and physical examination revealed no clinically relevant abnormalities. 
In general, three administrations of TA-CIN at doses up to 533 µg were safe and well tolerated.
TA-CIN elicits speciﬁ c IgG responses
It is conceivable that vaccination with whole antigen induces humoral immunity. Therefore, sera 
from all individuals were analysed for TA-CIN speciﬁ c IgG antibodies by ELISA (Table 2). Low levels 
of pre-existing TA-CIN-speciﬁ c IgG were seen in 2 (# 23 and 36) of the 40 individuals, although no 
reliable antibody titres could be determined. One of these subjects (# 36) received placebo and no 
further increase in speciﬁ c IgG was detected. In two other subjects (#  13 and 39), a high anti-TA-CIN 
IgG level was detected before vaccination and this response was boosted after vaccination in subject 
39 only (Table 2).
 Following vaccination all but 8 of 32 subjects receiving the active vaccine produced TA-CIN spe-
ciﬁ c serum IgG. Four of the non-responding subjects received the lowest dose (26 µg) of TA-CIN and 
as such the number of responders in this cohort was not signiﬁ cantly different from the placebo 
cohort (Fisher’s Exact Test, p=0.08). In contrast, the subjects receiving the  128 µg or 533 µg dose vac-
cine responded signiﬁ cantly better than the placebo cohort (Fisher’s Exact Test, p<0.05). 
TA-CIN induces HPV 16 speciﬁ c T cell responses
T cell cultures of all subjects responded to PHA and to one or more of the control antigens tetanus 
toxoid and HSV- 1 in the proliferation assay, indicating a generally good immune status of the tested 
subjects (not shown). To assess the HPV 16 L2E7E6-speciﬁ c T cell proliferation induced by TA-CIN, 
PBMC were stimulated with TA-CIN or the control protein. TA-GW, a clinical-grade HPV6 L2E7 fusion 
protein was used as a control because it was produced under highly comparable conditions as 
TA-CIN [20]. Responses were considered TA-CIN speciﬁ c if the proliferation to TA-CIN exceeded the 
response to TA-GW at least four times. The L2 proteins of HPV6 and HPV 16, in contrast to the E7 
proteins of these viruses, share several regions of considerable sequence homology implicating that 
this manner of scoring for positive proliferation responses is primarily aimed at detecting HPV 16 E6 
and E7-speciﬁ c T cell reactivity. TA-CIN speciﬁ c proliferation was detected after the second and third 
vaccination in cohort  1, and after the ﬁ rst, second or third vaccination in cohorts 2, 3 and 4 (Table 3). 
The number of responders in the  128 µg and 533 µg dose treated cohorts were signiﬁ cantly higher 
than in the placebo cohort (p< 0.0 1, Fisher’s Exact Test). In total 25 of the 32 vaccinated subjects 
responded to the vaccine in this assay. 
 The 26 µg and  128 µg TA-CIN dosed-cohorts were mainly used to assess safety. A more extensive 
analysis of TA-CIN induced T cell reactivity was performed on PBMC samples of individuals vac-
cinated with 533 µg TA-CIN (cohorts 3 and 4). PBMC were stimulated with pools of overlapping 
peptides that together covered the complete HPV 16 E6 and E7 protein. We have previously dem-
onstrated that this allows an accurate analysis of the HPV 16 E6- and E7-speciﬁ c T cell activity 
[2 1], which is expected to play a major role in therapeutic efﬁ cacy. Furthermore, it circumvents 
the possible (cross-) reactions to conserved parts of L2 or to contaminants present in TA-CIN and 
88
Table  1. Local and systemic adverse events after vaccination with TA-CIN.
   Vaccination  1 (Day 0)      Vaccination 2 (Day 28)   
   Injection Tenderness Redness Swelling Systemic   Injection Tenderness Redness  
  #a site pain2  (cm) (cm)     site pain  (cm)  
 P  14 · · · · ·   · · ·  
   18 · · · · ﬂ u-like symptoms  · · ·  
  20 ·  1 · · ·   · · ·  
  25 · · · · fatigue/malaise  · · ·  
  33 · · · · ·   · · ·  
  36 · · · · ·   · · ·  
  43 · · · · fatigue   · · ·  
  48 · · · · ·   · · ·  
 I  10 · · · · ·   · · ·  
   1 1 · · · · ·   · · ·  
   12 · · · · ·   · · ·  
   13 · · · · myalgia   · · ·  
   15 ·  1 · · headache/anorexia/   1 · ·  
  drowsiness/dry mouth
   16 · · · · ·   · · ·  
   17 ·  1 · · headache/rhinitis  · · ·  
   19 · · · · ·    1 · ·  
 II 2 1 · 2 · · fatigue/dizziness/   ·  1 ·  
         abdominal pain/syncope
  22  1 2 ·  1.5 fatigue   · · ·  
  23 · · · · arm weakness  · · ·  
  24 · · · · nausea/dizziness/myalgia  ·  1 ·  
  26 · · · · ·   · · ·  
  27 · 2 · · ·   · · ·  
  28 · 2 · · headache   · · ·  
  29 · · · · ·   · · ·  
 III 30 · · · · ·   · · ·  
  3 1 · · · · ·   · · ·  
  32 · · · · ·   · · ·  
  34 ·  1 · · dizziness   ·  1 ·  
  35 · 2 · · ·   ·  1 ·  
  37 · 2 · · ·   ·  1 ·  
  38 · · · · headache   · · ·  
  39 · · · · ·   · · ·  
 IV 40 · · · · ·   2 · ·  
  4 1 · 2 · · dizziness   · · ·  
  42 ·  1 · · ·   ·  1 ·  
  44 2 2  1.0  1.0 ·   ·  1 ·  
  45 · · · · headache   2 2 5.5  
  46 ·  1 · · ·   · · ·  
  47 · 2 · · ·   · · ·  
  49 · 2 · · dreaming abnormal  2 2 ·  
 a Indicate the different cohorts: placebo control ( 14,  18, 20, 25, 33, 36, 43, 48), group I; males vaccinated with 26 µg ( 10- 13,  15- 17, 19), group II; 
males vaccinated with  128 µg (2 1-24, 26-29), group III, males vaccinated with 533 µg (30-32, 34, 35, 37-39) and group IV; females vaccinated 
with 533 µg (40-42, 44-47, 49).
 b Local and systemic adverse events evaluation:  1 = mild, 2 = moderate.
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    Vaccination 3 (Day 56)
Swelling Systemic   Injection Tenderness Redness Swelling Systemic
(cm)    site pain  (cm) (cm)
· ·   · · · · ·
· ·   ·  1 · · ·
· ·   · · · · ·
· headache/fatigue/malaise  1  1 · · drowsiness
· ·   · · · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·    1  1 · · ·
· ·   · · · · ·
· ·   · · · · ·
· rhinitis   · · · · ·
· fatigue   · · · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·   2 · · · ·
· fatigue/rhinitis  · · · · headache
· ·   · · · · fatigue
· ·   · · · · ·
· nausea/abdominal pain · · · · nausea/abdominal pain
· ·   · · · · ·
· ·   · 2 0.5 0.5 headache/fatigue/inﬂ icted injury
· ·   · · · · ·
· ·   · · · · headache
· ·   · · · · ·
· headache   · · · · ·
· fatigue   · · · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·   ·  1 · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·   · · · · ·
· ·    1 · · · ·
· ·   · 2 · · ·
 1.5 ·   · · · · ·
· ·   ·  1 · · pain both arms
· ·   · 2  1.0 · menstrual disorder
· headache¾3/fatigue  · 2 · · headache
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Table 2. Individual anti-HPV  16 L2E7E6 IgG responses.
 Cohorta  Subject  Log titreb Log titre
   Pre-vaccination  Post-vaccination
 P  14 · ·
   18 · ·
  20 · ·
  25 · ·
  33 · ·
  36 · ·
  43 · ·
  48 · ·
 
 I  10 · 3.0
   1 1 · ·
   12 · 3.0
   13 2.2 2.3
   15 · ·
   16 · ·
   17 · ·
   19 · 2.4
 
 II 2 1 · 2.9
  22 · 2.4
  23 · 3.0
  24 · 2.4
  26 · ·
  27 · 2.9
  28 ·  1.7
  29 · 4.5
  
 III 30 · 4.4
  3 1 · 2.9
  32 · 2.5
  34 ·  1.4
  35 · 2.4
  37 · 2.4
  38 · ·
  39 2. 1 2.9
  
 IV 40 · ·
  4 1 · 3.0
  42 · 3.0
  44 · ·
  45 · 2.9
  46 · 3.0
  47 · 4.3
  49 · 4.3
 a  Indicate the different cohorts: Placebo control (P), vaccinated with 26µg (I),  128 µg (II), 533 µg (III+IV). Subjects  10-39 are 
males, subjects 40-49 are females.
 b  TA-CIN speciﬁ c antibody titers. Titers are expressed as the log of the reciprocal serum dilution that results in an OD value 
of  1. Sera that displayed an OD value of which no reliable titre could be determined are marked with a centerdot ( ·). Post-
vaccination titres are at week  12 following initial vaccination
91
Table 3. TA–CIN speciﬁ c induced proliferative responses.
   TA-CIN    TA-GW    TA-CIN:TA-GW ratio
Cohorta Subject 0b 4 8  12 0 4 8  12 0 4 8  12
 P  14 ·c · · · · · · · · · · ·
   18 9.7 8. 1 · 6. 1 3.7 6.5 · 3.7 · · · ·
  20 6.3 9.7  12 6.3 2.7 7.5 4.8  1. 1 · · · 5.7
  25 7.8 · · · 4.4 · · · · · · ·
  33 9.3 · · · 2.9 · · · · · · ·
  36 · 3.8 3.2 · · 3.3 2.2 · · · · · 
  43 · · 5.0 8.8 · · 3.7 6.8 · · · ·
  48 · · · · · · · · · · · ·
 I  10 7.3  15 7.7 26 3.7 6. 1  1.5 4.4 · · 5.2 5.9
   1 1 ·  16  10 3. 1 · 5.7 4.3 5.5 · · · ·
   12 7.7 9.2 6.0  19 3.2 4.2  1. 1 3.0 · · 5.7 6. 1
   13 · 5.8 · · · 2.3 · · · · · ·
   15 3.4  10  10 38 2.2 3.8 5.6  16    
   16 · ·  13 4.6 · · 6.2 0.8 · · · 5.9
   17 4. 1 25 2 1 3 1 4. 1  10 5.8  12 · · · ·
   19  1 1 8.6 24 4 1 7.5 5.5 5. 1 3.0 · · 4.7  14
 II 2 1 6.0 3.9 5.3  17 2.2  1.8 0.8 n.t.d · · 6.7 n.t.
  22 3.5 · 4.3  1 18  1. 1 ·  1.2 20    5.9
  23 · 3.2 8.4 58 · 0.6 0.9 3.9 · 5. 1 9.7   15
  24 3.7 3.0 7.3 3.6 2.5  1.7  1.7  1.2 · · 4.3 ·
  26 · ·  10 4.9 · ·  1.3  1.7 · 4. 1 7.5 ·
  27 3.0  1 1  160  16  1.9 4.4  13 6.5 · ·   12 ·
  28 · · 5.7 33 · · 0.9 2.7 · · 6. 1  12
  29 6.6 22  165 74  1 1 3.3 20  18 · 6.6 8.2 4. 1
 III 30 8. 1  12 43 36 4.5 3.9  19  1.0 · · ·  35
  3 1 3.7 3.8 93  16 2.0  1. 1 2.6 0.9 · ·  35   18
  32  10 23 24 72 4.8 4.0 2.8 24 · 5.7 8.6 ·
  34 ·  12  13 52 · 4.5 2. 1 20 · · 6.5 ·
  35 3.0 · · 4. 1 2. 1 · · 0.9 · · · 4.4
  37 ·  1 1 5 1 22 · 2. 1 3.5 2.9 · 5. 1   15 7.6
  38 · · 7.4  12 · · 2.7 2.9 · · · 4. 1
  39 · 5.5 5.2 36 ·  1.2  1.0 2.9 · 4.7 5.2  13
 IV 40 · 6.4 57  1 1 · 4.5  13 2.2 · · 4.5 4.8
  4 1 · ·  14 7.3 · · 7. 1 4.3 · · · ·
  42 ·  19 30 5.5 · 6.4  10 2. 1 · · · ·
  44 · 27 4.3 9.2 ·  13  1.0 2.4 · · 4.4 4.0
  45 · 24 47 8.4 · 2.5 7.6  1.4 · 9.6 6.2 6.5
  46 · 8.6 49 44 ·  1.9 5.0 3.6 · 4.5 9.9  12
  47 · 6. 1  12 8. 1 ·  1.0 0.5  1.6 · 6. 1  23 5. 1
  49  19 · 68 20  14 · 33  13 · · · ·
 a Indicate the different cohorts: Placebo control (P), vaccinated with 26 µg (I),  128 µg (II), 533 µg males (III) and 533 µg females 
(IV). Subjects  10-39 are males, subjects 40-49 are females.
 b Different timepoints: Week 0 (pre-vaccination), week 4 (4 weeks after ﬁ rst vaccination), week 8 (4 weeks after second 
vaccination) and week  12 (4 weeks after third vaccination). 
 c Indicated are the Stimulation Indices (SI) of subject-derived PBMC after stimulation with TA-CIN ( 10 µg/ml) or TA-GW (a 
control L2E7 fusion protein of HPV type 6;  10 µg/ml) that responded with an SI ≥ 3 and of which [3H]-thymidine incorporation 
≥ 5000 cpm to TA-CIN. A vaccination speciﬁ c response was deﬁ ned as a positive proliferative response to TA-CIN of which 
the SI was at least 4 fold higher than that induced by TA-GW.
 d n.t. = not tested
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TA-GW preparations. For extensive analysis of HPV 16 E6- and/or E7-speciﬁ c T cell activity sufﬁ cient 
amounts of high-quality PBMC samples were available of  14 subjects. Following the unblinding of 
treatment,  1 1 individuals had been given active vaccine and 3 of the subjects were vaccinated with a 
placebo. The three placebo-dosed subjects did not show HPV 16 E6 or E7-speciﬁ c reactivity. One of  14 
pre-vaccination samples demonstrated T cell reactivity against HPV 16 E7 pool II, suggesting T cell 
memory induced by a previous encounter with HPV 16. After vaccination, HPV 16 E6 and E7-speciﬁ c 
T cell responses were clearly detectable in the majority of individuals given 533 µg TA-CIN (Table 4 
and Figure  1). In general, detection of HPV 16-speciﬁ c T cells in ELISPOT coincided with detection of 
strong TA-CIN speciﬁ c responses in the proliferation assays (compare Table 3 with Table 4, TA-CIN 
speciﬁ c response versus ELISPOT of subjects 3 1, 37, 38, 39, 44 and 45). The most frequently found 
response in the subjects receiving active vaccine was against the E6 IV pool of peptides spanning 
amino acids  1 1 1 to  158. This response was present in >50 % (6 out of  1 1) of the evaluable individuals. 
Sporadic responses were seen against other peptide pools post-vaccination, in particular E6 pools 
II and III (3 of  1 1 subjects) and E7 pools I and II (3 of  1 1 subjects). In total 8/ 1 1 (>70 %) of all evalu-
able individuals vaccinated with the highest dose of TA-CIN showed enhancement of HPV 16 E6/E7-
speciﬁ c INFg-production at least at one point after vaccination. 
Discussion
TA-CIN, comprising the HPV 16 L2, E6 and E7 as a single fusion protein, effectively prevented out-
growth of HPV 16-positive tumour cells in a prophylactic setting as well as in a minimal residual 
disease setting in a pre-clinical mouse model [ 18]. We have subsequently analysed the safety and 
immunogenicity of TA-CIN in a phase I double blind, randomised and placebo-controlled dose-
Table 4. Individual T-helper cell responses to pools of HPV 16 E6 and E7 peptides.
 Cohorta Subject # week 0b week 4 week 8 week  12
 III 3 1 ·c · E6 III (26) ·
     E6 IV (55) ·
  32 · · · ·
  35 E7 II ( 10) · E6 II (24) ·
     E6 III ( 19)  ·
  37 · · E6 IV ( 14) ·
  38 · · E6 IV ( 15) E6 IV ( 17)
  39 · NA E6 IV (44) NA
 IV 4 1 · · NA ·
  42 · · E7 II (28) ·
  44 · · E6 IV ( 13) E6 III ( 10) 
      E6 IV (8)*
      E7 I ( 15)
  45 · E6 IV (42) E6 IV (49) E6 IV (7)*
  46 · · · NA
 a Indicate the different cohorts: vaccinated with 533 µg males (III) and 533 µg females (IV). Subjects 3 1-39 are males, subjects 
4 1-46 are females.
 b Different timepoints: Week 0 (pre-vaccination), week 4 (4 weeks after ﬁ rst vaccination), week 8 (4 weeks after second 
vaccination) and week  12 (4 weeks after third vaccination). 
 c Speciﬁ c spots per  100,000 PBMC are indicated. Speciﬁ c spots were calculated by subtracting the mean number of spots 
+ 2 ¾ SD of the medium control from the mean number of spots of experimental wells. Indicated are those peptide pools 
(and number of spots) to which speciﬁ c T cell frequencies are ≥  1/ 10,000 PBMC since these were considered to be increased 
compared to non-responders [2 1]. NA, not available for analysis. dot (·), no speciﬁ c response to E6 or E7. * The number of 
speciﬁ c spots is shown for comparison with previous time points.
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escalating study of three dose levels TA-CIN (26 µg,  128 µg and 533 µg) in 40 healthy volunteers. 
Vaccination resulted in TA-CIN speciﬁ c IgG antibody and T cell proliferative responses in the major-
ity of individuals. Moreover, in > 70 % of all evaluable individuals vaccinated with the highest dose, 
TA-CIN enhanced HPV 16 E6/E7-speciﬁ c immunity as demonstrated by IFNg ELISPOT. 
 TA-CIN was safe and well tolerated in healthy male (cohorts  1-3) and female (cohort 4) volunteers. 
No serious adverse events were reported. The incidence of adverse events was low and the events 
that did occur were of mild or moderate severity. The total number and relative severity of the 
reported adverse events were lower with TA-CIN than with a related HPV 6 L2E7 vaccine (TA-GW) 
given by the same route of immunisation with an Alum adjuvant [20] suggesting that most of these 
events in the previous study may have been the result of the adjuvant used.
  Pre-existing anti TA-CIN IgG was detected in 4 of the 40 subjects in this study, whereas another 
subject showed pre-existing HPV 16 E7-speciﬁ c T cell immunity. This may reﬂ ect immunological 
memory established by a previous infection with either the homologous virus (HPV  16) or with 
another HPV type. In ﬁ ve subjects TA-CIN speciﬁ c IgG antibodies were found in the absence of a 
clear proliferative response. In one of these subjects a high titre of TA-CIN reactive IgG was already 
present before vaccination. Clearly, injection of TA-CIN neither boosted the IgG response nor the 
T cell response in this subject. Three other individuals showed an increase of proliferation against 
TA-CIN after vaccination but the TA-GW response was also boosted. Bearing in mind the homology 
between L2 of HPV6 and HPV 16 this may well be the result of cross-reactive T cell reactivity against 
L2 of both types. Since we focused mainly at T cell reactivity against the oncoproteins E6 and E7, our 
analysis rather underestimates than overestimates TA-CIN-speciﬁ c reactivity. 
 Animal model studies have shown that cellular immune responses are critical for the resolution 
of HPV induced lesions. Indeed, one vaccination with TA-CIN at the same day of challenge with 
TC- 1 tumour cells protected mice against tumour growth [ 18] demonstrating the capacity of TA-CIN 
to induce effective anti-tumour immunity. Vaccination with TA-CIN induced T cell proliferative 
responses in the majority of human subjects (25 of 32) after 3 vaccinations. Six out of sixteen subjects 
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Figure  1. TA-CIN induces HPV 16 E6 and E7-speciﬁ c IFNg-responses. The mean number of spots and standard error bars 
per  100,000 PBMC induced by the medium control or the peptides present in the E6 and E7 peptide pools are depicted. As positive 
control a memory recall antigen mix (see Materials and Methods) was used. Two examples, representing an HPV 16 E6 and E7 
response are shown. (Top) Female 42 and (Bottom) female 45, at week 0 (pre-vaccination), week 4 (4 weeks after ﬁ rst vaccination), 
week 8 (4 weeks after second vaccination) and week  12 (4 weeks after third vaccination). *, indicate antigen-speciﬁ c responses with 
frequencies >  1/ 10,000.
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that were given a high dose of TA-CIN (533 µg) produced a proliferative response after only  1 vaccina-
tion with TA-CIN. This observation even exceeded our expectations because unadjuvanted proteins 
do not generally stimulate good T cell responses. The reason for the T cell stimulating capacity of 
TA-CIN may reside in the fact that it spontaneously forms a soluble molecular aggregate during the 
puriﬁ cation procedure. 
 Further analysis of the T cell response to TA-CIN using pools of overlapping 22 amino acid long E6 
and E7 peptides by IFNg ELISPOT showed that the dominant immunogenic region of the fusion protein 
mapped between amino acids  1 1 1 and  158 of the E6 protein. Six of eleven evaluable subjects that had 
received the high dose of TA-CIN responded to this C-terminal region of E6. Interestingly, E6-speciﬁ c 
proliferative responses were found associated with clearance of HPV and regression of CIN [22]. 
 The data presented in this paper demonstrate that TA-CIN is capable of enhancing HPV 16 E6- and 
E7-speciﬁ c immunity in humans. Continued boosting of E6/E7-immunity by TA-CIN, however, seems 
sub-optimal since responses tend to decrease after the last vaccination. Pre-clinical studies in mice 
have shown that vaccination with TA-CIN followed by vaccination with a recombinant vaccinia virus 
vaccine containing HPV  16 and  18 E6 and E7 (TA-HPV) stimulated greater T cell immunity than any 
other combination of the two vaccines [ 18]. Together these observations suggest that also in humans 
TA-CIN should preferably be applied together with TA-HPV in the context of a heterologous prime-
boost regimen. In view of this notion, phase II clinical trials have been initiated looking at the TA-
CIN/TA-HPV prime/boost regimen in women with high grade vulval intraepithelial neoplasia (VIN).
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Abstract · The majority of cervical cancers are caused by human papillomavirus type  16 (HPV 16). 
Cervical cancer is associated with an ineffective host immune response against the HPV 16 oncopro-
teins, characterized by the lack of the strong E6-speciﬁ c T-helper type  1 (Th 1) immunity that is gener-
ally present in healthy individuals, the presence of improperly polarized HPV 16E6- and E7-speciﬁ c 
CD4+ T cells and increased numbers of regulatory T cells. Therefore, immunotherapeutic interven-
tion is likely to require a modality that deletes the regulatory T cell component and enhances the 
HPV 16-speciﬁ c Type  1 T cell response. HLA-matched allogeneic stem cell transplantation may offer 
such a modality, because it involves the eradication of host immune cells and enables the transfer 
of donor-derived tumor-speciﬁ c T cells to the patient. As a ﬁ rst step in the development of such a 
treatment, we evaluated the success rate of a protocol for enrichment of HPV 16E6-speciﬁ c CD4+ 
T cells from healthy donor PBMC on the basis of their IFNg secretion. After a short in vitro stimula-
tion with overlapping 30 amino acid long HPV 16E6 peptides, we enriched the IFNg-secreting cells 
by magnetic cell sorting. The obtained polyclonal CD4+ T cell populations recognized distinct epit-
opes within HPV 16E6, as well as E6 protein, processed and presented by autologous professional 
antigen presenting cells. The described protocol proved successful in PBMC from more than half of 
the healthy adult blood donors. These HPV 16E6-speciﬁ c CD4+ T cells may turn out to be an essen-
tial component of future adoptive T cell therapy for advanced cervical cancer, by orchestrating CTL 
dependent and independent tumoricidal mechanisms.
Rapid enrichment of HPV-speciﬁ c 
polyclonal T cell populations for 
adoptive immunotherapy of 
cervical cancer
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Introduction
Cervical cancer is associated with persistent high-risk Human Papillomavirus (HPV) infection. It is 
the ﬁ rst major solid tumor that has been shown to be virally induced in essentially all cases, and 
HPV type  16 (HPV 16) is the high-risk type most frequently found in cervical cancer [ 1]. The HPV 16 
oncoproteins E6 and E7 are constitutively expressed in tumor cells and are required to maintain the 
malignant phenotype [2]. Therefore, these proteins are attractive targets for immunotherapy and, as 
such, have inspired the development of immunotherapeutic strategies for the treatment of patients 
with cervical cancer [3].
 Advanced cervical cancer is associated with tumor-related immunosuppression [4], the presence of 
increased numbers of regulatory T cells [5] and improperly polarized HPV-speciﬁ c T cells [6, 7]. Under 
these circumstances, active therapeutic vaccination will likely fail to establish effective immunity. 
An alternative approach is a passive therapeutic modality involving the adoptive transfer of tumor-
speciﬁ c T cells. In murine tumor models, adoptive T cell therapy has proven successful for the eradica-
tion of established solid tumors [8, 9]. In patients with solid tumors, the adoptive transfer of tumor-
speciﬁ c T cells has mainly been applied in the treatment of metastatic melanoma. These protocols 
have shown a variable success rate [ 10], probably due to the fact that the majority of the protocols 
focused on the generation of large numbers of CD8+ T cells [ 1 1] and dismissed the tumor-speciﬁ c 
CD4+ T cell population, which forms an essential component of the anti-tumor-immunity [ 12- 14]. In 
addition, the autologous setting in which these adoptive T cell transfers are performed, involves two 
major drawbacks. Firstly, ex-vivo expanded patient-derived T cell populations (especially tumor inﬁ l-
trating lymphocytes) may harbor improperly polarized and regulatory T cells that can hamper the 
treatment efﬁ cacy [ 15]. Secondly, pre-existing immunoregulatory mechanisms present in advanced 
cervical cancer patients may prevent the effector function of adoptively transferred tumor-speciﬁ c T 
cells. To overcome the aforementioned barriers, HLA-matched allogeneic stem cell transplantation 
(allo-SCT) involving the eradication of host immune cells – including regulatory T cells – and enabling 
the administration of tumor-speciﬁ c T cells of donor origin, may offer an alternative option. The infu-
sion of donor lymphocytes following allo-SCT has proven relatively successful in the treatment of 
relapsing hematological malignancies [ 16,  17]. In these cases, effective therapy is often based on the 
in vivo induction of T cells speciﬁ c for minor histocompatibility antigens expressed in host cells of 
hematological origin [ 18]. However, the incorporation of allo-SCT in the treatment of solid tumors 
has been less successful [ 19, 20]. This could be due to the lack of deﬁ ned tumor-speciﬁ c antigens, 
as well as tumor-induced tolerization of the donor-derived immune system [2 1, 22], which may occur 
during immune reconstitution. Cervical cancer has the advantage over several other solid tumors 
that it harbours well-deﬁ ned tumor-speciﬁ c antigens of viral origin. The allo-SCT can serve as a 
therapeutic platform to administer HPV 16-speciﬁ c T cells derived from the peripheral blood of the 
healthy stem-cell donor. The adoptive transfer of HPV 16E6-speciﬁ c Th 1-type CD4+ T cells, which are 
readily detected in the peripheral blood of the majority of healthy subjects, but are often lacking in 
HPV 16-positive cervical cancer patients [7, 23], may contribute to the anti-tumor immunity. Tumor-
speciﬁ c CD4+ Th 1 type T cells have emerged as an essential component in anti-tumor immunity, ful-
ﬁ lling a multifactorial role, including the activation of antigen presenting cell (APC) maturation for 
efﬁ cient CD8+ priming, the release of cytokines important in CD8+ T cell proliferation and differentia-
tion, and in the recruitment of other effector cells such as eosinophils and macrophages, capable of 
exerting anti-tumor reactivity [ 12, 24]. Furthermore, the anti-angiogenic activity of CD4+ Th 1 type T 
cell-derived IFNg can reportedly mediate tumor rejection [25]. All of these activities orchestrated by 
tumor-speciﬁ c CD4+ T cells are independent of MHC class II expression on the tumor. 
 As a ﬁ rst step in the development of a T cell based treatment modality, we set up a protocol 
for the enrichment of Th 1 type HPV 16E6-speciﬁ c T cells from the peripheral blood of healthy blood 
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donors. This protocol involves brief in vitro stimulation of PBMC with long overlapping HPV 16E6-
derived peptides, followed by the enrichment of E6-speciﬁ c memory T cells by magnetic cell sorting 
(MACS) on the basis of their IFNg secretion [26]. This ensures the isolation of in vivo functionally 
selected T cells with the desired cytokine proﬁ le for anti-tumor immunity [27]. We here demonstrate 
the feasibility to obtain enriched polyclonal CD4+ T cell populations with multiple HPV 16E6 speci-
ﬁ cities within a time span of 2-3 weeks. 
Materials and Methods
Blood bank donors · Buffycoats and plasma from healthy blood donors were obtained after 
informed consent. Peripheral blood mononuclear cells (PBMC) were prepared by Ficoll-amidotrizoate 
density gradient centrifugation. Citrated plasma was recalciﬁ ed by adding 0.0 1 1 mM Ca2+ (=3.3 mg 
calciumlaevulate) per ml of plasma. 
Antigens and antibodies · A set of 8 overlapping peptides spanning the HPV 16E6 antigen was used 
for the in vitro stimulation of memory T cell responses. The length of the peptides was 32 amino 
acids with an overlap of  14 residues. For the experiments with inﬂ uenza matrix protein as a model 
antigen, a set of  16 peptides with a length of 30 amino acids, and an overlap of  15 amino acids 
(C-terminal peptide with an overlap of  18 aa), were derived from inﬂ uenza A/PR/8/34 (M 1). The pep-
tides were synthesized and dissolved as described previously [28]. Recombinant HPV 16 E6 protein 
and HPV 16 E7 protein (the latter protein served as negative control protein in proliferation assays) 
were produced in recombinant E. coli transformed with pET- 19b-HPV 16 E6 and pET- 19b-HPV 16 E2 
[29]. The antibodies for ﬂ owcytometric analysis were obtained from BD Biosciences and were used 
in the indicated dilutions: anti-CD4 FITC (cat.no. 345768,  1: 12); anti-CD8 APC (cat.no. 345775,  1:50); 
anti-CD8 PerCP (cat.no.345774,  1: 12); anti-CD3 FITC (catno. 345763,  1:20); anti-CD 16 PE (cat.no. 
3476 17,  1:20); anti-IFNg PE (554552,  1:50). The antibodies used for T cell expansion were anti-CD3 
(Orthoclone, OKT3, Janssen-Cilag) and anti-CD28 (BD Biosciences, cat.no. 348040).
Isolation of antigen-speciﬁ c T cells directly ex-vivo by magnetic cell sorting (MACS) based on 
IFNg secretion · 9 ¾  107 freshly isolated PBMC derived from healthy blood donors were suspended 
in  18 ml IMDM (Cambrex, Verviers, Belgium) supplemented with  10 % recalciﬁ ed autologous plasma 
and seeded at a density of  15 ¾  106 per well in a 6 well plate (Costar, Corning, USA). The total set 
of overlapping HPV 16 E6- or inﬂ uenza M 1-derived peptides were added at a concentration of 2.5 
mg/ml/peptide. An unstimulated sample was taken along as a negative control for FACS analysis. 
After  16 hours, the cells were harvested and the IFNg-secreting c cells were isolated by MACS (IFNg 
secretion assay, Miltenyi Biotech, Bergisch Gladbach, Germany), according to manufacturers’ instruc-
tion. The samples for FACS analysis the cells were counterstained with anti-CD4 FITC, and prop-
idium iodide (0.4 µg/ml) was added prior to analysis. The isolated cells were cultured with irradiated 
autologous PBMC at a ratio of  1 :  10 (isolated cell culture : irradiated PBMC) and 5 % T cell growth 
factor (TCGF, Zeptometrix, NY, USA) without any further addition of antigen. TCGF was used as a 
source of IL-2 in the cell cultures. TCGF is not a well-deﬁ ned source of cytokine, and therefore not 
directly suitable for clinical ex vivo applications. For several cell cultures we compared TCGF with the 
combination of IL-2 ( 10 IU/ml, Proleukin, Chiron) and IL- 15 (5 ng/ml, PeproTech, USA). IL- 15 has been 
described to prevent T cell apoptosis [30], and we previously observed that the combination of IL-2 
and IL- 15 resulted in an increased expansion of memory T cells compared to IL-2 alone (unpublished 
observations). Both TCGF and IL-2/IL- 15 resulted in similar percentages of antigen-speciﬁ c cells, but 
TCGF was superior to IL-2/IL- 15 in terms of cell expansion. 
Isolation of antigen-speciﬁ c T cells after extended period of in vitro stimulation · 9 ¾  107 freshly 
isolated PBMC were incubated with HPV 16E6-derived peptides as described above. One day after 
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stimulation, TCGF (Zeptometrix, NY, USA) was added at a ﬁ nal concentration of 5 %. The enrichment 
procedure was performed 8- 1 1 days after stimulation. Two days before enrichment autologous mono-
cytes were derived from PBMC by adherence to a 24-well plate during 2 hours at 37° C in x-vivo 15 
medium (Cambrex). Adherent monocytes were cultured with GM-CSF (Leucomax, Novartis) 500 IU/ml 
to increase their accessory cell function [3 1], and then used as antigen presenting cells for the second 
stimulation of the T cell cultures. The autologous monocytes were incubated with E6 peptides ( 1 
µg/ml), after which the T cell cultures were added at a ratio of approximately  10 :  1 (T cell : monocyte). 
An unstimulated sample (incubated with monocytes without peptides) was taken along as a negative 
control for FACS analysis. Sixteen hours after stimulation, the T cells producing IFNg in response to 
the E6 peptides were enriched by MACS (IFNg secretion assay, Miltenyi Biotech, Bergisch Gladbach, 
Germany), according to manufacturers’ instruction. The isolated cells were cultured with irradiated 
autologous PBMC at  1 :  10 ratio and 5 % TCGF without any further addition of antigen. 
Intracellular cytokine staining (ICS) · Autologous monocytes were isolated from PBMC by adher-
ence to a ﬂ at-bottom 96-wells plate during 2 hours in x-vivo 15 medium (Cambrex) at 37° C. Adher-
ent monocytes were cultured for 2 days with GM-CSF (Leucomax, Novartis) 500 IU/ml, before they 
were used as APC in the ICS assay. 50 µl of peptide solution ( 10 µg/ml) or 50 µl of medium (nega-
tive control) was added to the monocytes, prior to the addition of 50 µl of cell suspension (4 ¾  106 
cells/ml). After  1 hour of incubation at 37° C, the Golgi-mediated secretion of cytokine was inhibited 
by the addition of  100 µl of Brefeldin A (Sigma; ﬁ nal concentration of  10 µg/ml), after which the 
cells were incubated for another 5 hours. The cells were then harvested, transferred into a V-bottom 
96-wells plate, washed twice with ice-cold PBS and ﬁ xed with 50 µl paraformaldehyde 4 % for 4 min-
utes on ice. Following ﬁ xation, the cells were washed once with cold PBS and once with PBS/NaAz 
0.02 %/BSA 0.5 %/Saponin 0. 1 % for permeabilization. This was followed by an incubation in 50 
µl PBS/NaAz 0.02 %/BSA 0.5 %/Saponin 0. 1 %/FCS  10 % for  10 minutes on ice. Cells were washed 
twice with PBS/NaAz 0.02 %/BSA 0.5 %/Saponin 0. 1 % and supernatant was removed before 25 µl 
of PBS/NaAz 0.02 %/BSA 0.5 %/Saponin 0. 1 % containing 2 µl of anti-CD4 FITC, 0.5 µl IFNg PE and 
2 µl anti-CD8 PerCP was added. Following 30 minutes of incubation on ice, the cells were washed, 
suspended in  100 µl  1 % paraformaldehyde and analysed by ﬂ ow cytometry.
Proliferation assay · The polyclonal T cell cultures were tested for recognition of E6 peptides (5 
mg/ml/peptide) and protein ( 10 mg/ml) in a 3-day proliferation assay. Autologous adherent mono-
cytes in a ﬂ at-bottom 96-well plate were used as antigen presenting cells. Per well 25,000 responder 
cells were seeded, and proliferation was measured in triplicate by [3H]-thymidine incorporation. 
Expansion of polyclonal T cell cultures · Round-bottom 96-well culture plates were coated overnight 
with anti-CD3 and anti-CD28  1 µg/ml/Ab in PBS at 4° C.  106 E6-speciﬁ c cells were mixed with  107 irradi-
ated autologous PBMC and TCGF 5 % in  10 ml IMDM supplemented with  10 % autologous plasma. The 
cells were seeded at  105 cells/well in a round-bottom 96-well culture plate. After 4 days the stimulated 
cells were transferred to an uncoated culture plate. The cell cultures were split whenever required. 
Results
Enrichment of inﬂ uenza M 1-speciﬁ c T cells after stimulation with 30-mer peptides
In order to set up a protocol for the enrichment of antigen-speciﬁ c T cells, we ﬁ rst made use of the 
memory T cell population speciﬁ c for the inﬂ uenza M 1 protein, which is readily detectable in the 
peripheral blood of most healthy donors. Freshly isolated PBMC from healthy blood donors were 
stimulated for  16 hours with a set of synthetic 30-mer peptides spanning the M 1 protein, after which 
the IFNg producing cells were isolated by MACS. The frequencies of the IFNg-secreting cells in the 
CD4+ fraction in response to M 1 peptides varied from <0.0 1 % (detection limit of our FACS analysis) 
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to 0.08 % (Table  1 and Figure  1). These T cell frequencies were increased up to  13.7 % after magnetic 
sorting of the IFNg-secreting cells (Table  1). No clear correlation was observed between the pre-
enrichment percentages of inﬂ uenza-speciﬁ c IFNg-secreting cells and the magnitude of enrichment. 
 The enriched IFNg-secreting cells were expanded without further antigenic stimulation for approx-
imately  12 days, after which the success of the enrichment procedure was determined by the enu-
meration of M 1-speciﬁ c T cells using intracellular cytokine staining. The use of a complete set of 
overlapping peptides covering the M 1 protein, allowed the establishment of an immunological ‘ﬁ n-
gerprint’, as illustrated by our data concerning charting of the CD4+ T cell immunity against vari-
ous antigens [23, 32, 33]. For a given antigen, these ‘ﬁ ngerprints’ differ considerably between PBMC 
isolates from different donors, indicating that the peptides within a certain antigen serve as each 
other’s controls. T cell cultures derived from all  10 donors displayed CD4+ responses against multiple 
M 1-derived peptides (Table 2 and Figure 2). The total percentage of M 1-speciﬁ c CD4+ T cells was in 
all cases higher after culture than directly after isolation, indicating the selective outgrowth of the 
stimulated M 1-speciﬁ c memory CD4+ T cells. Seven out of  10 donors also showed CD8+ responses 
against one or more M 1-derived peptides, indicating that the protocol resulted in the enrichment of 
M 1-speciﬁ c T cells of both CD4+ and CD8+ lineage (Table 2 and Figure 2). However, the percent-
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Figure  1. Enrichment of IFNg+ inﬂ uenza M 1-speciﬁ c cells after overnight peptide stimulation. Freshly isolated PBMC were 
stimulated for  16 hours with a set of overlapping peptides spanning the inﬂ uenza M 1 protein. One representative example is 
shown (Donor 7, Table  1). Both in the CD4 positive and negative fraction IFNg was secreted, which was increased upon peptide 
stimulation. The IFNg+ cells were strongly enriched after magnetic cell sorting (MACS). The percentages of IFNg+ cells in the 
CD4 positive and the CD4 negative PBMC fraction are depicted in the corresponding corners of the ﬁ gures. 
Table  1. Enrichment of inﬂ uenza M 1-speciﬁ c T cells after  16 hr stimulation with overlapping M 1 peptides
  CD4-positive PBMC   CD4-negative PBMC 
 donor control +M 1  after  control +M 1  after 
   peptides MACS   peptides MACS
  1 <0.0 1a 0.08 7.4  0.05 0.42  14.9
 2 0.0 1 0.07 7.2  0.05 0.20  12.4
 3 0.02 0.0 1  13.7  0.06 0.09 22.3
 4 0.02 <0.0 1 2. 1  0.05 0.06 4.4
 5 0.02 0.0 1  1.0  0.03 0.05 7.7
 6 0.0 1 0.02 2.2  0.03 0.09 7.9
 7 0.0 1 0.06 7.9  0.05 0. 15 8.4
 8 0.0 1 0.07 9. 1  0.04 0.05 6.5
 9 0.0 1 0.02 8.7  0.0 1 0.06  13.5
  10 0.0 1 0.05  1 1.3  0.05 0.07 5.3
 a Indicated are the percentages of IFNg+ cells in the CD4 positive and negative fraction of PBMC, before and after enrich-
ment by magnetic cell sorting (MACS). The controls represent the percentages of IFNg-secreting cells in the absence of the 
M 1-derived peptides.
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Table 2. Inﬂ uenza M 1-speciﬁ c T cells in isolated cell cultures.
   M 1        peptide
 donor control  1–45 3 1–75 6 1– 105 9 1– 135  12 1– 165  15 1– 195  18 1–225 2 1 1–255 pool
  CD4+
  1 0.7a 9.2  1 1.7  1 1.4 7.6  14  18.5 27.7  18.5 ·
 2  1. 1 · · · · · · · · 37.5b
 3 0.4 0.8 0.9  1.0 39.4  1.8 5.7 3.0 4.3 ·
 4  1.2  1.3 2.6  16.7 23.6 3. 1  1. 1 2.0 32.7 ·
 5  12.7 · · · · · · · · 73.6
 6 0.3 0.4 5.2 4.4 4.5 0. 1 5.0 2.3 3.0 ·
 7 0. 1 0.2 0. 1 2. 1  1.8 0.2 0. 1 26. 1 23.8 ·
 8 0.6 · · · · · · · ·  15.8
 9 0.2 3.9 2 1.0 4.6  14.7 2. 1  1 1.2 2.7 4. 1 ·
  10 0. 1  17.9 22.7 9.4 5.9 0.2 7. 1 0.8  12.2 ·
  CD8+
  1 0.2 0.2  13.0 0.4 0.3 0.3 0.4 0.2 0.4 ·
 2  1.0 · · · · · · · ·  15.8
 3  0.7 0.6  1.9 2.0 4.5 9.6 0.8 0.6 0.9 ·
 4 <0. 1 <0. 1  19.8 <0. 1 0.3 <0. 1 <0. 1 <0. 1 <0. 1 ·
 5 – c · · · · · · · · ·
 6 0.2 0.2 0.4 0. 1 0. 1 0.2 0. 1 0. 1 0. 1 ·
 7 <0. 1 <0. 1 <0. 1 <0. 1 <0. 1 <0. 1 <0. 1 <0. 1 <0. 1 ·
 8 0.3 · · · · · · · · 2.0
 9 0.5 0.3 9.9 0.5 3.8  1.9  1.7 0.5 0.7 ·
  10  <0. 1 <0. 1 0. 1 <0. 1 0.3 0.3 <0. 1 <0. 1 <0. 1 ·
 a Inﬂ uenza M 1-speciﬁ c T cells were analysed by intracellular IFNg staining  12 days after enrichment, and prior to further in vitro 
restimulation. Indicated are the percentages of cells producing IFNg in the CD4+ respectively CD8+ T cell fraction. Positive 
responses, deﬁ ned as a percentage of IFNg+ T cells > 3 ¾ unstimulated control, are depicted in bold. The overlapping M 1-derived 
peptides were pooled by 2 peptides, each pool indicated by the ﬁ rst and last amino acid of the region covered by the 2 peptides. 
 b Donors 2, 5 and 8 were analysed against a pool consisting of all M 1 peptides because of limited cell numbers. 
 c Insufﬁ cient cell number for analysis
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M1 121-165M1 91-135M1 61-105
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Figure 2. Both CD4+ and CD8+ T cells speciﬁ c for inﬂ uenza M 1 are present in isolated cell cultures. The speciﬁ cities of the 
polyclonal M 1-speciﬁ c cultures were tested in an intracellular IFNg staining assay against 8 pools of inﬂ uenza M 1 peptides. The 
peptide pools consisted of 2 peptides per pool and are indicated by the ﬁ rst and last amino acid of the region of the protein 
covered by the peptides. One representative example is shown (Donor 4, Table 2), gated for CD4+ and for CD8+ T cells. Multiple 
peptide speciﬁ cities were observed in the CD4+ T cell fraction, whereas in the CD8+ T cell fraction cells speciﬁ c for one pool 
M 13 1-75 was observed. 
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ages of M 1-speciﬁ c T cells in the CD8+ fraction were in all cases lower than in the CD4+ fraction, in 
contrast to their frequencies in the peripheral blood (unpublished observations). This suggests that 
the described protocol involving ex vivo stimulation with long peptides favors the enrichment and 
outgrowth of antigen-speciﬁ c CD4+ T cells.
Peptide stimulation enables the enrichment of HPV 16E6-speciﬁ c CD4+ T cells. 
Having shown that M 1-speciﬁ c T cells can be isolated directly ex-vivo using long overlapping pep-
tides, we applied the same protocol for the isolation of HPV 16 E6-speciﬁ c T cells. Previously, we have 
demonstrated the presence of Th 1 type HPV 16E6-speciﬁ c T cells in the CD4+CD45RO+ PBMC frac-
tion of the majority of healthy individuals ([23] and unpublished data). This suggests that a similar 
approach – involving a short in vitro stimulation and enrichment IFNg-secreting memory T cells – is 
feasible in a panel of randomly selected blood donors. 
 Both upon peptide stimulation and after enrichment by MACS, the percentages of IFNg+ T cells 
in the CD4+ fraction were signiﬁ cantly lower in the E6 than in the M 1-stimulated cell populations 
(Table 3). This corresponds with our previous observation that the frequency of M 1-speciﬁ c T cells 
is higher than E6-speciﬁ c T cells in PBMC of healthy subjects [23]. Following in vitro culture after 
enrichment, reactivity against one or more E6-derived peptides was observed in the CD4+ fraction 
of 5 out of 8 enriched T cell cultures (Table 4). In general, the percentages of E6-speciﬁ c CD4+ T 
cells were approximately  1 % of the CD4+ T cells, with one exception showing as much as 9.8 % of 
the CD4+ T cells speciﬁ c for E673- 104 (Figure 3). 
 In contrast to the M 1-stimulated cultures, no E6-speciﬁ c CD8+ T cells were detected after culture 
(Table 4 and Figure 3), despite the occasional detection of an increase in IFNg+ cells in the CD4 
negative fraction upon stimulation of PBMC with E6 peptides (Table 3). Direct ex-vivo ﬂ ow cytomet-
ric analysis of PBMC revealed that IFNg was generally secreted by a CD4–CD8– double negative 
population (data not shown). These CD4–CD8– cells were detected in both the M 1 and E6-speciﬁ c 
MACS isolated cell populations and they co-expanded upon culture. Further analysis revealed that 
the CD4–CD8– cell population was CD3–CD 16+, consistent with an NK cell like phenotype. The 
percentage of these cells after culture was variable and did not differ signiﬁ cantly between the E6 
and M 1-stimulated cultures (Figure 4). 
 In conclusion, the ex-vivo stimulation of healthy donor PBMC with HPV 16 E6-derived peptides 
allows the isolation of E6-speciﬁ c memory CD4+ T cells but not CD8+ T cells. The relatively low 
percentages of E6-speciﬁ c CD4+ T cells in the resulting cell cultures prompted the further optimisa-
tion of the enrichment protocol. 
Table 3. Enrichment of HPV 16E6-speciﬁ c T cells after  16 hr stimulation with overlapping E6 peptides.
  CD4-positive PBMC   CD4-negative PBMC 
 donor control +E6  after  control +E6  after
   peptides MACS   peptides MACS
 3 0.02a <0.0 1 0. 1  0.06 0.05 3.8
 4 0.02 <0.0 1 0.3  0.05 0.03 3.3
 6 0.0 1 0.02 4.2  0.03 0. 10  16.6
 7 0.0 1 0.0 1 0.3  0.05 0.05 6.4
 9 0.0 1 <0.0 1  1.9  0.0 1 0.05 6.8
  10 <0.0 1 0.02 0.8  0.05 0.05 3.9
 a Indicated are the percentages of IFNg+ cells in the CD4 positive and negative fraction of PBMC, before and after enrichment 
by magnetic cell sorting (MACS). The controls represent the percentages of IFNg-secreting cells in the absence of the E6-
derived peptides. 
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Table 4. HPV 16E6-speciﬁ c T cells in isolated cell cultures.
   E6        peptide
 donor control  1–32  19–50 37–68 55–86 73– 104 9 1– 122  109– 140  127– 158 pool
  CD4+
 3 0.2a 0.2 0. 1 0. 1 0.2 9.8 0.3  1.8  1.0 ·
 4  6.6 4.3 4.5 5. 1 5. 1 6.6 4.7 6.4 4.8 ·
 6 0. 1 0. 1 0.2 0.2 0. 1  1.8 0.2 0.2 0. 1 ·
 7 <0. 1 0. 1  1.6 0. 1 0. 1 0. 1 0. 1  1.3 0. 1 ·
 9 – b · · · · · · · · ·
  10   1.6 · · · · · · · ·  1.9c
  1 1 0.2 0.6 · 0.6 · 0.2 · 0.2 · ·
  12 0. 1 <0. 1 · 0. 1 · 0.9 · 0.7 · ·
  CD8+      
 3 0. 1 0. 1 0. 1 0. 1 <0. 1 0. 1 0. 1 0. 1 0. 1 ·
 4  <0. 1 <0. 1 0. 1 <0. 1 <0. 1 <0. 1 <0. 1 0. 1 <0. 1 ·
 6 <0. 1 0. 1 <0. 1 <0. 1 <0. 1 <0. 1 0. 1 0. 1 0. 1 ·
 7 0.2 0.2 0.2 0.2 0. 1 0. 1 0. 1 0.2 0.2 ·
 9 – b · · · · · · · · ·
  10  0.7 · · · · · · · · 0.9c
  1 1 0.2 0.2 · 0.2 · 0.2 · 0.3 · ·
  12 0.2 0.3 · 0.3 · 0.3 · 0.3 · ·
 a HPV 16E6-speciﬁ c T cells were analysed by intracellular IFNg staining  12 days after enrichment, and prior to further in vitro 
restimulation. Indicated are the percentages of cells producing IFNg in the CD4+ respectively CD8+ T cell fraction. Positive 
responses, deﬁ ned as a percentage of IFNg+ T cells > 3 ¾ unstimulated control, are depicted in bold. The overlapping 
E6–derived peptides were tested individually and are indicated by the ﬁ rst and last amino acid. 
 b Insufﬁ cient cell amount for analysis 
 c Cell culture from donor  10 was analysed against a pool consisting of all E6 peptides, and cell cultures from donors  1 1 and  12 
were analysed against pools of 2 peptides ( 1–32 +  19–50 etc), because of a limited amount of cells. Donors  1 1 and  12 are not 
depicted in Table 3, because no FACS analysis was performed of the enrichment of these cell cultures.
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Figure 3. HPV 16E6-speciﬁ c CD4+ T cells present in isolated cell cultures. The speciﬁ cities of the polyclonal E6-speciﬁ c cul-
tures, isolated after  16-hour stimulation with E6 peptides, were tested in an intracellular IFNg staining assay against 8 peptides 
spanning the HPV 16 E6 antigen. One example (Donor 3, Table 4), with the highest percentage of E6-speciﬁ c T cells, is shown, 
gated for CD4+ and for CD8+ T cells. The CD4+ fraction harbours T cells speciﬁ c for multiple E6 epitopes. 
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Optimised protocol for the enrichment of HPV 16E6-speciﬁ c T cells 
In order to increase the frequency of HPV 16E6-speciﬁ c CD4+ T cells, the stimulation period before 
enrichment was extended. PBMC from  17 healthy blood donors were stimulated for approximately  10 
days with E6 peptides and –  16 hours after an additional peptide stimulation – the IFNg-secreting 
cells were isolated by MACS (time scheme Figure 5). The extended stimulation period before isola-
tion generally resulted in a higher frequency of E6-speciﬁ c CD4+ T cells before isolation (mean 2.4 % 
of CD4+ T cells, range 0– 17.4 %, n= 17), compared to the cultures that were stimulated for  16 hours 
only (mean 0.0 1 %, Table 3). Magnetic cell sorting of these cell populations resulted in a strongly 
enriched IFNg+ CD4+ T cell fraction (Figure 6). In contrast to direct ex-vivo isolation of IFNg-secret-
ing cells, which often showed high percentages of NK-like cells, a stimulation period before isolation 
generally resulted in the isolation and outgrowth of >95 % T cells (data not shown). 
 No E6-speciﬁ c T cells could be isolated from PBMC of 4 out of  17 donors and the isolated cell pop-
ulations of another 3 donors showed no E6-speciﬁ c proliferative reactivity after the culture period. 
The cultures of the remaining  10 donors demonstrated strong E6-speciﬁ c responses with multiple 
speciﬁ cities (Table 5). Furthermore, all T cell cultures displaying E6 peptide reactivity also recognized 
recombinant E6 protein after exogenous uptake and presentation by APC (Table 5). This capacity to 
recognize naturally processed E6 epitopes is a prerequisite for the E6-speciﬁ c CD4+ T cells in order 
to activate professional APC that have taken up and processed E6 antigen in vivo. In general, the 
proliferation in response to protein-pulsed monocytes was lower than in response to peptide-pulsed 
monocytes, possibly due to the fact that on a molar basis the amount of peptide used was higher 
than that of protein. 
 We then questioned whether it was possible to expand the isolated E6-speciﬁ c T cell cultures 
without loss of antigen-speciﬁ city using plate-bound anti-CD3/CD28 (Figure 5). Following 4 days of 
incubation, the stimulated cells were transferred to non-coated plates and cultured for another  10 
days. By this method we obtained up to  108 cells, corresponding with an expansion of 20-75 fold. 
In 9 out of  10 cultures the E6-speciﬁ city was retained after expansion, with percentages of antigen-
speciﬁ c T cells in the CD4+ fraction ranging from  13.6–45 % (Figure 7a) as determined by intracel-
lular cytokine staining. Five out of 8 of the evaluable E6-speciﬁ c T cell cultures retained a broad 
reactivity against multiple peptides, whereas 3 cultures showed loss of several speciﬁ cities (Table 5, 
Figure 7b and data not shown). The cell culture of donor D25 was only tested against peptide pool 
in the proliferation assay, therefore not allowing conclusions regarding loss of speciﬁ city. Taken 
together, aspeciﬁ c expansion by plate-bound anti-CD3/CD28 generally retains a high percentage of 
HPV 16E6-speciﬁ c T cells. Occasionally, the breadth of the T cell response may be reduced, which sug-
gests that limited in vitro manipulation is preferred after the enrichment of HPV 16E6-speciﬁ c T cells. 
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Figure 4. Isolation and outgrowth of NK cells in isolated cell cultures. Both in the E6- and M 1-stimulated PBMC, enrichment 
of IFNg+ cells after  16 hours of stimulation resulted in the isolation of NK-like cells in addition to antigen-speciﬁ c cells. These 
cells grew out to a variable extent upon culture, and the percentages of NK-like cells after culture did not differ signiﬁ cantly 
between M 1 and E6-stimulated cultures. Four representative examples are shown of cell cultures approximately  10 days after 
enrichment. The cell cultures were stained for CD3 and CD 16, and the percentages of CD3+ respectively CD 16+ cells are depicted 
in the corners of the ﬁ gures. 
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The percentages of CD8+ T cell were low in the isolated cell populations and these cells showed 
variable outgrowth upon expansion. Intracellular cytokine staining revealed that none of the cell 
cultures displayed HPV 16E6-speciﬁ c IFNg secretion in the CD8+ fraction (data not shown). In con-
clusion, the stimulation of PBMC with HPV 16E6-derived peptides for approximately  10 days before 
isolation of the antigen speciﬁ c cells results in E6-speciﬁ c CD4+ T cell cultures with a better enrich-
ment than upon direct ex-vivo isolation. The HPV 16E6-speciﬁ c cell cultures generally display a broad 
speciﬁ city, and recognize naturally processed E6 protein. 
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Figure 5. Time scheme of culture and analysis of HPV 16E6-speciﬁ c T cells. 
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Figure 6. Increased purity of HPV 16E6-speciﬁ c CD4+ T cells by extended culture period before isolation of antigen-speciﬁ c cells. 
After a  10 day culture period of PBMC with HPV 16 E6 peptides, the T cells were restimulated for  16 hours after which the IFNg+ 
fraction was isolated. One representative example is shown. IFNg+ cells were observed mainly in the CD4+ fraction and these 
cells were strongly enriched upon magnetic cell sorting. In the right-hand corner of each ﬁ gure the percentage of IFNg+ cells in 
the CD4+ fraction is depicted. 
Table 5. Proliferation assay of HPV 16E6-speciﬁ c T cell cultures.
  E6        E2 E6 E2 
 donor  1-32  19-50 37-68 55-86 73- 104 9 1- 122  109- 140  127- 158  1-30 protein protein
  14 7.6 6.0  10.3  13. 1  13.8 8.7 4.0  10.6 2.2 5.7a  1.9
  15  1.2 4.0 6.0  14.3  13.9 9.9  10.4  13.8  1.0  10.0 2.7
  16  1.8 2.2  13.6  10.5  13.6  14.8  1.7  1.5  1. 1 4.3 0.6
 2 1   1.6b ·  14.6 ·  1.7 · 7.6 ·  1.5 5.0 3. 1
 22  3.4 · 5.8 · 4.2 · 6.6 ·  1.3 5. 1  1.2
 24  0.9 0.8  1.0 6.7  19.7 0.9 5.4  10.3  1. 1 7.4  1.9
 25  4.0 · · · · · · ·  1.0 6.9 2.2
 26   1. 1  1.2  1. 1 2.4 3.2 0.9 3.8 4.7 0.9 3.0 0.7
 27  1.4  1.5  1. 1  1.4 5.2 0.9  1.8 3.2  1.2 4.5  1.2
 28  0.9 0.9  1.3 2.3 2.9 2. 1  1.0 4. 1  1. 1 7.5  1.0
 a HPV 16E6-speciﬁ c T cell cultures were tested in short-term proliferation assays for the recognition of E6 peptides and naturally 
processed E6 protein. HPV 16E2-derived peptide and recombinant E2 protein were used as negative controls. Indicated are 
the stimulation indices (SI), deﬁ ned as proliferation in the test wells divided by the proliferation in the medium only control 
wells. In bold are positive proliferative responses with a SI > 3. 
 b Cell cultures from donors 2 1 and 22 were tested against pools of 2 peptides, and cell culture from donor 25 was tested against 
the pool of all E6 peptides, because of limited amount of cells.
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Discussion
In view of the limited treatment options and poor prognosis of advanced HPV 16+ cervical cancer, it is 
of interest to investigate whether allo-SCT followed by the transfer of donor-derived HPV 16-speciﬁ c T 
cells can make a signiﬁ cant clinical impact on this disease. We have studied the feasibility to enrich 
T cells that recognize the viral tumor antigen HPV 16E6 from the peripheral blood of healthy donors. 
 Enrichment of HPV 16-speciﬁ c T cells from the peripheral blood of in vivo primed healthy blood 
donors based on IFNg secretion has several advantages. First of all, Th 1 type responses – associated with 
the pro-inﬂ ammatory cytokine IFNg – are of major importance in anti-tumor immunity [ 13, 34]. There-
fore, enrichment of antigen-speciﬁ c T cells secreting this cytokine ensures selection of T cells with the 
desired cytokine proﬁ le [27]. Secondly, in contrast to protocols involving the in vitro induction of HPV-
speciﬁ c T cells by multiple in vitro stimulations [35, 36], direct ex-vivo stimulation results in the reactiva-
tion of memory T cells that have been selected for function in vivo. Finally, enrichment of antigen-
speciﬁ c T cells is desirable in the light of minimizing the alloreactivity that may occur following the 
adoptive transfer of donor T cells. Although this aspect has not been addressed in the present study, 
the inclusion of an HPV 16-speciﬁ c enrichment step will most likely minimize the risk of severe graft-
versus-host-disease (GVHD). Donor-derived polyclonal T cell lines speciﬁ c for cytomegalovirus (CMV) 
were shown to establish effective suppression of CMV disease without causing severe GVHD [37]. 
Although the required number of HPV 16-speciﬁ c T cells for adoptive transfer remains to be established, 
we obtained similar numbers of speciﬁ c T cells as described in several successful adoptive cellular 
therapy protocols [37, 38]. These studies suggest that large numbers of T cells are not a prerequisite for 
effective adoptive T cell therapy, as long as the in vivo expansion capacity of the cells is retained.
 The stimulation of healthy donor-derived PBMC with inﬂ uenza M 1 or HPV 16E6-derived peptides 
for a short period in vitro results in the reactivation of speciﬁ c memory T cells. With the inﬂ uenza M 1 
antigen we demonstrated that stimulation of PBMC with long overlapping peptides allows the isola-
tion of both CD4+ and CD8+ memory T cells speciﬁ c for M 1. With the same approach for the isola-
tion of HPV 16E6-speciﬁ c T cells, we were unable to isolate CD8+ T cells speciﬁ c for the E6 antigen 
from these healthy donors. A major reason for the absence of E6-speciﬁ c CD8+ T cells in the isolated 
cell cultures could be that HPV 16E6-speciﬁ c memory CD8+ T cells are present at very low frequency 
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Figure 7. HPV 16E6-speciﬁ c T cell cultures retain antigen-speciﬁ city after expansion by plate-bound anti-CD3/CD28 stimu-
lation. Polyclonal HPV 16E6-speciﬁ c T cell cultures derived from  10 different donors were expanded by anti-CD3/CD28 stimula-
tion for approximately  14 days after which the percentages of HPV 16E6-speciﬁ c CD4+ T cells were determined by intracellular 
IFNg staining. The cell cultures were stimulated with autologous monocytes pulsed with a pool of E6 peptides, and a pool of 
E2-derived peptides was taken along as a negative control (a). The percentages of E6-speciﬁ c T cells in the CD4+ fraction are 
depicted in the graph. The percentages of CD4+ T cells in the total cell culture were variable and are indicated in the graph below 
each individual donor. The T cell cultures were also tested against the individual peptides. Compared with the speciﬁ city before 
expansion (Table 5), several cell cultures retained a broad antigen-speciﬁ city, whereas others showed a partial loss of speciﬁ city 
after expansion. Representative examples are shown (b). Indicated are the percentages of IFNg+ cells in the CD4+ fraction.
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in the peripheral blood of healthy individuals, as has been shown for T cells against the E7 antigen 
[23, 39], and that the applied in vitro method relying on the use of long peptides – requiring uptake 
and cross-presentation – is only suitable for the stimulation of strong, high frequency memory CD8+ 
responses. In order to increase the frequencies of the HPV 16-speciﬁ c T cells in the peripheral blood, 
vaccination of the stem cell donors could be considered. Several clinical grade HPV 16 vaccines are 
currently available or being developed [40-42]. These vaccines have the capacity to boost both E6 
and E7-speciﬁ c immunity, thereby facilitating the isolation of T cells against both HPV 16 oncopro-
teins. Furthermore, in some cases we failed to isolate or expand HPV-speciﬁ c CD4+ T cells from the 
healthy subjects. On one hand, this may be due to the fact that these individuals simply have not 
encountered HPV 16, hence no memory T cell immunity was induced. On the other hand, the number 
of isolated cells was in some cases too small to allow proper expansion within 2 weeks. Vaccination 
of stem cell donors may thus also facilitate an increase in the number of individuals from whom 
HPV-speciﬁ c T cells can successfully be enriched and expanded. 
 Tumor-speciﬁ c CD4+ T cells have been shown to play a pivotal role in anti-tumor immunity [ 12- 14, 
43, 44]. In the case of HPV 16-positive cervical cancer, future studies are required to address the efﬁ -
cacy of donor-derived HPV 16E6-speciﬁ c CD4+ T cells in the allo-SCT setting. Ideally, these Th 1 type T 
cells contribute to the establishment of an effective anti-tumor immune response by proper polariza-
tion and maturation of dendritic cells, thereby preventing tumor-induced tolerization of newly gener-
ated T cells [2 1, 22], and supporting the activation of CD8+ CTL responses against HPV 16 or other 
unique tumor antigens. Furthermore, the HPV-speciﬁ c CD4+ T cells at the site of the tumor may 
attract and activate innate immune effectors, capable of exerting anti-tumor activity [24]. 
 In conclusion, by providing a method for the rapid enrichment HPV 16E6-speciﬁ c CD4+ T cells 
from healthy donor PBMC, this study is a ﬁ rst step in the development of a T cell-based therapy for 
advanced cervical cancer in an allo-SCT setting. 
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Summary · Our studies addressing the HPV 16-speciﬁ c cellular immune response in healthy individu-
als revealed that CD4+ memory T cells speciﬁ c for the viral proteins E2 and E6 were present in a 
large fraction of the healthy population (Chapters 2-4). These reports are the ﬁ rst to describe T cell 
memory against the HPV early proteins in non-diseased subjects. In contrast to HPV 16E2 and E6-
speciﬁ c T cell responses, E7-speciﬁ c responses were rarely observed, and this was reﬂ ected in the 
predominant detection of E6-speciﬁ c and not E7-speciﬁ c responses upon vaccination of healthy vol-
unteers with an HPV 16L2E7E6 fusion protein vaccine (Chapter 6). HPV 16-speciﬁ c T cell responses 
in patients with HPV 16-induced cervical cancer lacked the strong pro-inﬂ ammatory cytokine proﬁ les 
generally associated with HPV 16-speciﬁ c responses in healthy individuals, suggesting an impairment 
of HPV 16-speciﬁ c immunity in patients (Chapter 4). This was supported by detailed analysis of the 
local immune response in these patients, which pointed at an abundance of HPV-speciﬁ c CD4+ T 
cells with unfavorable anti-inﬂ ammatory cytokine proﬁ les, secreting IL- 10 in response to the viral 
antigens (Chapter 5). Finally, as a ﬁ rst step in the development of immunotherapeutic strategies 
for the treatment of advanced cervical cancer, we set up a protocol for the enrichment of Th 1 type 
HPV 16E6 CD4+ T cells from the peripheral blood of healthy individuals, based on their IFNg secre-
tion. Future treatment protocols may involve the adoptive transfer of these donor T cells following 
HLA-matched allogeneic stem cell transplantation (Chapter 7). 
General discussion
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HPV 16-speciﬁ c immune success versus failure 
The infection rate with oncogenic HPV types is extremely high and even in the pre-screening era the 
rate of cervical cancer has been only a fraction of that of HPV exposure [ 1, 2]. An important factor in the 
natural history of HPV infection is adaptive immunity, which is thought to play a major role in the con-
trol of HPV infections, preventing viral persistence and subsequent development of lesions. The results 
described in this thesis suggest that systemic Th 1/Th2 CD4+ T cells speciﬁ c for the HPV 16 early antigens 
E2 and E6 are a hallmark of successful control of HPV 16 infection. In patients with HPV 16-positive cer-
vical carcinoma, the impaired systemic HPV 16-speciﬁ c immunity and the local predominance of IL- 10 
secretion by HPV 16-speciﬁ c CD4+ T cells, likely represent HPV 16-speciﬁ c immune failure that allows 
outgrowth of HPV 16-induced malignancies. Based on results described in this thesis and on previously 
published data, this chapter presents a hypothesis of the role of HPV-speciﬁ c CD4+ T cells in HPV infec-
tion and disease. This hypothesis is depicted in Figure  1, and the background of several aspects visual-
ized in this ﬁ gure is provided throughout this chapter. In addition to HPV-speciﬁ c CD4+ T cell immunity, 
which is the main focus of this thesis, the possible roles in HPV-induced disease of HPV-speciﬁ c CD8+ T 
cells and capsid-speciﬁ c antibodies are brieﬂ y discussed. Finally, a personal view is given on the implica-
tions of the ﬁ ndings for rational immunotherapeutic intervention in HPV-induced disease. 
Successful HPV 16-speciﬁ c immunity 
Estimates of cervical HPV 16 infection prevalence by repeated sampling have revealed a  1 year cumula-
tive prevalence as high as 67 %, whereas single-point measurements showed markedly lower percent-
ages of infected individuals [3]. This suggests that active HPV infection (detectable HPV DNA) ﬂ ares up 
periodically and is present in a sub-clinical or latent state the remaining time, a notion that is sustained 
by the ﬂ uctuating HPV DNA presence observed during the menstrual cycle [4]. Adaptive immunity is 
likely of major importance in the continuous control of HPV infection, given the fact that a reduced cel-
lular immunocompetence rapidly results in the appearance of active HPV infections and lesions [5-8]. 
Figure  1. Hypothesis: The CD4+ T cell response in HPV infection and disease
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The presence of HPV 16-speciﬁ c CD4+ memory T cells with a strong pro-inﬂ ammatory cytokine proﬁ le 
in the peripheral blood of a large fraction of healthy individuals (Chapters 2,3,4 and 7) suggests that 
these cells participate in the control of HPV 16 infection (Figure  1). Longitudinal analysis of this T cell 
immunity along the course of infection, persistence or clearance is required in order to establish its 
exact role in the prevention of HPV 16 disease progression. Memory CD4+ T cells speciﬁ c for HPV 16 
early antigens are proposed to contribute to clearance of HPV 16 infected keratinocytes by direct 
and/or indirect effector mechanisms (Figure  1, I). Indirectly, once activated through the recognition 
of HPV antigens presented by e.g. Langerhans cells, the CD4+ memory T cells attract and activate 
macrophages and other immune effectors by local cytokine secretion [9]. Alternatively, HPV-positive 
HLA class II expressing keratinocytes are directly recognized and killed (e.g. via Fas-FasL) by resi-
dent CD4+ effector T cells [ 10,  1 1]. Various inﬂ ammatory mediators, especially interferons, have been 
shown to upregulate HLA class II on cervical epithelial cells, which would enable direct recognition 
by CD4+ T cells [ 12]. The release of type I interferons by keratinocytes themselves can be triggered 
by viral infection [ 13]. The direct mechanism of viral control by CD4+ T cells has been suggested for 
epithelial Herpes simplex virus (HSV) infection, by demonstrating that HSV-speciﬁ c cytotoxic CD4+ 
T cells targeted infected keratinocytes in an HLA class II restricted fashion [ 14,  15]. 
 HPV 16-speciﬁ c memory CD4+ T cells generally target the early antigens E2 and E6 (Chapters 2, 3 and 
4). Interestingly, both in the COPV and the CRPV model the systemic proliferative responses against 
early antigens, in particular E2, were strongly induced around the time of papilloma regression ([ 16] and 
M. Stanley, personal communication). This indicates that in these animal models the regression of a 
local epithelial infection is reﬂ ected in the peripheral blood by a PV-speciﬁ c T cell response. Simultane-
ously, local epithelial inﬁ ltrates of T cells – predominantly CD4+ – are observed [ 17]. The therapeutic 
efﬁ cacy of vaccination against the viral early antigens in both models suggest that T cells speciﬁ c for 
these antigens play an important role in the control of infection, and do not merely reﬂ ect responses 
that have been primed as a result of viral antigen release along with papilloma regression [ 18,  19].
Role of HPV-speciﬁ c CD8+ T cells and antibodies in control of HPV infection. In general, effective long-
term immunity against viral infections involves both CD4+ and CD8+ T cells speciﬁ c for the viral antigens 
[20-22]. Although limited data on HPV 16-speciﬁ c CD8+ T cells are presented in this thesis (Chapter 7), we 
have investigated the presence of these T cells both in healthy individuals and cervical cancer patients. In 
healthy individuals we were unable to detect CD8+ T cells speciﬁ c for HPV 16 E2 or E6. Previously, others 
have failed to detect CD8+ T cells speciﬁ c for HPV 16E6 and E7 epitopes in asymptomatic individuals 
[23-27]. By contrast, Nakagawa et al. described the presence of HPV 16-speciﬁ c CTL in the peripheral blood 
of healthy subjects. In this study, lysis of autologous vaccinia E6E7 infected EBV-transformed B cells 
was demonstrated after culture of donor PBMC with E6 and E7 protein, but the analyses lacked the 
proper controls to conclude that the observed target cell lysis was attributable to CD8+ T cells [28]. Sev-
eral other studies describe the detection of HPV-speciﬁ c CD8+ T cells in healthy donor PBMC, however 
only after extensive in vitro culture [29-3 1]. Based on cumulative data we cannot exclude that HPV 16-spe-
ciﬁ c memory CD8+ T cells are present in the peripheral blood of asymptomatic individuals, but – if pres-
ent – their frequency is expected to be low. In view of the epithelial restriction of HPV infections, it is 
possible that HPV 16-speciﬁ c CD8+ T cells reside primarily in the epithelium. However, the relative abun-
dance of HPV 16-speciﬁ c memory CD4+ T cells in the peripheral blood indicates that the local superﬁ cial 
epithelial infection does result in systemic CD4+ T cell immunity (Chapters 2-4), and the same would be 
expected for CD8+ T cells. For instance, epithelial herpes simplex and inﬂ uenza virus infection both result 
in the induction of a systemic CD4+ and CD8+ T cell response against the viral antigens [32-35]. Although 
analysis of the local HPV-speciﬁ c CD8+ T cell immunity or of systemic CD8+ T cell responses against 
HPV 16 antigens other than those studied (E2, E6 and E7) may reveal a different picture, the results so far 
point towards a limited role for CD8+ T cells in the control of transient HPV 16 infection.
114
Besides the cellular immune response, in transient HPV infection the humoral immune response may 
also contribute to the control of infection. HPV capsid-speciﬁ c IgA is frequently detected in the cervi-
cal mucosa during HPV infection, the levels of which rapidly decline after resolution of infection [36]. 
This suggests that local HPV-speciﬁ c antibodies induced in response to natural infection are not likely 
to protect against novel HPV infection. They may, however, assist the resolution of established HPV 
infection by limiting viral spread and reinoculation via neutralisation of released viral particles. This 
notion is supported by the observation that vaccine induced HPV 16L 1-speciﬁ c neutralising antibodies 
prevented viral persistence, despite the fact that they did not in all cases prevent HPV 16 infection [37]. 
Although the latter refers to vaccine induced antibodies and can therefore not readily be extrapolated 
to infection-induced humoral immunity, it does suggest that HPV-speciﬁ c antibodies are capable of 
intervening in present HPV infection and thus may play a role in viral control.
HPV 16-speciﬁ c immune failure
In the peripheral blood of approximately half of the patients with HPV 16-positive cervical cancer pro-
liferative responses against E2 and E6 were observed, whereas the other half lacked HPV 16-speciﬁ c 
proliferation altogether (Chapter 4). Compared to previous studies, relatively few cervical cancer 
patients showed responses against the E7 oncoprotein [38, 39]. This may be due to the readout 
(proliferation) and the relatively high cut off level in our study. Indeed, when a stimulation index of 
2 was taken as a cut off, a signiﬁ cantly larger fraction of patients responded to the E7 antigen as 
compared to healthy females. Cumulative data suggest that, in contrast to E2 and E6-speciﬁ c T cells, 
T cells speciﬁ c for the E7 antigen are not frequently induced in transient infection, but rather during 
disease progression [40]. The underlying reason for this could be that the availability of E7 protein 
for antigen processing and presentation is low in infection – due to limited expression and/or rapid 
degradation – whereas this availability is increased after viral integration [4 1, 42]. 
 In the group of cervical carcinoma patients, the supernatants of HPV 16-speciﬁ c microcultures often 
lacked detectable levels of pro-inﬂ ammatory cytokines, and occasionally the sole secretion of IL- 10 
was observed (Chapter 4). Detailed analysis of patients’ tumor-draining lymph nodes conﬁ rmed the 
notion that the HPV 16-speciﬁ c CD4+ T cell response was characterized by prominent production of 
the immunoregulatory cytokine IL- 10 (Figure  1, II). This phenomenon was likely HPV 16-speciﬁ c in this 
patient, given the strong Th 1 cytokine proﬁ le of the inﬂ uenza M 1-speciﬁ c CD4+ T cell response in the 
same lymph node (Chapter 5). Note that the HPV-speciﬁ c T cells did have the capacity to secrete pro-
inﬂ ammatory cytokines in addition to IL- 10, however, only at optimal stimulatory conditions. Therefore, 
we chose to refer to these T cells as IL- 10-secreting HPV-speciﬁ c T cells. The fact that strongly polarized 
HPV 16-speciﬁ c Th 1 cells can readily be isolated from the peripheral blood of healthy subjects (Chapter 
7), whereas they appear to be lacking in cervical carcinoma patients, suggests a qualitative difference in 
the HPV-speciﬁ c CD4+ T cell response and points at the predominance of IL- 10 secreting HPV-speciﬁ c T 
cells as a hallmark of HPV-induced disease. Further analysis, of cervix-draining lymph nodes of females 
undergoing surgery for reasons other than HPV-induced disease, is required to conﬁ rm this notion. 
 Not only in the tumor-draining lymph node, but also in the tumor itself, we have detected CD4+ T 
cells speciﬁ cally secreting IL- 10 in response to the viral oncoproteins (Chapter 5). These tumor inﬁ l-
trating lymphocytes (TIL) were isolated from tissue samples by culturing with cytokine only (IL- 15 and 
TCGF) and were detected in TIL both from patients with and without detectable HPV-speciﬁ c T cells 
in the peripheral blood. Therefore, the absence of detectable systemic HPV-speciﬁ c T cell responses 
does not exclude their overall presence. The direct ex-vivo proliferative capacity of the type of T cells 
with predominant IL- 10 secretion is likely to be low, which precludes their clear detection in short-
term proliferation assays. Culture of IL- 10 secreting T cells (e.g. Tr 1 cells) with IL- 15 has been shown to 
increase the in vitro proliferative capacity of these T cells [43, 44], which may explain their outgrowth 
in our lymph node and tumor tissue cultures (Chapter 5). Recently, we have obtained evidence of the 
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in vitro immunosuppressive capacity of the IL- 10 secreting HPV-speciﬁ c T cells. Co-culture of these 
T cells with polyclonal CD4+ T cell populations and anti-CD3 showed a cell-dose dependent sup-
pression of proliferation (data not shown). Importantly, this implies that the HPV 16-speciﬁ c CD4+ 
T cell response in cervical cancer patients does not only lack a pro-inﬂ ammatory component, but 
is essentially actively suppressed. The mechanism (IL- 10 and/or cell-cell contact dependent) of this 
immunosuppressive potential is subject to further study. 
 It remains to be explored how and at which stage of disease these IL- 10 secreting HPV 16-speciﬁ c 
CD4+ T cells have been primed (Figure  1, III). Conceivably the anti-inﬂ ammatory (IL- 10/TGF-b) cyto-
kine environment in cervical (pre)malignancy contributed to their induction by the modulation of 
the resident antigen presenting cells, as IL- 10 treated dendritic cells have been shown to induce IL- 10 
secreting T cells with immunoregulatory properties [45]. Alternatively, these T cells may be the result 
of direct priming of naive T cells by HLA class II positive keratinocytes harbouring HPV antigens. The 
frequent presence of lymphoid follicles in high-grade lesions suggests that at this stage of disease 
these lesions are accessible to naïve T cells [46, 47], and this mode of priming in the absence of 
proper co-stimulation can result in T cells with regulatory activity [48, 49]. 
HPV-speciﬁ c CD8+ T cells in HPV-induced disease. In high-grade CIN and cervical cancer, CD4+ 
T cells are clearly not the only players in the HPV-speciﬁ c immune response. Several studies have 
demonstrated the presence of CD8+ T cells speciﬁ c for the HPV 16 oncoproteins in the peripheral 
blood of patients with HPV 16-positive lesions [23-27, 50]. Their presence was generally associated 
with increasing disease severity, suggesting they are primed in later stages of disease. Underlying 
reason for this could be an increased availability of oncoprotein for cross-priming of CD8+ T cells in 
high-grade CIN and cervical carcinoma as compared to HPV infection [5 1, 52]. Furthermore, the exten-
sion of viral antigen expression to basal epithelial layer and the presence of micro-invasions in cervi-
cal carcinoma are likely to increase the accessibility of viral antigens to submucosal dendritic cells, 
which can then participate in the induction (cross-priming) of HPV-speciﬁ c T cell responses. Interest-
ingly, in our recent TIL analyses we have isolated HPV 16/ 18 E6E7 speciﬁ c CD8+ T cells from tumor 
biopsies of several patients (data not shown). In contrast to the HPV-speciﬁ c CD4+ TIL, the CD8+ T 
cells generally secreted IFNg only in response to antigenic stimulation, although IL- 10 secretion by 
CD8+ T cells was also occasionally observed. We and others have demonstrated the capacity of HPV-
speciﬁ c CD8+ T cells to lyse HLA-matched cervical tumor cell lines in vitro [26, 50]. Indirect evidence 
for the in vivo functionality of these CD8+ T cells is given by the allelic loss of HLA class I in a large 
fraction of primary cervical tumors and metastases, which points at a selective immune pressure of 
the HPV-speciﬁ c CD8+ T cells on the tumor [53, 54]. In contrast, the HPV-speciﬁ c CD4+ T cells are 
not expected to pose direct selective immune pressure on the tumor, given the fact that many cervical 
tumors and high-grade CIN lesions show de novo expression of HLA class II on their surface [55-57]. 
Implications for immune intervention
In Figure  1 (Hypothesis) the HPV response is presented as a dichotomy; IL- 10 secreting CD4+ T cells 
representing immune failure and polarized Th 1 (and Th2) T cells representing effective immunity. As 
with most hypotheses, the true situation is likely to be more subtle, and will in this case rather sug-
gest that ‘success’ versus ‘failure’ depends on a balance between HPV-speciﬁ c CD4+ T cells with a pro-
inﬂ ammatory cytokine proﬁ le (generally present in healthy donors) and those predominantly secreting 
IL- 10 (present in carcinoma patients). Supporting the presence of such a balance is the fact that several 
HPV-speciﬁ c T cell clones derived from the patients’ lymph nodes had cytokine proﬁ les that were more 
or less polarized towards Th 1 or Th2. Interesting in this respect is a recent study describing the immune 
response against common allergens in non-allergic and allergic individuals. This study demonstrated 
that in both groups three subsets of CD4+ T cells speciﬁ c for the allergen could be detected; Th 1, Th2 
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and Tr  1 (selection based in the secretion of IFNg, IL-4 and IL- 10 respectively in response to allergen). 
The net outcome of exposure to allergen (allergic reaction or tolerance) was dependent on the bal-
ance between the allergen-speciﬁ c Th2 and Tr  1 subsets [58, 59]. It is tempting to draw parallels to 
immune control of epithelial HPV infection. The epithelial exposure to HPV antigens may induce similar 
subsets of Th 1, Th2 and IL- 10 secreting T cells against the viral antigens. Similarly, the relative frequen-
cies of these T cell subsets and the timing of their induction may play a crucial role in the outcome of 
HPV infection. In individuals failing to sufﬁ ciently prime polarized Th 1 (Th2) HPV-speciﬁ c CD4+ T cells 
during active viral infection, the balance may tip towards IL- 10 secreting HPV-speciﬁ c CD4+ T cells, 
which are induced instead and subsequently expanded during persistent HPV infection. 
Persistent infection and low-grade CIN. If a balance between the pro- and anti-inﬂ ammatory cyto-
kine proﬁ les of HPV-speciﬁ c CD4+ T cells indeed determines the efﬁ cacy of HPV control, it is important 
to ‘tip the scale’ towards predominance of HPV-speciﬁ c CD4+ T cells with a pro-inﬂ ammatory cytokine 
proﬁ le at an early (premalignant) stage of disease. For inducing regression of low-grade lesions, it 
may prove sufﬁ cient to induce a local pro-inﬂ ammatory cytokine milieu, without the need for antigen-
speciﬁ c vaccination. In persistent low-risk HPV infections (e.g. genital warts), the local topical applica-
tion of imiquimod, an immunomodulator, has shown to trigger the regression of the warts as com-
pared to placebo [60]. Imiquimod acts as a ligand for toll-like receptor 7, activating macrophages and 
dendritic cells to release IFNa and other pro-inﬂ ammatory cytokines, and the establishment of local 
inﬂ ammation results in the attraction of immune effectors [6 1]. The modulation of the cytokine envi-
ronment in favour of Th 1-inducing milieu may trigger an effective adaptive immune response against 
the viral antigens. However, it is not clear if imiquimod treatment indirectly triggers the induction of 
an HPV-speciﬁ c T cell response or that the mechanism of regression relies primarily on the action of 
innate effectors. The fact that recurrence rates with imiquimod treatment are relatively low, suggests 
that the establishment of effective HPV-speciﬁ c immune memory may indeed occur [62]. 
 Taken together, the induction of a local pro-inﬂ ammatory environment in HPV-induced lesions, result-
ing in the attraction and activation of immune effectors may prove sufﬁ cient for inducing regression of 
lesions. However, to ensure the prevention of recurrence, an optimal therapeutic modality should addi-
tionally contain an HPV speciﬁ c component that induces long-term HPV-speciﬁ c T cell memory. Therapeu-
tic vaccination in low-grade CIN can potentially target a number of viral antigens, because at this stage 
productive viral infection still takes place and the whole array of viral proteins is expressed. In the COPV 
model, representing low-grade / low-risk PV disease, targeting of E 1 or E2 with a codon-optimized DNA vac-
cine has proven therapeutically successful [ 18]. However, in lesions caused by high-risk HPV types, target-
ing of these antigens should always be combined with targeting of E6 and E7 oncoproteins. Keratinocytes 
containing integrated HPV DNA may else selectively escape immune attack, because the expression of 
other viral early proteins is often reduced or absent in these cells [63]. Even in low-grade CIN the inte-
gration of high-risk viral DNA is occasionally observed [64]. Pre-clinical data suggest that targeting of 
the oncoproteins only may also prove effective. In the CRPV model, a vaccine comprising overlapping 
peptides spanning the E6 and E7 CRPV oncoproteins, effectively prevented the outgrowth of established 
CRPV induced papillomas [65]. Due to increased genomic instability, high-grade CIN will evidently pose 
a greater challenge than low-grade lesions in terms of effective immunotherapeutic intervention. Further-
more, the variable expression of viral genes other than E6 and E7 in high-grade lesions renders the onco-
proteins the only consistent viral targets for immune intervention at this stage of disease [66]. 
Cervical cancer. After malignant transformation has taken place, therapeutic vaccination will be 
an adjuvant therapy at best, because it has to overcome several important barriers that can hamper 
its efﬁ cacy. These barriers involving both the tumor and the immune system – which mutually affect 
one another – include:  1. The increasingly unfavourable local cytokine environment for the function 
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of effector cells [57, 67, 68]; 2. The genomic instability of the HPV-positive keratinocytes, readily 
allowing immune escape mechanisms (e.g. reduced sensitivity to pro-inﬂ ammatory cytokines and 
lysis, downregulation of HLA class I molecules, reviewed in [63]); and 3. The dominance of IL- 10 
secreting T cells in the HPV-speciﬁ c CD4+ T cell repertoire (Chapter 5). 
 These barriers should be taken into account when strategically designing immunotherapeutic pro-
tocols. Ideally, the intervention involves:  1. the establishment of a local pro-inﬂ ammatory cytokine/
chemokine milieu or at least neutralization of the local anti-inﬂ ammatory cytokines, for instance the 
combination of a toll-like receptor ligand in combination with IL- 10R blocking [69], 2. the provision 
of large numbers of E6 and E7-speciﬁ c CD4+ and CD8+ T cells targeting multiple epitopes, thereby 
minimizing the chance of immune escape. HPV-speciﬁ c Th 1 type CD4+ T cells will be essential for 
CTL dependent and independent effector mechanisms, the latter becoming increasingly important 
in case of allelic loss of HLA class I in cervical tumors, and 3. overruling of the unfavourable IL- 10 
dominated immune response (by skewing the overall immune response towards Th 1). Immunothera-
peutic approaches can involve either active vaccination or the passive transfer of ex-vivo cultured 
HPV 16-speciﬁ c T cells. Active vaccination should result in abundant de novo priming and expansion 
of a type  1 HPV-speciﬁ c immune response and/or skewing of the resident IL- 10 secreting HPV-speciﬁ c 
CD4+ T cells towards a Th 1 phenotype. Despite the fact that the latter may not prove feasible (Chapter 
5), the general prospects for overruling an overall antigen-speciﬁ c regulatory response are promising, 
as the counterpart has proven successful; allergen-speciﬁ c desensitisation shifted the balance from 
either Th 1-based contact hypersensitivity or Th2-based allergy towards IL- 10-mediated immunoregula-
tion [70, 7 1]. An important issue to address is whether vaccination also results in the in vivo expan-
sion of the IL- 10 secreting HPV-speciﬁ c T cell subset, as this would severely counteract effective vac-
cination. Overall, vaccination is likely to be adversely affected by both HPV-speciﬁ c and non-speciﬁ c 
regulatory T cells. In light of this, treatment with anti-CD25 before vaccination may improve vaccine 
efﬁ cacy, given the fact that naturally occurring and most induced regulatory T cells express CD25 
[72]. Alternatively, for advanced cervical cancer, the adoptive transfer of donor-derived HPV-speciﬁ c T 
cells in the allogeneic setting may be taken into consideration. In this setting several of the aforemen-
tioned barriers can be overcome at least partially, because conditioning of the patient before stem cell 
transplantation eradicates the host immune cells, including the regulatory component, and allows the 
administration of a broad repertoire of HPV 16 oncoprotein-speciﬁ c IFNg-secreting T cells, which can 
generally be derived from peripheral blood of healthy donors (Chapter7). 
Final remark
Although the presence of IL- 10 secreting HPV-speciﬁ c CD4+ T cells provides an explanation for the 
apparent impaired HPV-speciﬁ c immunity in cancer patients, it does not reveal as to why the patients 
failed to mount an effective immune response in the ﬁ rst place. The subsequent establishment of persis-
tent HPV infection may have been inﬂ uenced by a combination of genetic and environmental factors. In 
the case of genetic factors related to the innate or adaptive immune system, the ‘defects’ are expected 
to be subtle, because subjects with persistent PV infections generally do not show increased susceptibil-
ity to other opportunist pathogens. Several studies have addressed the contribution of polymorphisms in 
certain cytokine genes (e.g. IL- 10, TNFa) to the risk of developing cervical cancer, but so far this has 
not revealed a clear correlation [73-75]. This is not surprising, given that fact that in most studies one 
single polymorphism was investigated, and it is probable that genetic involvement will consist of large 
numbers of alleles conferring modest levels of risks [76]. Future efforts should determine the polymor-
phisms of numerous genes simultaneously, enabling the comprehensive assessment of immune gene 
pathways rather than a limited number of candidate genes. Finally, microarray technology for gene-and 
protein-expression may prove a powerful tool for the characterization of the cervical microenvironment 
in response to HPV infection, allowing the assessment of susceptibility factors for HPV persistence.
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Samenvatting
Humaan papillomavirus (HPV) en baarmoederhalskanker
Genitale HPV infecties zijn een van de meest voorkomende sexueel overdraagbare aandoeningen; 
naar schatting komt ruim 80% van de sexueel actieve vrouwen in contact met dit virus gedurende 
hun leven. HPV infecties van de baarmoedermond zijn over het algemeen vrij onschuldig, aangezien 
het merendeel van deze infecties na enige tijd door de afweer wordt opgeruimd. Als een HPV infectie 
echter voortduurt, bestaat de kans op ontwikkeling van baarmoederhalskanker. Er zijn vele verschil-
lende HPV typen, waarvan enkele in staat zijn deze kwaadaardige ontwikkeling van cellen te bevor-
deren. De grootste boosdoener is type 16 (HPV16), dat in meer dan de helft van de tumoren van 
de baarmoederhals wordt teruggevonden. HPV16 kan op allerlei plekken de slijmvliezen infecteren, 
maar doet dit bij voorkeur ter plekke van de baarmoedermond. Hier heeft het virus toegang tot de 
zogenaamde basaalcellen van het slijmvlies, die mogelijk ook dienen als reservoir voor het virus. 
Humaan papillomavirussen hebben zich wonderlijk goed aangepast aan hun gastheer. In tegenstel-
ling tot vele andere virusinfecties leidt HPV infectie niet tot massale inﬂ ammatie en verstoort het 
virus tijdens zijn vermenigvuldiging nauwelijks het normale proces van celdeling en differentiatie 
van het slijmvlies. Gevolg hiervan is dat een HPV infectie lange tijd onopgemerkt kan blijven voor 
het immuunsysteem (de afweer). Daarnaast zijn enkele HPV eiwitten in staat om te interfereren met 
signaaleiwitten die gewoonlijk het immuunsysteem activeren op het moment van virale infectie. 
 Ondanks het feit dat papillomavirussen verschillende strategieën gebruiken om activering van 
het immuunsysteem te voorkomen, worden uiteindelijk de meeste HPV infecties effectief door de 
afweer bestreden. Wanneer dit niet gebeurt en de HPV infectie blijft voortduren, bestaat de kans 
dat het virale DNA ingebouwd wordt in het DNA van de gastheercel. Een belangrijk gevolg van 
deze integratie is dat twee HPV eiwitten (E6 E7) in verhoogde mate worden geproduceerd. E6 en E7 
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kunnen binden aan cellulaire eiwitten die betrokken zijn bij het controleren van de celcyclus. Door 
deze binding raakt de celcyclus ontregeld, met als gevolg ongecontroleerde celdeling en uiteindelijk 
de vorming van kwaadaardig weefsel. 
De rol van het immuunsysteem 
Bij het bestrijden van virusinfecties speelt de zogenaamde ‘adaptieve’ of ‘speciﬁ eke’ afweer een 
belangrijke rol. Zoals de naam al suggereert, reageert deze component van het immuunsysteem zeer 
speciﬁ ek op afwijkende of lichaamvreemde structuren en vormt het een soort ‘geheugen’. Bij een 
volgend contact met dezelfde ziekteverwekker reageert de speciﬁ eke afweer sneller en krachtiger 
waardoor infectie wordt voorkomen of sneller wordt bestreden. Binnen de speciﬁ eke afweer zijn 
twee celtypen van belang: B en T cellen. Iedere B en T cel bezit een unieke receptor waarmee zeer 
speciﬁ ek een bepaald lichaamsvreemd eiwitfragment kan worden herkend. De extreme diversiteit 
van deze receptoren zorgt ervoor dat vrijwel elke lichaamsvreemde structuur potentieel herkend kan 
worden. Het principe van het geheugen van het immuunsysteem is onder andere gebaseerd op het 
feit dat bij een bepaalde infectie juist die B en T cellen die speciﬁ ek zijn voor de ziekteverwekker zich 
vermenigvuldigen, waardoor de dichtheid van deze speciﬁ eke cellen in het bloed sterk toeneemt. 
 B cellen maken na activatie antilichamen. Bij een virusinfectie zijn antilichamen – gericht tegen 
het eiwitomhulsel van het virus – in staat het binnendringen van het virus in de cel te voorkómen. 
Deze antilichamen hebben echter een geringe functie wanneer een virus eenmaal de cel is binnen-
gedrongen. Dit is waar de T cel een rol speelt. T cellen ‘herkennen’ met behulp van hun receptor 
stukjes eiwit (peptiden) die gebonden zijn aan zogenaamde HLA moleculen. Deze HLA moleculen 
bevinden zich op het oppervlak van vrijwel alle cellen en de peptiden die aan deze HLA moleculen 
gebonden zijn vormen een afspiegeling van de eiwitten binnenin de betreffende cel. Bijvoorbeeld, 
wanneer een cel geïnfecteerd is met een virus, dan zal het HLA ook peptiden afkomstig van virale 
eiwitten op het oppervlak presenteren, die vervolgens herkend kunnen worden door T cellen. Binnen 
de T cellen kunnen globaal de volgende soorten worden onderscheiden: CD8+ T cellen, die in staat 
zijn om andere cellen te doden en CD4+ T cellen die ook incidenteel cellen kunnen doden, maar 
hoofdzakelijk cytokinen produceren. Cytokinen zijn celsignaalstoffen die onmisbaar zijn voor het op 
gang brengen en houden van afweerprocessen. Binnen CD4+ T cellen is er weer onderscheid te 
maken tussen ‘helper’ T cellen, die ontstekingsbevorderende cytokinen produceren en ‘regulatoire’ T 
cellen, die juist ontstekingsonderdrukkende cytokinen produceren. 
 De exacte rol van de speciﬁ eke afweer bij de bescherming tegen en het onder controle houden 
van van HPV infecties is niet geheel bekend. Wel is vanuit epidemiologische studies duidelijk gewor-
den dat T cellen en met name CD4+ T cellen een belangrijke rol hierin spelen. Patiënten met alge-
meen verminderde cellulaire afweer (HIV geïnfecteerden / transplantatiepatiënten) en speciﬁ ek ver-
minderde CD4+ populaties (idiopathische CD4 lymfocytopenie) vertonen een extreme toename in 
voorkomen en ernst van HPV infecties. 
Dit proefschrift
De ‘link’ tussen HPV infectie en baarmoederhalskanker biedt een belangrijk aangrijpingspunt voor 
mogelijke behandeling van deze vorm van kanker met behulp van immunotherapie. Belangrijk hier-
bij is het feit dat virale eiwitten tot expressie komen in de tumorcellen. Het activeren van T cellen 
gericht tegen de virale eiwitten, zal mogelijk een effectieve ‘aanval’ op tumorcellen in gang zetten. 
Effectieve HPV-speciﬁ eke afweer. Voor het ontwikkelen van effectieve immunotherapeutische strate-
gieën is het van belang vast te stellen hoe de HPV-speciﬁ eke T cel immuniteit er uit ziet bij individuen 
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die in staat zijn geweest een HPV16 infectie op te ruimen en hoe deze T cel immuniteit zich kwantitatief 
en kwalitatief verhoudt ten opzichte van die in vrouwen met HPV16-geïnduceerde baarmoederhalskan-
ker of voorstadia daarvan. Bij het beantwoorden van deze vraag zijn we eerst uitgegaan van de gezonde 
populatie waarin zich – gezien de hoge incidentie van HPV16 infecties – een groot aantal individuen 
bevindt die in het verleden een HPV16 infectie hebben doorgemaakt. In eerste instantie hebben we 
gekeken naar de afweer tegen het E2 eiwit, dat vroeg in infectie hoog tot expressie komt. Al gauw werd 
duidelijk dat bij ruim de helft van de gezonde mensen zogenaamde ‘memory’ CD4+ T cellen tegen E2 
in het bloed aanwezig waren. Hiermee werd voor het eerst aangetoond dat T cellen tegen eiwitten van 
HPV16 zeer frequent aanwezig zijn in individuen zonder HPV16-geïnduceerde ziekte. Ook tegen het E6 
eiwit van HPV16 werden memory CD4+ T cellen gedetecteerd in het bloed van gezonde bloeddonoren. 
Dit gold echter niet voor T cel responsen tegen het E7 eiwit, mogelijk omdat E7 minder accumuleert in 
de geïnfecteerde cellen en minder beschikbaar is voor presentatie aan het immuunsysteem. Het gege-
ven dat memory CD4+ T cellen tegen HPV16 E2 en E6 zeer frequent voorkomen in gezonde individuen 
suggereert dat deze cellen een rol spelen bij het onder controle houden van HPV16 infectie. Dit zal 
echter nog bevestigd moeten worden in een zogenaamde longitudinale studie, waarin de ontwikkeling 
van HPV16-speciﬁ eke T cel responsen gedurende een periode wordt bekeken in relatie tot het al dan 
niet opruimen van de HPV16 infectie.
Falende HPV-speciﬁ eke afweer. Bij patiënten met baarmoederhalskanker (of voorstadia) veroor-
zaakt door HPV16 verschilde het beeld van de virus-speciﬁ eke T cel immuniteit opmerkelijk van die 
bij gezonde individuen. Hoewel T cel responsen tegen HPV16 E2 en E6 (en ook E7) wel gezien 
werden bij een deel van de patiënten, waren deze responsen zwakker en vaak geassocieerd met een 
sterk verminderde productie van cytokinen. Dit terwijl deze patiënten meestal niet een signiﬁ cant 
verminderde afweer hadden tegen andere ziekteverwekkers. Ook het soort cytokinen dat geprodu-
ceerd werd verschilde; terwijl bij gezonde vrouwen overwegend ontstekingsbevorderende cytokinen 
werden gemeten (interferon-gamma (IFNg) en interleukine-5 (IL-5)), werd bij patiënten vaak het ont-
stekingsonderdrukkende cytokine, interleukine-10 (IL-10), gemeten. 
 Bij een aantal patiënten met baarmoederhalskanker hebben we in detail HPV-speciﬁ eke T cellen 
kunnen bestuderen die zich in de tumor of de drainerende lymfeklieren bevonden. Het merendeel 
van deze HPV16-speciﬁ eke T cellen produceerde zowel het ontstekingsonderdrukkende IL-10 als het 
ontstekingsbevorderende IFNg. Belangrijke observatie hierbij was dat de balans tussen deze 2 cyto-
kinen afhing van de hoeveelheid HPV16 peptide waarmee de T cellen in contact kwamen. Bij lage 
concentraties maakten de T cellen alleen IL-10, terwijl pas bij hogere concentraties IL-10 én IFNg 
werden geproduceerd. Hoewel de betekenis van deze bevindingen nog niet helemaal duidelijk is; 
lijkt het er wel op dat bij patiënten de balans van de HPV16-speciﬁ eke afweer bij patiënten in 
het voordeel is van IL-10, hetgeen suggereert dat de afweer tegen HPV16, en dus tegen de tumor, 
speciﬁ ek wordt onderdrukt. Recentelijk hebben we de eerste aanwijzingen gevonden dat de HPV-
speciﬁ eke T cellen afkomstig uit de baarmoederhalstumoren en lymfeklieren inderdaad in staat zijn 
om activatie en deling van andere CD4+ T cellen te onderdrukken.
Tot slot • De bevindingen beschreven in dit proefschrift geven inzicht in de afweer tegen HPV in 
gezonde individuen en in patiënten met baarmoederhalskanker. De observatie dat bij patiënten de 
afweer tegen HPV niet alleen verminderd is, maar mogelijk zelfs speciﬁ ek onderdrukt, heeft conse-
quenties voor de aanpak van baarmoederhalskanker met behulp van immunotherapie. Dit betekent 
dat de gekozen behandelingsstrategie niet alleen gericht moet zijn op het activeren van ‘nieuwe’ T 
cellen tegen HPV. Ook het inactiveren of verwijderen van reeds aanwezige IL-10 producerende HPV-
speciﬁ eke T cellen is van belang, aangezien deze mogelijk de effectiviteit van de immunotherapie 
kunnen verminderen. 
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Curriculum vitæ
De schrijfster van dit proefschrift werd op 4 oktober 1971 geboren te Amsterdam. Na het behalen van 
haar VWO diploma (Rijnlands Lyceum te Oegstgeest), begon zij in 1990 met de studie Farmacie aan 
de Universiteit Utrecht. Tijdens de doctoraalfase, welke in 1995 werd afgerond, heeft zij onderzoek 
gedaan naar bepalingsmethoden voor bot-turnover markers bij metabole botziekten aan The Insti-
tute of Medical and Veterinary Science, afdeling Biochemie, Adelaide, Australië. Het postdoctoraal 
apothekersdiploma behaalde zij in 1997, waarna zij in dienst trad als projectapotheker bij de afdeling 
Klinische Farmacie en Toxicologie van het Leids Universitair Medisch Centrum. In het kader van het 
zogenaamde Zapico curriculum (promotieonderzoek gecombineerd met de opleiding tot ziekenhuis-
apotheker) begon zij in april 1999 aan een promotieonderzoek op de afdeling Immunohematologie & 
Bloedtransfusie. Bij de sectie Tumorimmunologie van deze afdeling heeft zij tot eind 2003 onderzoek 
gedaan naar de cellulaire afweer tegen Humaan Papillomavirussen, waarvan de resultaten beschre-
ven staan in dit proefschrift. Dit onderzoek werd begeleid door prof. dr. C.J.M. Melief, dr. R. Offringa 
en dr. S.H. van der Burg. Gedurende deze ‘onderzoeksjaren’ heeft zij haar toekomstplannen gewij-
zigd. In plaats van de opleiding tot ziekenhuisapotheker heeft zij gekozen voor een verdere carrière 
in wetenschappelijk onderzoek. In 2004 heeft zij nog wel een bescheiden ‘come-back’ gemaakt in 
de Farmacie. Gedurende dit jaar was zij werkzaam op de Interdivisionele GMP faciliteit (IGFL) van 
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postdoctoral fellow in de groep van Branch Moody, Division of Rheumatology, Immunology and 
Allergy van Brigham & Women’s Hospital en Harvard Medical School. Zij zal daar werken aan CD1-
gemediëerde T cel immuniteit. 
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Nawoord
In de continue stroom die wetenschap heet, is het voltooien van een proefschrift niet meer dan een 
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ciperen in de studies. Buiten de HPV club heb ik de sectie Tumorimmunologie en ook de verdere IHB 
afdeling ervaren als een zeer stimulerende werkomgeving. Hier is bij mij een groot enthousiasme 
voor de immunologie ontstaan en de afdeling mag het denk ik als een compliment beschouwen 
dat ik door dit enthousiasme een toekomst in de ziekenhuisfarmacie heb verruild voor een onder-
zoekspad in de immunologie. Dank ook aan alle medewerkers van de afdeling Klinische Farmacie en 
Toxicologie. Al was ik het afgelopen jaar slechts tijdelijk terug bij de afdeling, heb ik mij nog steeds 
welkom gevoeld. 
 Ik wilde Sam bedanken voor de mooie vormgeving van dit proefschrift en de organisatie rondom 
het drukwerk. 
 Tot slot, veel dank aan lieve vrienden en familie voor alle belangstelling en bovenal voor de aﬂ ei-
ding en het relativeren! 


